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Zusammenfassung 
I 
Zusammenfassung 
In den vergangen Jahren ist die Anzahl der in der präklinischen und klinischen Entwicklung 
befindlichen monoklonalen Antikörper und abgewandelten Derivaten, wie Antikörper-
Wirkstoff-Konjugate, zur Behandlung von Krebserkrankungen rapide gestiegen. Abhängig 
davon, ob Antikörper-Wirkstoff-Konjugate zusätzliche Effektorfunktionen vermitteln sollen, 
wird häufig der IgG1 oder andernfalls der IgG4 Subtyp verwendet. Letzterer ist bekannt dafür 
nahezu keine antikörperabhängige zellvermittelte Zytotoxizität oder komplementabhängige 
Zytolyse zu vermitteln und wird daher hinsichtlich der Patentensicherheit bevorzugt. Eine 
weitere Besonderheit unveränderter IgG4 Antikörper ist ihre Fähigkeit einen zufälligen 
Halbantikörperaustausch in vivo zu vollziehen, der in der Bildung von bivalenten, 
bispezifischen Antikörpern resultiert. CD138 ist ein Oberflächenrezeptor, der in Zell-Zell 
Interaktionen, Proliferation und Migration involviert ist und in verschiedenen Krebsarten, u.a. 
dem Multiplem Myelom, stark überexprimiert wird. BT062 (Indatuximab Ravtansine) ist ein 
monoklonaler, Wildtyp IgG4-basierter anti-CD138 Antikörper, an den zytotoxische DM4 
Moleküle (ein Derivat des Maytansinoids) gekoppelt sind. Aktuell wird BT062 in einer 
klinischen Studie zur Behandlung des Multiplen Myeloms getestet. Um die Auswirkungen 
des Halbantikörperaustausches auf die Funktionalität und Wirksamkeit von Antikörper-
Wirkstoff-Konjugaten am Beispiel von BT062 zu untersuchen, wurden folgende 
Modelantiköper generiert: Ein (I) Wildtyp nBT062; ein (II) stabilisierter nBT062, der durch die 
Mutationen S228P und R409K nicht mehr in der Lage ist einen Halbantikörperaustauch zu 
vollziehen; ein (III) halber nBT062, der durch Substitution von Cystein zu Serin an Position 
226 und 229 keine kovalente Dimerisierung bilden kann; und ein (IV) bispezifischer 
nBT062-Natalizumab Antikörper, der jeweils monovalent die Antigene CD138 und CD49d 
erkennt. Alle vier nBT062 Antikörper wurden in CHO-S Zellen exprimiert und durch 
Affinitätschromatographie mit Protein A aufgereinigt. Die analytische Charakterisierung durch 
elektrophoretische Methoden, Western Blot und Größenausschlusschromatographie 
bestätigte die Reinheit und durch die Mutationen eingefügten strukturellen Eigenschaften der 
Antikörper. Analysen mit NCI-H929 (CD138+/CD49d+), Ba/F3-hCD138 (CD138+/CD49d-) und 
Jurkat (CD138-/CD49d+) Zellen zeigten, dass alle Modelantikörper spezifisch und mit 
nanomolarer Affinität an CD138 binden konnten und anschließend in die Zellen internalisiert 
wurden. Nach erfolgreicher Konjugation mit dem zytotoxischen Agens DM4 wurde mittels in 
vitro Zellzytotoxizitätsversuchen gezeigt, dass alle nBT062-DM4 Varianten das Wachstum 
von Tumorzellen inhibieren konnten (IC50: ~80-460 pM). Der direkte Einfluss des 
Halbantikörperaustauschs auf die Wirksamkeit wurde in vivo in einem Xenograft-Mausmodel 
getestet. nBT062-Natalizumab-DM4 zeigte dabei nur ohne zusätzliche Anwesenheit von 
humanen IgG4 Antikörpern eine geringe Wirksamkeit. Wildtyp, stabilisierter und halber 
nBT062-DM4 hatten eine sehr gute antitumorale Wirkung. Allerdings wurde die Wirksamkeit 
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des Wildtyp und halben nBT062-DM4 in einer niedrigen Dosierung durch die Anwesenheit 
von humanem IgG4 reduziert. In Mausplasmen konnte für diese beiden Modelantikörper der 
Halbantikörperaustausch nachgewiesen werden, wohingegen der stabilisierte nBT062-DM4 
diesem Mechanismus nicht unterlag. Die Ergebnisse zeigen, dass sich der Einbau von 
Mutationen zur Unterbindung des IgG4 Halbantikörperaustausches positiv auf die 
antitumorale Wirksamkeit von Antikörper-Wirkstoff-Konjugaten ausübt.  
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Abstract 
A high number of therapeutic antibodies and their derivates e.g. antibody-drug conjugates 
(ADC) are under preclinical or clinical evaluation for the treatment of cancer. Most of those 
ADCs are based on the IgG1 or IgG4 subtype, depending on whether additional effector 
functions are desired or not. In contrast to IgG1, IgG4 is hardly capable to induce antibody-
dependent cell-mediated or complement-dependent cytotoxicity and thus IgG4-based ADCs 
with cytotoxic payloads targeting only proliferating cells may have a preferred safety profile. 
Another unique property of the IgG4 subtype is the in vivo exchange of half-antibodies, 
resulting in random bispecific antibodies. BT062 (indatuximab ravtansine) is an ADC 
composed of an anti-CD138 IgG4 antibody conjugated to the highly cytotoxic maytansin 
derivate DM4. BT062 is currently evaluated in a clinical trial for the treatment of multiple 
myeloma. To investigate the influence of IgG4 half-antibody exchange on the functional 
properties and efficacy of ADCs, the following BT062 model antibodies mimicking the 
different process-derived antibody species were generated: (I) Wildtyp (WT) nBT062; (II) 
stable nBT062, comprising S228P and R409K mutations to prevent IgG4 shuffling in vivo; 
(III) half nBT062, serving as a model of the transistant state as C226S and C229S amino 
acid substitutions lead to the lack of covalent half antibody dimerization; and (IV) bispecific 
nBT062-natalizumab monovalently recognizing CD138 and CD49d antigens. All nBT062 
variants were produced in FreeStyle CHO-S cells and purified by protein A affinity 
chromatography. Electrophoresis, western blotting and size exclusion chromatography were 
used to confirm the purification quality and provide first evidence on the aimed characteristics 
of each antibody due to the introduced mutations. In vitro analyses on NCI-H929 
(CD138+/CD49d+), Ba/F3-hCD138 (CD138+/CD49d-) and Jurkat (CD138-/CD49d+) cells 
demonstrated nanomolar binding activities of all nBT062 variants towards CD138 followed by 
antigen-mediated internalization. After successful conjugation with model-corresponding 
quanities of DM4, resulting ADCs were investigated by an in vitro cytotoxicity assay. All 
nBT062-DM4 variants were capable to inhibit tumor cell proliferation by picomolar quanitities 
(IC50: ~80-460 pM). The MAXF 1322 xenograft mouse model was used to directly assess the 
influence of IgG4 shuffling in vivo. Bispecific nBT062-natalizumab-DM4 was the least potent 
model demonstrating only a boarderline efficacy even without the presense of human IgG4. 
WT nBT062-DM4, stable nBT062-DM4 and half nBT062 were highly effective against the 
tumor cells. At a low dosage, the efficacy of WT nBT062-DM4 and half nBT062-DM4 was 
reduced by the presence of human IgG4, while stable nBT062-DM4 was hardly affected. 
Analysis of mouse plasma samples confirmed the formation of bispecific antibodies out of 
WT nBT062-DM4 and half nBT062-DM4, but no half-antibody exchange was detected within 
samples of stable nBT062. These data clearly demonstrate an advantage of incorporating 
half-antibody exchange-preventing mutations into IgG4-based ADCs. 
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1 Introduction 
1.1 The human immune system 
The immune system consists of a variety of effector cells and molecules that protect the body 
from four categories of disease-causing microorganisms: Viruses, fungi, bacteria and 
parasites (Murphy, Weaver 2017; Male et al. 2007). It can be subdivided into the innate and 
adaptive immune system. Innate immunity represents the first line of defense against 
pathogens: It reacts in an antigen-unspecific manner within minutes after pathogen entry. 
Neutrophils, eosinophils, basophils, monocytes, macrophages, natural killer (NK) cells and 
dendritic cells (DCs) are the major cell types of the innate immune response. Antigen-
presenting cells (APCs) like DCs bridge the innate and adaptive immunity by activating the 
latter one, including B and T cells. These cells are mainly responsible for the characteristics 
of the adaptive immune system: It reacts antigen-specific e.g. by antibodies 
(immunoglobulins) or Teffector cells and it features immunological memory, leading to a more 
effective response at a repeated antigen exposure (Male et al. 2007). These properties 
render the adaptive immunity highly effective against pathogens.  
 
1.2 Cancer evolves when the immune system fails 
Cancer is one of the major causes of death worldwide besides cardiovascular diseases in 
industrialized nations (World Health Organization (WHO) 2017). The most common deathly 
cancers are female breast, lung, liver, stomach, colorectal, and prostate cancer (Torre et al. 
2015). Hanahan and Weinberg described eight major hallmarks of cancer, namely sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, reprogramming of 
energy metabolism, enabling replicative immortality, inducing angiogenesis, activating 
invasion and metastasis, and evading immune destruction (Hanahan, Weinberg 2011). 
Genome instability, fostering genetic diversity, seems to be the major underlying cause of 
these hallmarks (Hanahan, Weinberg 2011). As single mutations are rarely unable to induce 
tumor development, multiple alterations in several tumor-related genes are necessary for 
malignant tumor growth (Croce 2008). Besides protecting the host from pathogens, the 
immune system does also survey transformed cells which may induce cancer (Smyth et al. 
2001). A number of different immune cells can be involved by several mechanisms: Cluster 
of differentiation (CD) 4+ and CD8+ T cells are able to recognize either tumor specific 
antigens or overexpressed, non-mutated proteins on the cell surface (e.g. p53 and Her2/neu) 
due to their T cell receptors (TCR) and induce apoptosis of those cells (Igney, Krammer 
2002). As cells of the innate immune system macrophages and neutrophils are involved in 
cancer immunosurveillance by either destruction of tumor vessels, inhibition of angiogenesis 
Introduction 
2 
or even by direct cell killing. Furthermore, macrophage s and neutrophils are capable to 
stimulate cytotoxic T cells, NK cells and APCs by tumor antigen presentation (Elgert et al. 
1998; Di Carlo et al. 2001; Igney, Krammer 2002). NK cells survey body cells for appropriate 
expression of self-antigens. If no self-antigen is expressed on the surface of a cell, it will by 
lyzed by the NK cell (Kärre 2008). Tumor cells have evolved several mechanisms to escape 
the immune response: The tumor stroma can serve as physical barrier between tumor and 
immune cells (Igney, Krammer 2002). Furthermore, tumor cells are able to downregulate the 
tumor antigens or mutate them to escape from an initial immune response (Kim et al. 1975; 
Stackpole et al. 1980). In addition, major histocompatibility complex (MHC) I is 
downregulated to prevent presentation of foreign antigens to T cells. Cancer cells could also 
express MHC surrogates to prevent NK cell activation (Farrell et al. 1997; Cretney et al. 
1999). By the expression of cytokines (e.g. TGF-ß and IL-10) malignant cells are able to 
suppress the immune response. The expression of anti-apoptotic molecules and or 
downregulation of pro-apoptotic molecules saves the tumor from apoptosis (Torre-Amione et 
al. 1990; Matsuda et al. 1994; Medema et al. 1999; Igney, Krammer 2002). Tumors might 
also induce apoptosis through CD95L expression of CD95-sensitive immune cells as 
reported by Walker and coworkers (Walker et al. 1998). To stop malignant tumor growth, 
there are several types of cancer treatments, including surgery, chemotherapy, radiation 
therapy, stem cell transplantations, immunotherapy and others. As one type of the 
immunotherapy, monoclonal immunoglobulins are one of the most successful therapeutic 
strategies for hematologic and solid tumors (Scott et al. 2012a). 
 
1.3 Immunoglobulins 
In the 1890s, immunoglobulins (Igs) were first discovered by Emil von Behring and 
Shibasaburo Kitasato as an agent in the serum of animals which was able to induce a short-
lived protection in humans against diphtheria or tetanus toxin (Murphy, Weaver 2017; 
Schroeder, Cavacini 2010). Igs or frequently designated as antibodies are glycoproteins of 
the immunoglobulin superfamily which further includes for example MHC proteins, antibody 
receptors, many lymphocyte cell-surface proteins, but also growth factor receptors and 
others (Lander et al. 2001). Igs are able to bind specifically to particular surface structures 
referred to as epitopes present on foreign, native proteins, glycoproteins, polysaccharides, 
bacteria, and viral particles. They can be membrane-bound to B cells as B cell receptors 
(BCR) or are present as soluble proteins in the blood and tissue fluids (Male et al. 2007). 
Due to their binding, soluble Igs can participate in host defense either by direct neutralization 
of these foreign objects or by inducing effector functions such as activating the classical 
complement pathway or effector cells depending on the type of Ig. This Ig mediated immunity 
is known as humoral immunity (Navolotskaya 2014; Murphy, Weaver 2017).  
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1.3.1 B lymphocytes produce antibodies 
In response to a foreign antigen, antibodies are secreted by differentiated B cells. To initiate 
antibody production, APCs have to internalize respective pathogens at the place of infection. 
During the APCs migration to the lymphatic tissues, e.g. lymph nodes, the pathogen is 
processed within the endosome due to acid-dependent proteases. Pathogen-specific 
peptides are loaded intracellularly onto the MHC II and the resulting complex is further 
presented on the APC’s surface. Naïve CD4+ T-lymphocytes (TH cells) recognize those MHC 
II peptide complexes and become activated. In parallel, circulating naïve B cells must 
encounter their specific pathogen and bind it by their BCR. Antigen-mediated crosslinking of 
the BCRs induces internalization followed by pathogenic proteolyzation. While migrating to 
lymphatic tissues, pathogenic peptides are presented in complexes with MHC II molecules 
on the B cell surface. Those MHC II antigen complexes are recognized by TCRs of TH cells. 
Additionally, co-stimulatory signals are required and induced by interactions of CD28 and 
CD40 on the surface of the B cell with B7 and CD154 expressed on the TH cell’s surface. 
This induces cytokine secretion by the TH cell, causing B cell proliferation and differentiation 
into either antibody-secreting plasma cells or memory cells (Murphy, Weaver 2017) (see 
Figure 1-1).  
 
Figure 1-1: Activation of humoral 
immunity.  
Pathogens are internalized and 
processed by antigen presenting 
cells (APCs). Respective antigens 
are presented in complex with 
MHC II molecules. Naive TH cells 
become activated by recognizing 
those antigen-MHC II complexes. 
Naive B cells bind pathogens by 
their B cell receptors (BCR) and 
process them upon internalization 
for MHC II antigen presentation. 
This MHC II antigen complex is 
bound by activated TH cells, while 
CD40/CD154 and B7/CD28 
interactions mediate a co-stimulatory 
signal. Cytokine secretion of the TH 
cells results in B cell activation 
leading to differentiation into either 
antibody-secreting plasma cells or 
memory B cells, depending on the 
cytokine milieu (adapted from 
Bachmann, Jennings 2010).  
Introduction 
4 
1.3.2 Antibody isotypes and structure 
Igs belong to the immunoglobulin superfamily (IgSF) (Williams, Barclay 1988). Five different 
classes, referred to as isotypes, are known in humans: IgA, IgD, IgE, IgG and IgM. IgA is 
further divided into IgA1 and IgA2, while IgG is separated in four subtypes, namely IgG1, 
IgG2, IgG3, and IgG4. Serum IgA, IgD, IgE and IgG are present as monomers, but IgA is 
also available as dimer in secretions. IgM is the only multimeric antibody, present as 
pentamer or hexamer (Male et al. 2007; Rojas, Apodaca 2002; Navolotskaya 2014) (see 
Figure 1-2 A). The monomeric structure represents a Y-shaped molecule which is based on 
two identical heavy (H) and two identical light (L) chains (Berlot et al. 2015). Five different H 
chain molecules α, γ, δ, ε or μ define the immunoglobulins isotypes. L chains are separated 
in κ or λ. Within one immunoglobulin neither the isotype, subclass nor the light chain 
classification is mixed (Bayry et al. 2007). Each H and L chain comprises a variable domain 
(V) on the N-terminal protein site and a C-terminal constant region (C). While L chains are 
built up of one C domain, H chains have three to four. Both, V and C domains consist of 110 
to 130 amino acids, resulting in a molecular weight of approx. 12,000 to 13,000 Da. Each of 
both domains contains two sandwiched ß-pleated sheets linked by a disulfide-bond of two 
conserved cysteines (Williams, Barclay 1988; Schroeder, Cavacini 2010)(see Figure 1-2 B). 
L chains are attached and covalently bound by a disulfide bond to the V and first C (CH1) 
domain of the H chain, thereby creating the fragment antigen binding (Fab) region. Within 
this, the dimerized variable domains of the H and L chain create the variable fragment (Fv) 
mediating the antigen-specific binding (Inbar et al. 1972). This distinct specificity is mediated 
by three hyper-variable complementarity-determining regions (CDR) within the V domains. 
These CDRs are surrounded by four conserved framework regions (Schroeder, Cavacini 
2010). The Y-shape results from dimerization of two heavy chains. H chains comprising only 
3 C domains tend to have a space region, referred to as hinge, between the CH1 and CH2 
domains which is absent in H chains comprising 4 C domains (Schroeder, Cavacini 2010). 
Cysteins in the hinge region stabilize H chain dimerization by covalent disulfide bonds. The 
dimerized C domains of the H chain result in the fragment-crystallizable (Fc) region. The Fc 
portion mediates effector functions by interacting with Fc receptors on several immune cells, 
induces the complement system due to C1q binding and influences the antibodies' half-life by 
neonatal Fc receptor (FcRn) recycling mechanisms (Morea et al. 2000; Bayry et al. 2007; 
Murphy, Weaver 2017).  
Immunoglobulins are expressed by B lymphocytes upon interaction with TH cells and 
cytokine secretion due to the latter cell type (see 1.3.1). The cytokine milieu defines the 
expression of the Ig isotype and subclass based on nine CH genes. During B cell 
differentiation, the antigen specificity of the Ig's V domain is defined by complex 
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recombination of V, D and J gene cluster downstream to the CH genes (Honjo 1983; 
Schroeder, Cavacini 2010). 
 
 
1.4 Effector functions of IgG  
The IgG isotype accounts for approx. 70-75% of all antibodies in human serum and approx. 
10-20% of all plasma proteins, thus it is one of the most abundant proteins besides albumin. 
The four IgG subclasses IgG1, IgG2, IgG3 and IgG4 split in proportions of approx. 60, 32, 4, 
and 4 %, respectively (Male et al. 2007; Vidarsson et al. 2014). In contrast to other IgG 
subclasses, the serum concentration of IgG4 has a high variability in the human population 
ranging from less than 10 µg/ml to > 2 mg/ml (Aucouturier et al. 1984). IgG antibodies have 
several mechanisms to inactivate invading microorganisms and foreign pathogens. They can 
bind to receptors or their ligands, thereby inhibit their interactions or neutralize infectious 
agents such as bacterial toxins by blocking their function sites (Capra 1997). However, most 
Figure 1-2: Antibody isotypes and basic 
IgG structure.  
A: Humans have five different 
immunoglobulin isotypes: IgD, IgE and IgG 
are monomeric, IgA is a dimer in secretions 
and IgM is typically a pentamer. Each 
monomeric backbone is composed of two 
heavy (H, green) and two light chains (L, 
yellow), while the number of constant 
domains within the H chains differs between 
isotypes. Multimeric antibodies incorporate 
an associated J chain (polypeptide, red box) 
(adapted from Rojas, Apodaca 2002). 
B: Typical structure of an IgG molecule. The 
two upper boxes represent L and H chains 
structured into regions encoded by specific 
genes. Variable (V) and constant (C) 
domains are marked as well as regions 
expressed by D and J genes. The two boxes 
at the bottom represent the IgG’s protein 
domains. Antibodies contain a fragment-
crystallizable (Fc) region mediating an 
immune response (e.g. receptor binding) 
and a fragment antigen-binding (Fab) region. 
Three complementarity-determining regions 
(CDR) define the antigen specificity 
surrounded by four sections of the 
framework region (Fr). Both H chains are 
covalently bound by two disulfide bonds in 
the hinge region (Adapted from Schroeder, 
Cavacini 2010). 
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effector functions are mediated by the antibodies’ Fc interacting with certain innate receptors 
or adaptor molecules. The major adaptor molecule is C1q, inducing complement-dependent 
cytotoxicity (CDC). Upon IgG binding to antigens on cellular surfaces, C1q attaches to the 
antibody resulting in a disposition of C3b to enable further phagocytosis of the target 
(opsonization), while simultaneously the formation of the membrane attack complex (MAC), 
C5-C9, is initiated. The latter one is a transmembrane channel inducing osmotic lysis of the 
target cell. Neither IgG2 nor IgG4 antibodies are able to induce the complement pathway as 
they lack C1q binding activities (Tao et al. 1993; Nirula et al. 2011; Vidarsson et al. 2014; 
Murphy, Weaver 2017). Another major effector function is antibody-dependent cellular 
cytotoxicity (ADCC). For its activation, IgG antibodies specifically bound to target cells, are 
detected by fragment crystallizable gamma receptors (FcγR) expressed on the surface of 
effector cells. Upon binding, these cells release several molecules such as cytokines and 
cytotoxic enzymes e.g. perforines, inducing membrane damage, and granzymes leading to 
apoptosis induction. ADCC is mainly mediated by IgG1 or IgG3 antibodies activating NK 
cells, but neutrophils, macrophages and eosinophils are also compatible (Woof, Burton 2004; 
Murphy, Weaver 2017). Antibody-dependent cell-mediated phagocytosis (ADCP) is a further 
important mode of action induced by antibodies. It is primarily guided by IgG3 and IgG1 
antibodies interacting with FcγRIIa on macrophages. However, monocytes, neutrophils and 
DCs are also capable to phagocytose antibody-bound microorganisms or particles 
(Weiskopf, Weissman 2015).  
In general, the IgG1 and IgG3 subtypes interact with high affinity and efficiently with most of 
the FcγR, while IgG2 and IgG4 have a diminished affinity to several of those receptors. For 
example, FcγRI is bound by IgG1, IgG3 and IgG4 but the latter one demonstrates a reduced 
binding resulting in decreased phagocytic activity and subsequent degradation of 
antibody-antigen complexes (Nimmerjahn, Ravetch 2008; Vidarsson et al. 2014). FcγRIII is 
mainly responsible for NK cell activation during ADCC and has a very low affinity for IgG4. 
Thus, this subtype is hardly capable to induce this effector function. Nevertheless, the 
allotype of the receptor and the glycoform of the antibody can influence this binding (Jefferis 
2012). In addition, IgG4 has a minor binding activity to the inhibiting FcγRIIb/c making them 
hardly able to reduce active immune responses (Murphy, Weaver 2017). The binding affinity 
to FcRn is similar among the four IgG subclasses (Jefferis 2005, 2007; Nirula et al. 2011). 
FcRn mediates bidirectional IgG transcytosis across epithelial cells (Kuo, Aveson 2011). This 
very weak affinity for FcγRs and the lack of C1q binding results in reduced effector functions 
and the lack of CDC due to IgG4 antibodies, which might be the reason why IgG4 antibodies 
are a preferred subclass for immunotherapy, where host's effector functions are undesired 
(Nirula et al. 2011).   
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1.5 IgG4 is exchanging half-antibodies 
Besides demonstrating strongly limited effector functions, the IgG4 subclass possesses a 
further unique property: They are able to exchange half-antibodies (H+L) in vivo leading to 
the formation of bispecific antibodies (see Figure 1-3A). This phenomenon was disabused by 
several findings: While blood-derived, polyclonal IgG4 antibodies are not capable to crosslink 
two identical antigens and thus act functionally monovalent, chimeric, monoclonal IgG4 
antibodies are able to do so (Aalberse et al. 1983; Schuurman et al. 1999). In 1999, 
Schuurman and colleagues have demonstrated the existence of bispecific antibodies: In 
human sera of patients containing IgG4 antibodies against house dust mites and grass 
pollen, they found antibodies crosslinking both, radiolabeled house dust mite and sepharose-
coupled grass pollen allergens (Schuurman et al. 1999; Nirula et al. 2011). Furthermore, 
non-reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of 
IgG4 antibodies has obtained half-antibody fractions (Aalberse, Schuurman 2002). The 
presence of IgG4 half-antibody exchange was finally proven by injecting anti-Betv1 and anti-
Feld1 IgG4 antibodies into immunodeficient nude mice: Administration of equal amounts of 
anti-Betv1 and anti-Feld1 antibodies resulted in approx. 50% bispecific anti-Betv1/Feld1 
antibodies. Administration of both antibodies in combination with 20-fold excess of an IgG4 
with irrelevant specificity strongly decreased the detection of bispecific anti-Betv1/Feld1 
antibodies in the antigen crosslinking assay, indicating a random exchange of half-antibodies 
(van der Neut Kolfschoten, Marijn et al. 2007). Young et al. additionally demonstrated in 
2014 that endogenous polyclonal IgG4 antibodies undergo half-antibody exchange in 
humans as they detected antibodies containing both, one κ and one λ light chain (Young et 
al. 2014).  
The sequence and structure of IgG4 and IgG1 are highly similar but two important amino 
acid changes are mainly responsible for the ability of IgG4 to perform half-antibody 
exchange: P228 and K409 in IgG1 are changed to S228 and R409 in IgG4. S228 is located 
in the IgG4 hinge region and constitutes a CXXC motif, which contains two cysteines building 
the two covalent disulfide bonds linking the two half-antibodies. IgG1 molecules comprise a 
CPPC motif creating sufficient space between the two cysteines, that they are only able to 
form interchain disulfide bonds with a second IgG1 half antibody. In contrast, IgG4 antibodies 
comprise a CPSC motif resulting in a decreased distance between the two cysteines allowing 
the formation of either inter- or intrachain disulfide bonds (Aalberse, Schuurman 2002; 
Schuurman et al. 2001)(see Figure 1-3B). R409 is the crucial residue at the CH3-CH3 
interface, weakening the non-covalent interactions between these domains and allowing half-
antibody exchange (Labrijn et al. 2011; Davies et al. 2014). Incorporation of S228P and 
R409K mutations into IgG4 antibodies separately prevent IgG4 shuffling, while P228S and 
K409R mutations in IgG1 antibodies result in half-antibody exchange (Labrijn et al. 2011). 
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However, the function of naturally occurring half-antibody exchange of endogenous IgG4 
antibodies has not yet been fully clarified. It has been proposed that bispecific IgG4 
antibodies may dampen inflammatory responses, as they lack antigen cross-linking besides 
lacking major effector functions (van der Neut Kolfschoten, Marijn et al. 2007).  
 
Figure 1-3: Mechanism of IgG4 half-antibody exchange. 
A: Schematic illustration of the dynamic half-antibody exchange process in vivo. B: 3D peptide models of the 
hinge region of IgG4 (left) and IgG1 (right) with respective amino acids indicated. Demonstrated is the reduced 
distance of the two cysteines by the IgG4’s CPSC motif resulting in intrachain disulfide bonds. In contrast, IgG1 is 
only capable of H interchain disulfide bond bridging based the CPPC motif. Cysteines are shown in yellow, 
prolines in red (B adapted from Aalberse, Schuurman 2002). 
 
1.6 Generation of monoclonal antibodies 
A method for the unlimited production of antibodies with a known antigen specificity was 
published by Köhler and Milstein in 1975. Apart from minor changes, it is still the most 
commonly used technique for antibody production today. It is based on the immunization of 
mice with an antigen of interest to produce spleen cells secreting antibodies with the 
respective specificity. These spleen cells are isolated and fused with polyethylene glycol to 
immortal, antibody non-secreting myeloma cells lacking the enzyme hypoxanthine:guanine 
phosphoribosyl transferase (HGPRT) to generate hybrid cells referred to as hybridoma. For 
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hybridoma selection, the cells are grown in hypoxanthine-aminopterin-thymidine (HAT) 
medium. HGPRT metabolizes hypoxanthine to purines, which are necessary for DNA 
synthesis, while aminopterin blocks purine as well as thymidine synthesis. Therefore, non-
fused myeloma cells die due to the lack of HGPRT and non-fused spleen cells die after a few 
days because of their limited lifespan. Antibody-producing hybridoma cells are isolated and 
single clones are used to produce monoclonal antibodies (Murphy, Weaver 2017). 
Application of murine monoclonal antibodies induces immune responses in humans (Sgro 
1995; Mak, Saunders 2006; Harding et al. 2010). To reduce this risk chimeric or humanized 
antibodies are used. For chimerization, murine genes encoding the constant H and L regions 
are replaced in the hybridoma genome by homologous human genes through homologous 
recombination (Fell et al. 1989). For the generation of humanized antibodies, CDRs within an 
expression vector containing the sequence of a fully human antibody are replaced by the 
antigen specific, murine CDRs. Transfection of cell lines (e.g. CHO, HEK-293, SP2) with 
these vectors results in the secretion of humanized, antigen-specific antibodies. Since both 
antibody types, chimeric and humanized, still have a likelihood to induce an immune 
response against the administered therapeutic antibody, it is also possible to create fully 
human therapeutic antibodies by the use of transgenic mice. These mice are generated by 
introducing human immunoglobulin loci segments into the germlines of mice deficient in 
murine antibody production. After immunization with an antigen and the use of the hybridoma 
technique fully human, monoclonal antibodies can be produced in vitro (Green et al. 1994; 
Jakobovits 1995).  
 
1.6.1 Isotype selection of therapeutic monoclonal antibodies 
Currently, most of the approved therapeutic monoclonal antibodies (mAb) are based on the 
IgG class, mainly because of practical and functional concerns (Salfeld 2007; Jefferis 2012; 
Irani et al. 2015). Beside the antigen specificity, the isotype selection is an importent aspect 
during the generation of therapeutic mAbs as it defines effector functions (see section 1.4) 
and antibody half-life. If effector functions like ADCC and CDC are desired, IgG1 and IgG3 
are suitable as they bind all FcγRs with high affinity. However, IgG3 has not been used for 
therapeutic mAb development so far, probably due to the reduced serum half-life, lack of 
protein A binding for purification or the high number of IgG3 allotypes across populations 
(Irani et al. 2015). For neutralization of soluble antigens, where effector functions are less 
relevant, IgG1, IgG2 and IgG4 are suitable. In contrast to other IgG subclasses, IgG4 has 
superior anti-inflammatory activity which is preferred for targeted delivery of therapeutic 
conjugates or receptor blocking without cell depletion (Labrijn et al. 2009). The strongly 
diminished effector functions of IgG4 antibodies reduce the risk of side effects by undesired 
immune reactions. However, several mutations for each IgG subclass are known to further 
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enhance or diminish interactions with FcγRs or extending the half-life by increasing FcRn 
binding (Wang et al. 2017).  
 
1.6.2 Generation of bispecific antibodies 
Within recent years, bispecific antibody formats capable to bind two distinct antigens have 
gained high interest for therapeutic or diagnostic approaches (Brinkmann, Kontermann 
2017). First, recombinant bispecific antibodies were produced in the 1980s by simple 
coexpression of both different IgGs due to the fusion of two different hybridoma cells, 
referred to as hybrid hybridomas or quadroma cells (Milstein, Cuello 1983). This resulted in 
up to 9 unwanted H and L chain pairings leading to only up to 10-50% of the desired 
bispecific species (Milstein, Cuello 1983; Suresh et al. 1986a, 1986b). Since then, several 
approaches for heterogenic H chain – H chain interactions were developed e.g. (I) disulfide 
bond pairing by introduction of cysteine pairs into the CH3 domains, (II) salt bridges by 
oppositely charged residues for each of the different H chains, and (III) the knobs-into-holes 
(KiH) strategy based on the substitution of either smaller or respectively bigger amino acids 
in the opposite H chains (Ridgway et al. 1996; Merchant et al. 1998; Carter 2001). The 
heterogenic H chain pairing of the letter KiH strategy was further improved by phage display 
and incorporation of cysteine based disulfide bridging resulting in up to 95% heterodimers 
(Atwell et al. 1997; Carter 2001). However, all attempts of heterogenic H chain pairing 
suffered from random L chain pairing resulting in approx. 25% of the desired bispecific 
antibody. If possible, this was avoided by the use of a common light chain (Kontermann, 
Brinkmann 2015). The first genetic solution for this issue was provided by the CrossMab 
technology (Schaefer et al. 2011): The CH1 domain of the H chain was exchanged with the 
C domain of the respective L chain leading to mostly correct H-L chain pairing. Another 
elegant method for overcoming the H-L chain pairing problem is based on the introduction of 
several mutations within the respective C and V regions of each H and L chains, termed 
orthogonal Fab interface leading to nearly 100% correct pairing (Lewis et al. 2014). However, 
beside classical bispecific antibodies comprising two H and two L chains several other 
bispecific formats have been developed making it possible to choose from a pool of up to 50 
different approaches e.g. double-variable domain (DVD)-Igs, double svFcs, diabodies, 
SEEDbodies and so on (Kontermann 2012; Brinkmann, Kontermann 2017).  
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1.7 Immunotherapy: monoclonal antibodies for cancer treatment 
For the treatment of solid tumors and hematological malignancies antibody-based 
immunotherapy is one of the most promising strategies. These antibodies can mediate tumor 
cell killing by several mechanisms: (I) Indirectly by mediating ADCC or ADCP, (II) by inducing 
the complement pathway (CDC), (III) by activation and regulation of T cells, or (IV) directly by 
the antibody (see Figure 1-4). In the latter case, the therapeutic antibody might cause 
receptor blockade, induction of apoptosis or target-mediated delivery of a drug. Several 
antibodies having effects on tumor vasculature and stroma have been successfully applied in 
the clinic (Scott et al. 2012b). Tumor antigens bound by therapeutic monoclonal antibodies 
can be separated into several categories: Hematopoietic differentiation antigens, 
cancer/testes antigens, glycoproteins expressed by solid tumors, glycolipids, carbohydrates, 
anti-angiogenic targets, growth factors or receptors and stromal and extracellular matrix 
antigens (Scott et al. 2012b). Today, there are 23 therapeutic monoclonal antibodies 
approved by the US Food and Drug Administration (FDA) against different tumor-associated 
antigens and many more are under investigation (Cai 2016). In 1997, the first monoclonal 
antibody referred to as rituximab was approved by the FDA to treat B-cell non-Hodgkin 
lymphomas which were resistant to other chemotherapy regimens (Grillo-López et al. 2002). 
Rituximab binds to CD20 expressed on B cells, induces effector functions like ADCC and 
CDC and decreases the number of malignant B cells in the circulation (Weiner et al. 2010). 
Trastuzumab, the second approved monoclonal antibody, inhibits breast tumor growth by 
preventing the activation of human epidermal growth factor receptor 2 (HER2) on the tumor 
cells (Hudis 2007). The first approved IgG4 therapeutic antibody was gemtuzumab 
ozogamicin. The antibody was conjugated to calicheamicin, an antitumor anthracycline 
antibiotic. It was used for the treatment of CD33-positive acute myeloid leukemia (AML) after 
the first relapse. However, it was withdrawn in 2010 after a post approval clinical trial, 
because no sufficient benefit was provided for the patients (Rowe, Lowenberg 2013). In 2017 
it was re-approved by the FDA to treat AML patients above 60 years of age. The newest 
approach of monoclonal antibodies leading to a breakthrough in the clinic is designated as 
immune checkpoint inhibitors. Immune checkpoints are immunologic surface proteins 
mediating co-stimulatory or inhibitory signals for regulation and activation of T cells (Pardoll 
2012). The anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody ipilimumab was the first 
FDA approved immune checkpoint inhibitor for the treatment of melanoma (Traynor 2011). 
Due to antibody binding to CTLA-4 on the T cell's surface, it inhibits the immunosuppressive 
signal between CTLA-4 and B7 expressed on an APC. Thus, B7 is free to bind CD28 on the 
T cell leading to T cell activation and proliferation. Thereby, T cell-mediated immunity is 
amplified (Tarhini et al. 2010; Lipson, Drake 2011). 
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Figure 1-4: Tumor cell killing mechanisms of therapeutic antibodies. 
A: Direct tumor cell killing can be mediated by antibody binding to receptor antagonists e.g. surface receptors for 
kinase activation leading to reduced proliferation and apoptosis or agonist binding leading directly to apoptosis. 
Tumor cell death can also occur by enzyme neutralization due to antibody binding or target-orientated toxin 
transfer. B: Immune-mediated tumor cell killing can be realized either through antibody induced phagocytosis by 
macrophages, the activation of the classical complement pathway by C1q binding, antibody-dependent cellular 
cytotoxicity (ADCC) by the activation of NK cells or activation of T cells by immune checkpoint inhibitors. C: The 
death of vascular and stromal cells is mediated either by antibodies delivering toxins to stroma cells, the 
vasculature or directly by inhibition of stroma cells by antibodies (adapted from Scott et al. 2012b). 
 
1.7.1 Antibody-drug conjugates 
Despite antibody-drug conjugates (ADCs) have been investigated for decades, they have 
just become successful within the recent years due to the development of new linker and 
conjugation technologies. Based on the complex structure consisting of the three main units 
antibody, cytotoxic agent and the linker, ADC design includes a lot of challenges to gain the 
different properties and desirable characteristics of each unit (Diamantis, Banerji 2016). The 
antibody’s target antigen should be exclusively expressed or highly up regulated on tumor 
cells without down regulation during treatment and promote a fast internalization of the ADC. 
To prevent a loss of efficacy it is an advantage if the antigen is not shed from the cells’ 
surface or the antibody binds a membrane-bound specific epitope on the antigen (Mack et al. 
2014). However, there is no minimal threshold of antigen expression since many variables 
like internalization rate, binding affinity and cytotoxic potential of the drug need to be 
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considered (Diamantis, Banerji 2016). For efficient tumor cell killing, potent cytotoxic 
payloads are necessary. Today those drugs are targeting either the inhibition of microtubule 
or induce DNA damage. For example, microtubule assembly is interrupted by maytansinoids 
and auristatins leading to cell cycle arrest in the G2/M phase during cell proliferation (Sapra, 
Shor 2013; Bouchard et al. 2014). Duocarmycin and calicheamicin act independently from 
the cell cycle leading to rapid cell death by alkylating the minor groove of the DNA or cause 
double-strand DNA breaks at the minor groove, respectively (Diamantis, Banerji 2016). 
Specific linkers are used to attach those drugs in an optimal manner. They directly influence 
the ADC’s pharmacokinetics (PK) and the efficacy and should ensure that the drug is 
released only once the ADC is internalized but not during circulation (Teicher, Chari 2011; 
Shefet-Carasso, Benhar 2015). Two categories of linkers are currently used: cleavable and 
non-cleavable linkers. During lysosomal ADC degradation non-cleavable linkers remain 
intact and cytotoxic drugs are acting when still attached to the linker and amino acid residues 
from the antibody. Cleavable linkers can be either pH-, lysosomal protease- or glutathione-
sensitive (Shefet-Carasso, Benhar 2015; Senter, Sievers 2012; Sapra et al. 2011). Since 
resulting active drugs are smaller due to the lack of amino acids and linker residues, 
cleavable linkers increase the potential of bystander effects when the cytotoxic agents diffuse 
into neighboring cells. This gives an advantage for the treatment of heterogenic antigen-
expressing tumors (Diamantis, Banerji 2016).  
 
1.8 BT062 for treatment of multiple myeloma 
Multiple myeloma is a malignant disease and a distinct type of B cell lymphoma. It is defined 
by an uncontrolled clonal proliferation of plasma cells in the bone marrow, resulting in the 
production of complete Igs (typically IgA or IgG) or immunoglobulin L chains (plasmacytosis) 
which are detectable in the urine or serum of the patient (Kyle, Rajkumar 2004). Multiple 
myeloma increases the risk of organ damage and infection diseases and it potentially leads 
to bone structure destructions (osteolysis) (Longo et al. 2012). The disease is responsible for 
approx. 10% of hematologic cancers and 1% of all cancers (Harousseau, Moreau 2009). 
CD138, also referred to as Syndecan-1, is a transmembrane heparin sulfate proteoglycan 
and belongs to the syndecan proteoglycan family. Surface expression of CD138 is restricted 
to endothelial cells and distinct hematopoietic cells: While CD138 is present on precursor 
B cells and antibody-producing plasma cells, the surface protein is absent on mature B cells 
and CD34+ stem cells (Sanderson et al. 1989; Wijdenes et al. 2002; O'Connell et al. 2004). In 
comparison to healthy plasma cells, CD138 expression is highly upregulated on multiple 
myeloma cells and it is therefore used as a reliable biomarker for diagnosis (Wijdenes et al. 
1996; Bayer-Garner et al. 2001). Besides this, the surface receptor can also be found on 
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distinct solid tumors including bladder, lung, pancreatic, breast and prostate cancer 
(O'Connell et al. 2004). CD138 is participating in many cellular functions, such as cell-matrix 
interactions, cell-cell adhesion, migration, signaling and proliferation. It interacts with a 
variety of growth factors all also known to be involved in tumor development including 
fibroblast growth factor 2 (FGF-2), transforming growth factor β 1 (TGF-β1), hepatocyte 
growth factor (HGF) and vascular endothelial growth factor (VEGF) (Bernfield et al. 1992; 
Bernfield et al. 1999; Derksen et al. 2003; Ramani et al. 2013; Lee et al. 2013). BT062, also 
termed indatuximab ravtansine, is an ADC. It is composed of the anti-CD138 antibody 
nBT062 (naked BT062) covalently conjugated to the cytotoxic agent DM4. nBT062 is a 
chimeric IgG4 antibody based on the murine B-B4 precursor. The latter one is shown to bind 
to the linear epitope between residues 90 to 93 of the CD138 core protein (Ikeda et al. 2009; 
Dore et al. 1998). Since nBT062 is an IgG4 antibody, it is not capable to induce ADCC or 
CDC. DM4 is a highly toxic maytansinoid, a chemical derivate of maytansine, which was first 
isolated from the bark of the Ethiopian shrub Maytenus ovatus (Kupchan et al. 1972). An 
average of 3.5 DM4 molecules are attached to one nBT062 via N-succinimidyl-4-(2-
pyridyldithio)butanoate (SPDB) linkers. Currently BT062 is evaluated in clinical trials for the 
treatment of multiple myeloma, breast and bladder cancer. Upon administration to patients, 
BT062 is supposed to bind CD138 on the target tumor cell and gets internalized by 
endosomal uptake (see Figure 1-5). Within the lysosome, the ADC is proteolytically 
degraded leading to the release of DM4. Those free maytansinoids diffuse through the 
lysosomal membrane, bind to the microtubule, inhibit tubulin polymerization and thereby 
induce cell cycle arrest during the G2/metaphase. Finally, this results in the apoptosis 
induction of the tumor cell (Lopus et al. 2010). An additional antitumor effect might be 
mediated by the diffusion of free DM4 molecules into the surrounding tumor cells. In contrast, 
antibody-conjugated DM4 is not able to diffuse through plasma membranes (Weill et al. 
2008). Thus, in line with the restricted CD138 expression pattern in healthy cells and high 
upregulation in a variety of tumors, BT062 should possess low systemic toxicity.  
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Figure 1-5: BT062’s proposed mode of action for tumor cell killing. 
Blood circulating BT062 attaches to membrane-bound CD138, highly overexpressed on the tumor cell's surface 
(1). Once bound, the antibody-drug conjugate (ADC) is internalized by endocytosis (2) and followed by entering 
the lysosome. Proteolytic degradation of BT062 releases the cytotoxic, maytansine-derivate DM4 (3). During cell 
proliferation, DM4 inhibits polymerization of tubulin leading cell cycle arrest within the metaphase (4) and thereby 
inducing tumor cell apoptosis (5). An additional bystander effect may be achieved by diffusion of DM4 molecules 
into surrounding tissue leading to further killing of tumor cells (6) (adaped from Peters, Brown 2015). 
 
1.9 Natalizumab as α4-integrin binding therapeutic antibody 
Natalizumab, commonly known under its trade name Tysabri, is a commercially available 
therapeutic antibody approved for the treatment of multiples sclerosis and Crohn’s disease. It 
is a humanized monoclonal antibody against integrin α4, based on the IgG4 subtype 
containing κ light chains and produced by Biogen Inc. in non-immunoglobulin secreting 
(NS/0) murine myeloma cells (Baldo 2016). Yu et al. have shown that natalizumab binds a 
non-linear epitope of integrin α4 involving the amino acids Gln-152, Lys-201 and Lys-256 (Yu 
et al. 2013). Integrin α4 (CD49d) is a subunit present in integrin α4β1, termed Very Late 
Antigen 4 (VLA-4) and in integrin α4β7, named Lymphocyte Peyer patch adhesion molecule 
(LPAM). Both cell surface receptors are expressed on leukocytes with the exception of 
neutrophils. They are involved in migration of these cells across the endothelium towards an 
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inflamed tissue by interactions with vascular cell adhesion molecule-1 (VCAM-1) and 
mucosal addressin cell adhesion molecule-1 (MAdCAM-1), respectively (Yu et al. 2013; 
Cavaliere et al. 2017). Multiple sclerosis is an autoimmune disease affecting the central 
nervous system (CNS) due to infiltration of mononuclear leukocytes leading to myelin and 
axon damage. Initially, it is characterized by transient inflammation and durable remyelination 
afterwards. Over time, extensive and chronic neurodegradation occurs (Compston, Coles 
2002, 2008). Natalizumab can prevent activated lymphocyte migration across the blood brain 
barrier into the CNS by blocking integrin α4β1 from interactions with VCAM-1 expressed on 
activated vascular endothelial cells and thereby protects neuronal cells from damage of 
inflammatory responses (Yu et al. 2013). Crohn's disease is a relapsing systemic 
inflammatory disease mainly affecting the gastrointestinal tract by inducing immune 
responses against commensal microbiota (Baumgart, Sandborn 2012). MAdCAM-1 is 
expressed on vascular endothelial cells of the gastrointestinal tract and mediates homing of 
lymphocytes to Peyer's patches and their recruitment to sites of inflammation (Ruiz-Velasco 
et al. 2000). By blocking the interaction of MAdCAM-1 on gut endothelial cells with 
lymphocyte-expressed integrin α4β7, natalizumab decreases the recruitment and migration of 
lymphocytes towards the site of infection (Biogen Idec 2013).  
Since natalizumab comprises a wild type IgG4 hinge region without stabilizing mutations, it 
was demonstrated by Labrijn et at. that the therapeutic antibody exchanged half-antibodies 
with endogenous IgG4 in patients affected with multiple sclerosis. Those bispecific antibodies 
were observed by the detection of natalizumab antibodies containing both, λ-L chains beside 
original κ-L chains. Additionally, bispecific natalizumab/IgG4-CD20 antibodies were found in 
vitro after reduced glutathione treatment by online electrospray ionization time-of-flight mass 
spectrometry (LC-ESI-MS) and enzyme-linked immunosorbent assay (ELISA) as well as in 
vivo, after monospecific antibody administration into severe combined immunodeficient 
(SCID) mice (Labrijn et al. 2009). Based on the IgG4 shuffling characterization of 
natalizumab and availability of its DNA sequence, it was used in this study for the 
recombinant generation of a bispecific IgG4 antibody model. 
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2 Aims of this work 
It is known that endogenous human IgG4 antibodies as well as unstabilized therapeutic IgG4 
such as natalizumab undergo half-antibody exchange in vivo and are thus able to form 
bispecific antibodies (Labrijn et al. 2009; Young et al. 2014). Biotest is currently evaluating 
BT062, an ADC consisting of an unstabilized anti-CD138 IgG4 antibody conjugated to the 
cytotoxic agent DM4 in clinical trials. In this thesis it was examined if potential in vivo derived 
IgG4 species of BT062 -as example for unstabilized IgG4-based ADCs- were still functional 
in terms of specific antigen binding, receptor-mediated cellular internalization and induction 
of apoptosis via DM4 release. Furthermore, the direct influence of IgG4 shuffling on the 
therapeutic efficacy was evaluated in vivo.  
To address those issues, beside wild type (WT) nBT062 three further model antibodies 
mimicking potential IgG4-shuffling related variants were recombinantly generated: stable 
nBT062, half nBT062 and bispecific nBT062-natalizumab. All nBT062 variants were 
expressed, purified and characterized by analytical methods. Questions on the antibodies’ 
functionality were investigated by fluorescence-activated cell sorting and fluorescence 
microscopy using human and transgenic, murine cell lines. The nBT062 model variants were 
conjugated to DM4 and resulting CD138-specific ADC models were studied on their cytotoxic 
potency in vitro. The influence of endogenous IgG4 antibodies on the efficacy of the different 
nBT062 variants was assessed in a xenograft mouse model and blood samples of mice were 
analyzed to draw qualitative conclusions with respect to IgG4 half-antibody exchange.  
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3 Methods and Materials 
3.1 Cultivation of mammalian cells 
3.1.1 General cultivation conditions 
NCI-H929, Jurkat, Ba/F3 and Ba/F3-hCD138 cell lines were cultured at 37°C, 5% CO2 and 
100% atmospheric humidity in a static Thermo Scientific Incubator. FreeStyle CHO-S cells 
were cultured at 37°C, 8% CO2 and 100% atmospheric humidity under shaking conditions of 
125 rpm with 3 cm orbit (Kuhner). Cell operations were performed under sterile conditions 
using a lamina flow hood (Thermo Scientific). Cell line specific media are listed in section 
3.8.1. 
3.1.2 Thawing of frozen cells 
Frozen cells were retrieved from liquid nitrogen stocks and were thawed in a 37°C water 
bath. Cells were transferred into a centrifugal tube containing 10 ml of pre-warmed cell 
culture medium and centrifuged at 306 x g for 8 min. The supernatant was discarded, the cell 
pellet was resuspended in 10 ml of the respective growth medium (see section 3.8.1) and the 
cell suspension was transferred into 25 cm2 culture flasks (Sarstedt). 
3.1.3 Passaging for maintenance of suspension cells  
Cell suspensions were split every 3 to 4 days depending on their density. Clustered cells 
were separated by gentle pipetting. The cell number and viability was determined by mixing 
10 µl cell suspension with 10 µl of 0.2% trypan-blue. The solution was transferred to a 
Neubauer cell counting chamber, cells were counted under the microscope and the cell 
number was determined using to the following formula: 
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑚𝑚𝑐𝑐� =  𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∗ 104𝑐𝑐𝑣𝑣𝑐𝑐𝑐𝑐𝑐𝑐𝑣𝑣𝑐𝑐𝑐𝑐 𝑓𝑓𝑣𝑣𝑐𝑐𝑐𝑐𝑐𝑐𝑓𝑓  (I) 
The viability was calculated according to the following formula: 
% 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑐𝑐𝑐𝑐𝑐𝑐𝑣𝑣𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∗ 100 (II) 
The respective cell number was adjusted (see Table 3-1) and the cells were centrifuged at 
300 x g for 8 min. The supernatant was discarded, the cells were resuspended in 
pre-warmed growth medium and transferred into a cultivation flask (25 or 75 cm³). FreeStyle 
CHO-S cells were transferred into shaking flasks (125 or 250 ml). 
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Table 3-1: Doubling time and cell counts of suspension cells. 
Cell line Species Doubling time 
Cell number before 
splitting [cells/ml] 
Adjustment of cell 
number for passaging 
[cells/ml] 
FreeStyle CHO-S Hamster ~ 19 h 1 – 1.5 x106 3 x 105 
NCI-H929 Human ~ 70 h 1 – 1.5 x106 4 x 105 
Jurkat Human ~ 25-30 h 1 – 1.5 x106 1.5 x 105 
Ba/F3 Mouse ~ 21 h 1.2 – 1.8 x 106 0.8 x 105 
Ba/F3-hCD138 Mouse ~ 21 h 1.2 – 1.8 x 106 0.8 x 105 
 
3.1.4 Freezing of cells 
Suspension cells were harvested and counted as described in section 3.1.3. Cells were 
centrifuged at 306 x g for 8 min and the cell pellet was resuspended in freezing medium 
(90% respective growth medium, 10% DMSO) to adjust the cell number to 2x106 cells/ml. 
1 ml of the cell suspension was transferred into each cryovial (Life Technologies), which 
were placed into a Nalgene freezing container (Thermo Fisher Scientific) containing 
2-propanol for constant cooling to -80°C. After 3 days the cryovials were transferred to liquid 
nitrogen for long-term storage. 
 
3.1.5 Generation of transgenic Ba/F3-hCD138 cells 
A stable genetically modified murine Ba/F3 cell line expressing human CD138 was 
generated by Sirion Biotech GmbH (Martinsried, Germany). The coding region of human 
CD138 (933 bp, reference sequence NM_002997) was cloned into the multiple cloning site 
(MSC) of the lentiviral vector pcLV-CMV-MCS-IRES-Puro. The vector contains a 
cytomegalovirus (CMV) promotor for transgene expression, an internal ribosome entry site 
(IRES) as bicistronic element and a puromycin (Puro) resistance gene for positive selection 
of transfected cells. Cloning of the hCD138 into the lentiviral vector was verified by DNA 
sequencing. Lentiviral packaging plasmids and the generated expression vector were 
co-transfected into HEK293TN cells to produce lentiviral HIV-based, vesicular stomatitis virus 
glycoprotein (VSVG) pseudotyped, self-inactivating particles for transduction. Ba/F3 cells 
were incubated with these particles at a multiplicity of infection (MOI) of 50. After 72 h, 
puromycin was added to a final concentration of 0.75 µg/ml and cells were selected for 
12 days.  
For quantification of CD138 expression, transgenic cells were analyzed via semi-quantitative 
real time polymerase chain reaction (qRT-PCR) by Sirion Biotech GmbH. Total RNA of 
Ba/F3-hCD138 cells was isolated and 1 µg was reverse transcribed using a mixture of 
random hexamer and oligo-dT primers. A Light Cycler 480 (Roche) qRT-PCR system was 
used to determine the relative expression level of human CD138 in Ba/F3-hCD138 cells. 
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Murine peptidylprolyl isomerase A (PPIA) was used as housekeeping gene and parental 
Ba/F3 cells were tested as negative control. Results are shown in Table 3-2. 
 
Table 3-2: qRT-PCR results for CD138 expression in Ba/F3-hCD138 cells.  
Cell line Cp* human CD138 Cp* PPIA 
Ba/F3-hCD138 18.36 15.84 
Ba/F3, parental no detection 16.28 
*Cp: crossing point. 
 
Since Ba/F3-hCD138 cells were tested negative for lentiviral particles (< 1 x 103 genomic 
copies/ml) by qRT-PCR using a Lenti X qRT-PCR Titration Kit (Clontech), cells were handled 
under biosafety level 1. 
 
3.2 Generation of different CD138-specific nBT062 antibodies 
3.2.1 Plasmid generation of nBT062 antibody variants  
The protein sequence of WT nBT062 as disclosed in patent WO2009080829, SEQ No. 1 and 
2 (Kraus et al. 2008) was used as basis for the generation of stable nBT062, half nBT062 
and bispecific nBT062-natalizumab molecules. All mutations were introduced in silico into the 
DNA sequence using VectorNTI (Thermo Fisher Scientific) followed by full length DNA 
synthesis and subsequent cloning into pEF expression vectors at Thermo Fisher Scientific, 
Germany.  
3.2.1.1 Sequence design of stable nBT062  
For the generation of stable nBT062 DNA sequence, the stabilizing amino acid mutations 
S228P and R409K (Labrijn et al. 2011) were introduced into respective DNA sequence of the 
WT nBT062 heavy chain. Further, a L235E mutation was introduced into this variant to 
reduce FcγR binding.  
3.2.1.2 Sequence design of half nBT062 
The cysteines building up the disulfide bonds of the hinge region were exchanged by serines 
(C226S + C229S) to create half nBT062. Respective DNA sequences of WT nBT062 heavy 
chains were modified.  
3.2.1.3 Sequence design of bispecific nBT062-natalizumab 
For the generation of the bispecific nBT062-natalizumab antibody, the available CDR and 
framework regions of natalizumab H and L chains as disclosed in patent US5840299 (Bendig 
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et al. 1995) were used. The regions were aligned to the stable nBT062 amino acid sequence 
by SIM tool (Swiss Insitute of Bioinformatics) to identify the respective amino acid sections at 
the DNA level. To ensure correct H - H chain pairing during eukaryotic co-expression of the 
two different H and two different L chains, the 'knobs-into-holes' technology was used (Carter 
2001). It is based on the introduction of sterically complementary regions in the CH3 domains 
of both H chains e.g. by exchanging larger amino acids with smaller ones in the one H chain 
and exchanging smaller amino acids with larger ones in the second H chain. S354C and 
T366W 'knob'-mutations were introduced into the CH3 domain of the nBT062 H chain, while 
Y349C, T366S, L368A, and Y407V 'hole'-mutations were inserted into the CH3 domain of the 
natalizumab H chain. To ensure correct H to L chain pairing, orthogonal Fab interfaces were 
used (Lewis et al. 2014). The nBT062 Fab of the bispecific nBT062-natalizumab was 
modified with D1R and Q38D mutations in the L chain and Q39K and K62E mutations in the 
variable region of the H chain. Q38R, S176W and L135Y mutations were introduced into the 
L chain of the natalizumab Fab of bispecific nBT062-natalizumab, while Q39Y, F174G and 
H172A mutations were applied to the H chain. An overview of the introduced mutations is 
shown in Figure 3-1. 
3.2.1.4 Plasmid cloning 
Full length DNA sequences of the model antibodies were synthesized and cloned into pEF 
expression vectors (Biotest adapted, see appendix 7.1). These vectors contain an origin of 
replication and an ampicillin resistance for prokaryotic replication, a cytomegalovirus (CMV) 
promotor for eukaryotic transgene expression, and a puromycin or methotrexate (MTX) 
resistance gene for positive selection of transfected cells. Puromycin is able to inhibit protein 
translation by binding the A site of the ribosome instead of tRNA and is thus transferred to 
the assembling peptide chain causing its premature release. MTX selection is used in cell 
lines which lack dihydrofolate reductase (DHFR), a protein essential in purine metabolism. 
The DHFR gene is located on the vector and as MTX inhibits DHFR activity it is forcing the 
cells to produce more DHFR and conditionally more recombinant protein of interest. Site-
directed cloning of the antibodies coding regions was performed by insert and vector 
digestion with HindIII and NotI restriction enzymes and subsequent ligation. H and L chains 
of monospecific antibodies WT nBT062, stable nBT062 and half nBT062 were cloned into 
separate vectors containing either a puromycin or a MTX resistance and used for co-
expression.  
To co-express two individual H and two individual L chains of the bispecific nBT062-
natalizumab antibody from two plasmids, a T2A elements was used. The first T2A element 
was originally derived from thosea asigna virus and was shown to enable the expression of 
two proteins from one mRNA (Szymczak, Vignali 2005). This was achieved at the 
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translational level by inducing ribosome skipping (Donnelly et al. 2001a; Donnelly et al. 
2001b). The addition of an N-terminally furin cleavage site leads to the deletion of any C-
terminally introduced spacer residues from the T2A element. The performed cloning 
procedure was as follows: H and L chain sequences of the nBT062 part were synthesized as 
one DNA molecule containing a furin cleaving site and a T2A element (Chng et al. 2015) 
between the individual chains (see Figure 3-1). The DNA was cloned into the pEF vector 
containing a puromycin resistance. H and L chains of the natalizumab part, also separated 
by a furin recognition site and a T2A element, were cloned into the pEF vector harboring a 
MTX resistance.  
The sequences were synthesized and plasmids were delivered in TE buffer by Thermo 
Fisher Scientific as 500 µg plasmid preparations.  
 
 
Figure 3-1: Modified nBT062 and natalizumab DNA constructs for coexpression to generate bispecific 
nBT062-natalizumab.  
The coding regions (CDS) of the synthetic inserts of modified nBT62 and modified natalizumab are shown. Heavy 
chain (HC) and light chain (LC) of each antibody part are transcripted into one mRNA and separation is done on 
the translational level due to a T2A element. For antibody stabilization and to enable correct chain pairing, several 
amino acid substitutions were introduced (highlighted). 
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3.2.2 Expression of different nBT062 antibody variants 
3.2.2.1 Nucleofection of FreeStyle CHO-S cells  
For transfection of WT nBT062, stable nBT062, half nBT062 and bispecific nBT062-
natalizumab plasmid DNA (see section 3.2.1) into FreeStyle CHO-S cells the SG Cell Line 
4D-Nucleoctor X Kit (Lonza) was used. Two days prior to transfection cells were split (see 
section 3.1.3) to ensure that they were in the growth phase. Cells were counted as described 
in section 3.1.3 and 1x106 cells per antibody were centrifuged at 90 x g for 10 min. The 
supernatant was discarded by pipetting and the cell pellet was resuspended carefully in 90 µl 
per 1x106 cells in room temperature, fully supplemented Nucleofector Solution (Lonza, 
included in the kit). 5 µg of each plasmid were gently mixed with 90 µl cell suspension, the 
volume was adjusted to 100 µl with Nucleofector Solution and the cells were subsequently 
transferred into nucleofection cuvettes. Cells were nucleofected using program FF-137 on 
Lonzas 4D-Nucleofector. Subsequently, the nucleofected cells were diluted with 1.5 ml of 
pre-warmed CHO-S expression medium and seeded in one well of a 6 well plate under static 
conditions.  
3.2.2.2 Selection of stable expressing cells 
For the generation of stable cell pools expressing the different nBT062 variants via 
spontaneous plasmid DNA integration into the genome, selection pressure was applied. Two 
days after nucleofection, cells were counted and split into two samples: 2x105 cells/ml were 
seeded into CHO-S expression medium supplemented with either 10 µg/ml puromycin (Life 
Technologies) and 100 nM methotrexate (MTX, Sigma-Aldrich) or 20 µg/ml puromycin and 
200 nM MTX as selection markers. The cells were seeded in 800 µl/well in 12-well plates and 
transferred into a CO2 incubator without shaking. The viability was monitored twice weekly. A 
full media exchange was performed once per week. When the cells entered growth phase, 
they were expanded up to 20 ml cultures and transferred to shaking conditions (see section 
3.1.1). The supernatant of the cell culture was occasionally tested for CD138 specific 
antibody production via electrochemiluminescence assay (see section 3.6.3). Once the 
viability of the cells was stable above >90 %, cells were transferred in CHO-S expression 
medium containing either 30 µg/ml puromycin and 500 nM MTX or 50 µg/ml puromycin and 
1000 nM MTX to boost protein expression in a second selection phase. As soon as the 
viability was stable above 95%, cell pools expressing CD138-specific antibodies were frozen 
to create a master cell bank.  
3.2.2.3 Batch cultivation for antibody production 
Stable cell pools expressing the different antibody variants were cultured as described in 
section 3.1 in their respective selection medium. For batch production 3x 300 ml cells were 
seeded in puromycin- and MTX-free FreeStyle CHO-S Expression Medium at a density of 
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3x105 cells/ml in 1L shaking flasks (Corning). Cells were cultured for 8 days and their viability 
was checked at least three times a week. On day 3 and day 6, 21 ml of complex feed #1 
(Biotest) were added to each culture flask. On day 8, cell suspensions were transferred into 
centrifugation tubes (Corning) and centrifuged for 30 min at 2000 x g. Subsequently, the 
supernatant was sterile filtered using a Mini Kleenpak Fluorodyne II 0.2µm (Pall) filter 
connected to a Watson Marlow 323 Pump. The harvest was stored at -20°C until purification. 
 
3.2.3 Purification of nBT062 variants from cell harvest 
3.2.3.1 Affinity purification with HiTrap MabSelect column 
For purification of antibodies from cell harvests, HiTrap MabSelect 5 ml Protein A affinity 
columns (GE Healthcare) connected to an Äkta Avant 150 system with Unicorn 6.2 software 
(GE Healthcare) were used.  
Supernatants from batch productions were thawed over night at room temperature, the pH 
value was checked and if necessary adjusted to pH ~7 with 1 M NaOH or 1 M HCl. After 
start-up, the tubes of the Äkta system were applied to the respective solutions as described 
in Table 3-3, the pump wash program was performed to remove any air bubbles. The whole 
system was equilibrated with ~25 ml DPBS at a system flow rate of 20 ml/min. The S1 tube 
was carefully transferred from DPBS into the harvest solution and the sequence for 
purification (Table 3-4) was initiated using a system flow rate of 3 ml/min. After the elution 
step, the 50 ml tube containing the purified antibody in 0.1 M citrate buffer pH 3.75 was 
removed from the fractionator and the pH was neutralized to pH ~7 with 1 M Tris base pH 
8.0. Subsequently, buffer exchange against nBT062 formulation buffer was performed using 
Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific). The process was carried out at 
4°C for 2 h, the dialysis buffer was changed and the protein was dialyzed for another 2 h. A 
last dialyzing step was done overnight.  
 
Table 3-3: Äkta Avant 150 connection settings for antibody purification. 
Insert connection tubes Solution 
A1 DPBS 
A2 DPBS + 1M NaCl 
B1 0.1 M citrate pH 3.75 
B2 0.1 M citrate pH 2.7 
S1 System equilibration: DPBS;  
Purification: Harvest 
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Outlet connection tubes Target vial 
Outlet 1 Empty bottle for flow through 
Fractionator A1 Empty tube for column wash 
Fractionator A2 Empty tube for elution 
Fractionator A3 Empty tube for post elution wash 
 
Table 3-4: Sequence for antibody purification. 
Step Buffer Volume 
Equilibration DPBS 10x CV* 
Sample loading Harvest Total (until air) 
Wash 1 DPBS 3x CV* 
Wash 2 DPBS + 1 M NaCl 3x CV* 
Wash 3 DPBS 3x CV* 
Elution 0.1 M citrate pH 3.75 6x CV* 
Post elution wash 0.1 M citrate pH 2.7 3x CV* 
*CV = Column volume 
 
3.2.3.2 Cleaning-in-place (CIP) of HiTrap MabSelect column 
To remove very tightly bound, precipitated or denatured substances and to recover the 
affinity resin in the column, a cleaning protocol was used. Directly after the purification run, 
the insert connection tubes A2, B1, B2, and S1 were transferred into H2O and air bubbles 
were removed by pump wash. B1 was connected to 0.01M NaOH pH 12.0 and a second 
pump wash was performed. A system wash with ~25 ml DPBS using insert connection tube 
A1 was applied and the CIP sequence according to Table 3-5 was initiated with a flow rate of 
3 ml/min. For system and column storage, all insert connection tubes were transferred into a 
20% ethanol solution and the whole system including the column was rinsed. 
 
Table 3-5: CIP sequence for HiTrap MabSelect column. 
Buffer Volume / Time 
DPBS 3x CV* 
0.01 M NaOH pH 12.0 4x CV* 
Incubation break 30 min 
DPBS 10x CV* 
*CV = Column volume 
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3.3 Analytical characterization of nBT062 variants 
3.3.1 SDS-PAGE and Coomassie Brilliant Blue staining 
To separate antibodies according to their molecular weight and determine half-antibody 
proportions, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed. It is based on the potency of proteins to move within an electrical field. The 
intrinsic charge of the proteins is covered by SDS to achieve a proportional ratio of negative 
charge to protein length. Denatured, reducing SDS-PAGE is used to separate the single 
subunits of a protein. For this purpose, a reducing agent is used to disrupt disulfide bonds 
after boiling the samples. Under non-reducing conditions, proteins retain their secondary and 
tertiary structures. 
3.3.1.1 Sample preparation 
Reducing sample preparation 
Antibodies were used at a concentration of 2 mg/ml. Reducing sample buffer was produced 
by combining 2.5 parts of NuPAGE LDS Sample Buffer (4x, Thermo Fisher Scientific) with 1 
part of NuPAGE Sample Reducing Agent (10x, Thermo Fisher Scientific). 15 µl of an 
antibody sample were mixed with 15 µl of reducing sample buffer in a 1.5 ml vial and heated 
for 10 min at 70°C using a thermoshaker (Eppendorf).  
Non-reducing sample preparation 
For production of the non-reducing sample buffer, 1 part of 400 mM N-Ethylmaleimide 
solution (NEM) was mixed with 1 part of NuPAGE LDS Sample Buffer (4x, Thermo Fisher 
Scientific). 15 µl of this solution was transferred into a vial with 15 µl of antibody solution 
(stock concentration 2 mg/ml), mixed by vortexing and incubated for 30 s at 70°C using a 
thermoshaker (Eppendorf). 
3.3.1.2 Electrophoresis procedure 
A Novex 4-12% Tris-Glycine Mini Protein Gel was inserted into the XCell SureLock Mini-Cell 
Electrophoresis System (Thermo Fisher Scientific) and inner and outer chambers were filled 
with 1x MOPS Running buffer (Thermo Fisher Scientific). 7.5 to 10 µl of the prepared sample 
(7.5 – 10 µg) and 10 µl of SeeBlue Plus2 Pre-stained Protein Standard (Thermo Fisher 
Scientific) were loaded onto the gel. The sample separation was achieved by running the gel 
at a constant voltage of 200 V for 45 to 60 min.  
3.3.1.3 Coomassie Brilliant Blue Staining 
Immediately after the run, the gel was transferred into a staining tray filled with approximately 
50 ml of fixation solution and was incubated for 45 min on an orbital shaker (Heidolph) to 
prevent diffusion of the proteins within the gel. To visualize the protein bands, the fixation 
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solution was discarded, 50 ml final staining solution (see section 3.8.4) was added and 
incubated for 2 - 4 h on an orbital shaker. For destaining the background of the gel, the fast-
destaining solution was added for 30 s. Afterwards the gel was destained twice for 10 min 
and once for 16 h with slow-destaining solution. It was scanned using the Argus software on 
Epson Perfection V700 photo. For storage, the gel was transferred into 1% glycerol for 1 h, 
clamped between two cellophane sheets and dried for 3 h in a Gel Air Dryer (Bio-Rad). 
 
3.3.2 Isoelectic focusing and Western Blotting 
Isoelectric focusing is used to separate proteins within a gel matrix based on their relative 
amount of acidic and basic amino acid moieties. Since the protonation status of amino acid 
moieties is pH dependent, proteins are either positively, negatively or not charged. A protein 
net charge of zero is reached at a specific pH-value: the isoelectric point (pI). By loading 
proteins onto a pH-gradient electrophoresis gel and by applying a constant voltage, proteins 
in a pH-range below their pI move within the electric field towards the cathode. Proteins in a 
pH range over their pI migrate towards the anode. All molecules move within the electric field 
until they reach their pI. 
3.3.2.1 Isoelectric focusing procedure 
Isoelectric focusing was performed using the XCell SureLock Mini-Cell electrophoresis 
system (Thermo Fisher Scientific). For sample preparation, antibodies were diluted to a 
concentration of 2 mg/ml with water, subsequently mixed with 50% Novex IEF Sample Buffer 
pH 3-10 (Thermo Fisher Scientific) and 20 µl (5 µg) were applied to a Novex pH 3-10 IEF gel. 
For pH identification, 10 µl of the Serva IEF Marker 3-10 were pipette into a gel pocket. The 
inner system chamber was filled with chilled 200 ml IEF Cathode Buffer (Thermo Fisher 
Scientific) and the outer chamber was filled with chilled 600 ml IEF Anode Buffer (Thermo 
Fisher Scientific). Antibodies were separated in a stepwise process: 100 V for 60 min, 200 V 
for 60 min and 500 V for 30 min. IEF gels were further processed by Coomassie Brilliant Blue 
staining or Western Blotting. 
3.3.2.2 Coomassie Brilliant Blue Staining 
Protein visualization on IEF gels was carried out as already described for Tris-Glycine Mini 
Protein Gels in section 3.3.1.3. The procedure was identical except for the fixation step: IEF 
gels were fixed for 30 min at room temperature in 50 ml 12% trichloroacetic acid/ 3.5% 
sulfosalicylic acid. 
3.3.2.3 Western Blotting 
To further investigate the separated proteins, they were transferred onto a polyvinylidene 
fluoride (PVDF) membrane (Thermo Fisher Scientific) by using the XCell II Blot module 
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(Thermo Fisher Scientific) for semi-wet protein transfer. The PVDF membrane was directly 
applied to the IEF gel and the system was filled with Novex Tris-Glycine Transfer Buffer (25x, 
Thermo Fisher Scientific) according to the manufacturer’s instructions. Protein blotting was 
performed for 1 h at 25 V. After protein transfer, the membrane was blocked over night at 
4°C in Odyssey Blocking buffer (Licor) and incubated afterwards simultaneously with 1 µg/ml 
anti-BT062-Biotin (Biotest) and anti-natalizumab-HRP (Bio-Rad) for 2 h at room temperature. 
Binding of anti-idiotypic antibodies was visualized after 2 h of simultaneous incubation with 
anti-HRP-800CW (Licor) and Streptavidin-680RD (Licor) on Licors Odyssey Imager. 
 
3.3.3 Size exclusion chromatography  
Size exclusion chromatography (SEC) is used to separate proteins based on their 
hydrodynamic radii. SEC columns have a defined pore size, wherein large molecules are not 
retained. In contrast, smaller molecules fit into these pores and are retained. Thus, 
molecules are eluted from the column in reverse order of their molecular weight. Unretained 
compounds are released in the column's void volume defined as the space between particles 
in the resin bed. A fully retained molecule is eluted at the column's included volume defined 
as the sum of the void volume and pore volume. SEC analysis can be performed under 
different buffer conditions, which might either maintain or interrupt covalent and non-covalent 
associations. 
3.3.3.1 Non-denaturing SEC 
To analyze the ability to form aggregates, antibody samples were analyzed by non-
denaturing SEC. A TSKgel G3000 column (Tosoh Bioscience) was connected to the Ultimate 
3000 nano HPLC system (Thermo Fisher Scientific) and used for protein separation. nBT062 
SEC buffer (see section 3.8.6) was applied to the HPLC system on position "buffer A". 
Antibody samples were diluted with DPBS to a concentration of 1 mg/ml in a final volume of 
100 µl and put into the system's autosampler. 100 µl of nBT062 SEC buffer were used as 
negative control. System parameters are listed in Table 3-6 and the program defined in Table 
3-7 was applied for the sample run. Data evaluation was done with Chromelion Software 
(Thermo Fisher Scientific). 
 
Table 3-6: System parameters for non-denaturing SEC. 
System parameter Set value 
Column temperature 30°C 
Autosampler temperature 5 ± 3°C 
Lower pressure limit 5 bar 
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Upper pressure limit 50 bar 
Flow rate 0.25 ml/min 
Injection volume 50 µl 
Detection Absorption at 280 nm 
 
Table 3-7: Program for non-denaturing SEC. 
Step Retention time Pump device 
Injection 0 min 50 µl; Autozero 
Isocratic elution 60 min 100% buffer A 
End 60 min n/a 
 
3.3.3.2 Denaturing SEC 
This test method was used to denature any non-covalently paired half-antibodies by 
isopropanol in the SEC buffer. The percentage of half-antibodies present was determined by 
relating the peak areas of full and half-antibodies obtained by UV detection at 280 nm.  
The experiment was performed on the same system and column as described in section 
3.3.3.1. Denaturing SEC buffer (see section 3.8.6) was applied to the instrument on position 
“buffer A”. Antibody samples were diluted first to a concentration of 1.2 mg/ml with DPBS and 
were further mixed 1:2 with denaturing SEC buffer to a final volume of 100 µl. The samples 
were loaded into the instrument’s autosampler and the run was initiated using the system 
parameters and program settings as indicated in Table 3-8 and Table 3-9. Data evaluation 
was done with Chromelion Software (Thermo Fisher Scientific). 
 
Table 3-8: System parameters for denaturing SEC. 
System parameter Set value 
Column temperature 30°C 
Autosampler temperature 5 ± 3°C 
Lower pressure limit 5 bar 
Upper pressure limit 50 bar 
Flow rate 0.25 ml/min 
Injection volume 50 µl 
Detection Absorption at 280 nm 
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Table 3-9: Program for denaturing SEC. 
Step Retention time Pump device 
Injection 0 min 50 µl; Autozero 
Isocratic elution 60 min 100% buffer A 
End 60 min n/a 
 
3.3.4 In vitro half-antibody exchange testing 
To qualitatively evaluate the prevention of half-antibody exchange due to the incorporation of 
stabilizing S228P and R409K mutations into the IgG4 backbone, antibodies were exposed to 
mild reducing conditions to potentially enable half-antibody formation followed by oxidization 
for random H chain dimerization.  
nBT062 variants were mixed with natalizumab, DPBS and reduced glutathione (GSH) to 
produce a 200 µl solution containing 2 mg/ml of each antibody and 10 mM GSH. The 
antibodies were reduced at 37°C over night at 300 rpm in a thermoshaker (VWR). GSH was 
removed by dialysis against DPBS (2x 4 h) using Slide-A-Lyzer MINI Dialysis Device (Pierce) 
with a 10 kDa molecular weight cut off. The solution was transferred into a 1.5 ml vial and 
oxidized glutathione (GSSG) was added to a final concentration of 5 mM. Random 
reoxidization of half-antibodies was carried out over night at 37°C and 300 rpm. 
 
3.4 Biological characterization of nBT062 variants 
3.4.1 Antibody labeling with Dylight fluorescent dyes 
For direct detection of antibodies during flow cytometric analysis or fluorescence microscopy, 
nBT062 model antibodies and natalizumab were labeled with fluorescent dyes using the 
Dylight 488 (Dy488) antibody labeling kit (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. The conjugation with Dylight dyes is based on activated N-
hydroxysuccinimide (NHS) esters reacting with primary amines within the protein and forming 
stable, covalent amide bonds, while NHS groups are released. Antibody solutions were 
diluted with DPBS to a concentration of 2.2 mg/ml in a final volume of 500 µl and 40 µl of 
0.67 M borate buffer were added. The prepared protein solution was transferred into the vial 
containing the Dylight dye powder and mixed gently by vortexing. The labeling reaction was 
carried out for 60 min at RT in the dark and unbound dye was subsequently removed by kit-
containing dye-removal spin columns. Final antibody concentrations and the antibody-to-dye 
ratios were determined by photometric absorption: 20 µl of the dye-conjugated antibody were 
mixed by pipetting up and down with 180 µl of DPBS and transferred into a UV-transparent 
F-bottom plate (Cell star, Greiner). The absorption was measured at 280 and 493 nm on a 
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POLARstar Omega photometer (BMG Labtech) using DPBS as blank. As indicated in the 
manual, the following formulas were used to calculate the protein concentration and dye-to-
protein ratio: 
𝑃𝑃𝑓𝑓𝑐𝑐𝑐𝑐𝑐𝑐𝑣𝑣𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑓𝑓𝑣𝑣𝑐𝑐𝑣𝑣𝑐𝑐𝑐𝑐 �𝑔𝑔
𝑐𝑐
� = 𝐴𝐴280 − (𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚 ∗ 𝐶𝐶𝐶𝐶)
ε𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
∗ 𝐷𝐷𝐶𝐶 ∗ 𝑚𝑚 (III) 
 
𝑓𝑓𝑣𝑣𝑐𝑐𝑣𝑣𝑐𝑐 𝑐𝑐𝑑𝑑𝑐𝑐:𝑝𝑝𝑓𝑓𝑐𝑐𝑐𝑐𝑐𝑐𝑣𝑣𝑐𝑐 = 𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚 ∗ 𝐷𝐷𝐶𝐶
ε𝐷𝐷𝐷𝐷𝑝𝑝 ∗ 𝑐𝑐𝑃𝑃𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
 (IV) 
DF (dilution factor) 10 
εprotein 210,000 for IgG  
m (specific mass) 150,000 Da 
Amax (Excitation wavelength in nanometers) 493 
CF (Correction factor (A280/Amax)) 0.147 
εDye (Molar extinction coefficient (M-1 cm-1) at Amax) 70,000 
 
Table 3-10: Determined antibody concentration and dye to protein ratio. 
Antibody Concentration [mg/ml] Dye-to-protein ratio 
WT nBT062-Dy488 1.92 2.6:1 
Stable nBT062-Dy488 2.17 2.6:1 
Half nBT062-Dy488 1.82 2.8:1 
Bispecific nBT062-natalizumab-Dy488  1.99 2.7:1 
Natalizumab-Dy488 2.05 2.8:1 
 
3.4.2 Fluorescence-activated cell sorting 
Fluorescent-activated cell sorting (FACS) is based on the principle of flow cytometry. Cells 
are separated and can be individually analyzed for their size, granularity, viability and the 
expression of specific proteins or even proteins’ phosphorylation status. The cell size is 
measured by the forward scatter, while the sideward scatter detects the granularity. The 
viability and the presence of specific surface proteins is determined by DNA-intercalating 
dyes or fluorescent labeled antibodies, respectively. Intracellular proteins can be investigated 
by cell fixation and membrane permeabilization prior to antibody staining. Fluorescent dyes 
are excited by a specific wavelength and subsequently emit light of a longer wavelength. The 
resulting emission spectrum is compared to control cells. By the amount of specifically bound 
antibodies, conclusions can be drawn for expression pattern of proteins. 
3.4.2.1 Procedure for flow cytometric analysis 
Cell density and viability was determined by trypan blue staining as described in section 
3.1.3. The required amount of cells was centrifuged at 300 x g for 8 min, the supernatant was 
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discarded and cells were adjusted to a density of 1.5x106 cells/ml. 100 µl cell suspension 
(100,000 to 150,000 cells) were pipetted into each well of a 96-well U bottom plate and the 
plate was centrifuged at 450 x g for 5 min. The supernatant was discarded.  
Surface binding 
To compare the binding activity of the different nBT062 antibody variants and natalizumab, 
the cells were resuspended in 100 µl of antibody solution containing the respective 
antibodies in a serial dilution ranging from 5x10-7 to 2.82x10-12 mol/L in DPBS/3%FCS. Cells 
were incubated for 30 min at 4°C and subsequently washed twice with DPBS/3%FCS by 
centrifugation at 450 x g for 5 min. The supernatant was discarded by vacuuming and 
pelleted cells were resuspended in 150 µl DPBS/3%FCS. 100 µl of a 10 µg/ml concentrated 
Alexa Fluor 647-labeled goat anti-human secondary antibody was added and cells were 
incubated again for 30 min at 4°C. To remove unbound antibodies, cells were washed twice 
with DPBS/3%FCS, resuspended in 150 µl DPBS/3%FCS and analyzed using a BD FACS 
Canto II flow cytometer (Beckton Dickinson) with FACSDiva Software. Data evaluation was 
done using Flowjo and GraphPad Prism. 
Flow cytometric internalization analysis 
To analyze CD138-mediated antibody internalization, cells were resuspended in 100 µl of a 
15 µg/ml concentrated Dylight-488 labeled antibody solution containing nBT062 variants or 
natalizumab in DPBS/3%FCS (see section 3.4.1). Cells were either incubated for 0.5 h at 
4°C or for 24 h at 37°C to analyze either antibody surface binding or internalization, 
respectively. Cells expressing CD49d were also co-incubated with a 50-times excess of 
natalizumab to block potential CD49d-mediated internalization. After incubation, cells were 
washed once with DPBS/3%FCS and incubated either for 10 min at 4°C with DPBS/3%FCS 
or for 10 min at 37°C with Trypsin to digest CD138 surface receptors including bound 
antibodies. Cells were washed twice with DPBS/3%FCS and analyzed with a FACS Canto II 
flow cytometer with FACSDiva Software. Flowjo and GraphPad Prism were used for further 
data processing. 
 
3.4.3 Fluorescence microscopy 
To investigate the internalization of nBT062 model variants by fluorescence microscopy, 
1.5x105 Ba/F3 (CD138+/CD49-) and Ba/F3-hCD138 (CD138+/CD49-) cells/well were seeded 
into 96-well U-bottom plates (see section 3.4.2.1). Cells were centrifuged at 450 x g for 5 min 
and the supernatant was discarded. Cell pellets were resuspended in 100 µl of the respective 
fluorescently labeled nBT062 antibody variant (see section 3.4.1; 10 µg/ml) in DPBS/3%FCS 
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and incubated for 30 min at 4°C for antibody surface binding. Unbound antibodies were 
washed away by pelleting the cells at 450 x g for 5 min, discarding of the supernatant, 
resuspension of the cells in 150 µl DPBS/3%FCS and another centrifugation and 
resuspension step in 150 µl DPBS/3%FCS. To study internalization of cell surface bound 
antibodies, cells were incubated for 3 h at 37°C. Subsequently, cells were centrifuged at 
450 x g, the supernatant was discarded and the cell pellet was resuspendend in 100 µl 
Trypsin (PAA) to digest surface-anchored CD138 including bound antibodies during 
incubation for 10 min at 37°C.  
Cells were washed once and fixed for 10 min at 37°C in paraformaldehyde (4% in PBS, 
Santa Cruz). After another washing step the cells were permeabilized in 100 µl 0.02% 
Saponin (Sigma-Aldrich) for 30 min at RT. To avoid further unspecific antibody binding, 
intracellular blocking was performed in 1x BMB/DPBS (Boehringer Blocking Agent, Roche) 
for 10 min at RT. Cells were washed twice with DPBS/3%FCS. To investigate the type of 
internalization, lysosomal-associated membrane protein-1 (LAMP1) was costained by 
resuspending the cells with 100 µl of a rabbit anti-LAMP1 antibody solution (Abcam, 1:500 in 
1x BMB/DPBS) and incubation for 30 min at 4°C. Cells were washed twice and incubated for 
30 min at 4°C with 100 µl of a Cy3-labeled goat anti-rabbit H+L secondary antibody (Jackson 
ImmunoResearch, 1:500 in 1xBMB/DPBS). To finalize the samples, cells were washed twice 
with DPBS/3%FCS, resuspended in 40 µl of Prolong Gold Antifade Mountant with DAPI 
(Thermo Fisher Scientific) and transferred onto glass microscopy slides. Samples were cured 
for 24 h in the dark. Fluorescence microscopy and data evaluation was performed using an 
Olympus IX53 inverted fluorescence microscope (Olympus) and cellSens Software 
(Olympus). 
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3.5 Generation and characterization of DM4-conjugated nBT062 
variants 
3.5.1 DM4-conjugation of nBT062 variants 
To generate CD138 specific ADCs, the different anti-CD138 antibodies WT nBT062, stable 
nBT062, half nBT062 and bispecific nBT062-natalizumab were conjugated to the tubulin-
inhibiting maytansinoid DM4 using the conjugation technology developed by Immunogen 
(USA; Figure 3-2).  
In a first step, the antibody formulation buffer was exchanged to buffer A (see section 3.8.9) 
by using illustra NAP-25 columns (GE Healthcare). According to the manufacturer’s 
instructions, columns were pre-equilibrated with 25 ml buffer A. 2.5 ml per antibody variant 
were applied onto the middle of the resin bed followed by an elution step by applying 3.5 ml 
buffer A. The eluate was collected. The procedure was repeated until approx. 25 mg of the 
respective CD138-specific antibody were obtained. Antibody concentrations were determined 
by photometric absorption at 280 nm as described in section 3.5.2 using formula (II). 
Subsequently, antibody solutions were concentrated to approx. 10 mg/ml by using 0.5 ml 
Amicon Ultra 30 kDa molecular weight cut off (MWCO) centrifugation filters (Merck). The N-
succinimidyl-4-(2-pyridyldithio)butanoate (SPDB) linker (Immunogen, solved in 100% 
Ethanol) was added in a 6.5-times molar quantity to the antibody. Buffer A and ethanol were 
added resulting in a final antibody concentration of 8 mg/ml and 5% ethanol. The antibody-
linker conjugation reaction was carried out for 4 h at RT under stirring conditions. 
Unconjugated SPDB linker was removed by the use of illustra NAP-25 columns and the 
concentration was measured by photometric absorption. To conjugate DM4 (N2′-deacetyl-
N2′-(4-mercapto-4-methyl-1-oxopentyl)-maytansine) with the unmodified, functional group of 
the antibody-attached SPDB linker, DM4 (Immunogen, 15 mM in Dimethylacetamid (DMA, 
Merck)) was added in a 7.1-times molar quantity to the antibody. Buffer A and DMA were 
added to a final antibody concentration of 5 mg/ml and 6% DMA. The reaction was 
performed under stirring conditions for 16 h at RT. Unconjugated DM4 was removed and 
buffer was exchanged to BT062 formulation buffer (Biotest) in a single step by using the 
illustra NAP-25 columns as mentioned before. ADC samples were sterile filtered (0.2 µm) 
and the protein concentration and DM4-to-antibody ratio was measured as described in 
section 3.5.2. The half nBT062 was conjugated on the calculation of a full length antibody. To 
mimic the situation of a shuffled antibody in vivo, the bispecific nBT062-natalizumab was 
conjugated with 50% of SPDB and 50% of DM4. 
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Figure 3-2: SPDB modification and DM4 conjugation reactions 
Generation of ADCs by two separated reactions: A: ε-amino groups of lysines in nBT062 variants were randomly 
conjugated with an SPDB linker by acylation and release of N-hydroxysuccinimide (NHS). B: DM4 was 
conjugated to the second functional group of the antibody-attached SPDB linker.  
 
3.5.2 Determination of DM4 to antibody ratio  
To determine the antibody concentration and total amount of DM4 within nBT062-DM4 
variants, 50 to 100 µl of a sample were added to a final volume of 1 ml with BT062 
formulation buffer. Samples were mixed by gentle vortexing, transferred into 1 ml cuvettes 
and the absorbance was measured in duplicates at 252 and 280 nm using an Ultrospec 2100 
pro photometer (Amersham Biosciences). BT062 formulation buffer was used as blank.  
The molar concentration of DM4 was calculated as follows: 
 
𝐷𝐷𝐷𝐷4 [µ𝐷𝐷] = �(𝐴𝐴252 ∗ 𝐷𝐷𝐶𝐶) − (0.344 ∗ 𝐴𝐴280 ∗ 𝐷𝐷𝐶𝐶)� ∗ 100000024377  (V) 
 
Molar BT062 concentration was calculated: 
 
𝐵𝐵𝐵𝐵062 [µ𝐷𝐷] =  (1000000 ∗ 𝐴𝐴280 ∗ 𝐷𝐷𝐶𝐶) − (5180 ∗ 𝐷𝐷𝐷𝐷4 [µ𝐷𝐷])216060  (VI) 
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The DM4-to-antibody ratio (DAR) was calculated: 
 
𝐷𝐷𝐴𝐴𝐷𝐷 = 𝐷𝐷𝐷𝐷4 [µ𝐷𝐷]
𝐵𝐵𝐵𝐵062 [µ𝐷𝐷] (VII) 
 
A252 measured absorption at a wavelength of 252 nm 
0.344 ratio of absorbance of BT062 antibody at 252 nm and 280 nm 
DF dilution factor 
A280 measured absorption at a wavelength of 280 nm 
1000000 conversion factor M : µM 
24377 molar extinction coefficient of DM4 at 252 nm 
5180 molar extinction coefficient of DM4 at 280 nm 
216060 molar extinction coefficient of nBT062 at 280 nm 
 
3.5.3 Determination of DM4 distribution in nBT062-DM4 variants by LC-MS 
analysis 
Human IgG4 antibodies carry approx. 30 lysines in each H chain and 12 lysines in each L 
chain, which are potentially available for the conjugation with SPDB-DM4. Since in ADC 
development a striven average DAR is much lower than the number of conjugatable lysines, 
several species containing different DARs are generated. To investigate the distribution 
range of conjugated DM4 in WT nBT062, stable nBT062, half nBT062 and bispecific 
nBT062-natalizumab model variants, an intact mass spectrometric analysis with upstream 
liquid chromatography (LC-MS) was performed at Triskelion B.V. (Netherlands). In a first 
step, the different molecules in the sample solution were separated by reversed phase LC to 
concentrate the nBT062 variants and to remove residual buffer. During this procedure 
hydrophobic molecules are adsorbed by a hydrophobic solid in a polar mobile phase. 
Decreasing the polarity of the mobile phase reduces the hydrophobic interactions between 
the analytes of the sample and the solid phase leading to desorption. The more hydrophobic 
the analytes, the more time they spend on the column. In a second step concentrated 
nBT062 variants were injected into a mass spectrometer. This analyzer ionizes the injected 
molecules, which are then passed through a mass analyzer for separation by their mass-to-
charge ratio. A detector acquires the signals and the abundance of each ion can be 
calculated.  
Reversed phase LC was performed prior to the MS analysis to enhance the MS signals by 
direct injection of selected protein peaks. A Zorbax RRHD 300-Diphenyl column (Agilent), 
Eluens C and Eluens D (see section 3.8.10) were connected to a Dionex Ultimate 3000 
HPLC System (Thermo Fisher Scientific). The column was heated to 75°C and the auto 
sampler was set to 10°C. 10 µl of each nBT062-DM4 model variant (0.2 – 0.5 µg) was 
injected at a flow rate of 0.5 ml/min running the gradient program as indicated in Table 3-11. 
Methods 
37 
Antibody peaks were detected at 280 nm and peaks between 4.0 and 6.5 minutes were 
directly injected into the Thermo Q Exactive Orbitrap MS instrument using heated 
electrospray ionization (HESI). The resolution was set to 17,500, since the average mass 
determination of the molecular species was accurate and the signal to noise ratio 
appropriate. Further instrument settings are indicated in Table 3-12. Data evaluation and MS 
spectra deconvolution was done using OPTON-20159 Protein Deconvolution software 
(Thermo Scientific). 
 
Table 3-11: Gradient program for reversed phase LC.  
Time (min) % Eluens C % Eluens D Divert value 
0 
80 20 
Waste 
0.5 
MS 
6.5 50 50 
8 10 90 
Waste 
8.5 10 90 
8.6 80 20 
10 80 20 
 
Table 3-12: Thermo Q Exactive Orbitrap Instrument settings. 
Parameter Value 
Spray voltage (kV) 4.0 
Capillary temperature (°C) 275 
Sheath gas 60 
Aux gas 20 
Spare gas 0 
Probe temperature (°C) 320 
S-lens RF level 80 
In-source CID (eV) 80 
AGC target 1e6 
Maximum IT (ms) 100  
Microscan 2 
Scan range (m/z) 1600-6000 
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3.5.4 DM4 conjugation site mapping 
To investigate and identify the DM4 conjugation sites in the different nBT062 model variants, 
peptide mapping was performed at Immungen by LC-MS analysis (USA). 
In a first step, samples were diluted to approx. 2 mg/mL with water prior to desalting. An 
illustra NAP-5 column (GE Healthcare) was equilibrated with 5 mL of ultra-pure water and 
500 µL ADC sample was loaded onto the resin of the NAP-5 column. Subsequently, 1000 µL 
of water was added and the eluate containing the antibody was collected. The desalted ADC 
was dried overnight in a centrifugal vacuum concentrator. The dried conjugate was 
reconstituted by adding 200 µL of denaturing buffer (see section 3.8.11) and 5 µL of 1 M 
dithiothreitol (DTT) solution. Under these conditions disulfide bonds were reduced in order to 
cleave H and L chains and DM4 within the SPDB linker. The sample was incubated at 37°C 
for 1 hour. Alkylation was carried out following addition of 12 µL of 1 M iodoacetic acid at 
ambient temperature in the dark for 40 minutes. The alkylation reaction was quenched by 
adding 7 µL of 1 M DTT solution. 
The alkylated sample was loaded onto another NAP-5 column equilibrated with 5 mL of 
digestion buffer (see section 3.8.11). The column was washed with 500 µL of digestion 
buffer, and the antibody was eluted with another 500 µL of digestion buffer. The protein 
concentration in the eluate was determined by UV absorption spectroscopy so that the 
amount of enzyme needed for digestion can be calculated accordingly. The sample was 
enzymatically digested with trypsin using a protein-to-enzyme ratio of 1:25 (w/w). The 
digestion was stopped by adding 2.5 µL of trifluoroacetic acid (TFA) after 2 hours incubation 
at 37°C. 
A 20 µl aliquot of the digested sample was injected onto a reversed phase C18 column 
connected to a UPLC-QTOF (Waters) LC-MS system. Peptides were separated by applying 
a gradient of eluent A and B (see section 3.8.11) and eluted proteins detected at absorption 
at 280 nm were directly injected into the MS instrument. The UV and mass spectrometry data 
were acquired by MassLynx 4.1 (Waters). The raw LC-MS data were processed using 
Biopharmalynx1.3.2 (Waters) for peptide peak identification.  
 
3.5.5 In vitro cytotoxicity assay 
To determine the cytotoxic effect of DM4-conjugated WT nBT062, stable nBT062, half 
nBT062 and bispecific nBT062-natalizumab model antibodies in vitro, NCI-H929 
(CD138+/CD49d+) cells were incubated with different concentrations of these ADC's for 5 
days. Jurkat (CD138-/CD49d+) cells were used as negative control. Viability of the cells was 
analyzed by WST-1 substrate metabolism. Due to mitochondrial dehydrogenase activity of 
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the cells, the tetrazolium salt WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulfonate) is reduced to formazan, while NADH is oxidized. Thus, the amount 
of formazan detected by absorbance at 450 nm wavelength correlates with the amount of 
viable cells. 
3.5.5.1 Procedure  
NCI-H929 or Jurkat cells were cultured according to section 3.1. On day 0, 18 to 24 h prior 
seeding the cells into 96-wells they were passaged as described. On day 1, viable cells were 
counted by mixing 10 µl of cell culture with 10 µl of 0.2% trypan blue solution and 
subsequent counting in a Neubauer counting chamber. The appropriate amount of cells was 
diluted with respective growth medium to a cell number of 1.12 x 105 cells/ml. To minimize 
evaporation of samples, boarder wells of a 96-well F-bottom plate (CellStar, Greiner) were 
filled with 100 µl medium and the inner wells were filled with 90 µl of the NCI-H929 or Jurkat 
cell solution (10,000 cells/well). Cells were incubated for 18 to 24 h at 37°C and 5% CO2. On 
day 2, DM4-conjugated nBT062 model antibodies were added. Antibodies were diluted with 
assay buffer (see section 3.8.12) to the following concentrations: 40, 10, 4, 2, 1, 0.6, 0.4, 0.2, 
0.1 nM. 10 µl of each antibody concentration were mixed with the respective 90 µl of the cell 
suspension within the plate to results in a 10-times diluted final concentration. As negative 
control, 90 µl of cells were mixed with 10 µl of assay buffer (0 nM). All samples were 
measured in triplicates. Cells were incubated for 120 h at 37°C and 5% CO2. 
On experiment day 7, the viability of the cells was determined by adding 10 µl of WST-1 
(Roche) to each well. Plates were incubated for 3 h at 37°C and 5% CO2. The intensity of the 
WST-1 color reaction was determined by absorbance at 450 nm using a 690 nm reference 
wavelength.  
3.5.5.2 Data evaluation 
Microsoft Excel 2007 was used for primary data evaluation. Average and standard deviation 
of triplicates including the medium samples (blank) were calculated. Grubbs outlier test was 
performed for each triplicate and single values, which did not satisfy the following formula, 
were eliminated: 
𝑐𝑐𝑣𝑣𝑐𝑐𝑔𝑔𝑐𝑐𝑐𝑐 𝑣𝑣𝑣𝑣𝑐𝑐𝑐𝑐𝑐𝑐 − 𝑣𝑣𝑣𝑣𝑐𝑐𝑓𝑓𝑣𝑣𝑔𝑔𝑐𝑐
𝑐𝑐𝑐𝑐𝑣𝑣𝑐𝑐𝑐𝑐𝑣𝑣𝑓𝑓𝑐𝑐 𝑐𝑐𝑐𝑐𝑣𝑣𝑣𝑣𝑣𝑣𝑐𝑐𝑣𝑣𝑐𝑐𝑐𝑐 ≤ 1.513 (VIII) 
1.513: critical value for n=3 at a confidence interval of 95% 
Blank subtracted average OD values were normalized to the positive control (cells incubated 
with 0 nM antibody) including standard deviations of triplicates. A graph of these normalized 
values was drawn as shown in Figure 3-3B (example). The antibody concentration killing 
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50% of the cells, referred to as IC50, was calculated using the next-neighbor method shown in 
Figure 3-3A. 
 
A 
 
𝑚𝑚 =  𝑑𝑑2 − 𝑑𝑑1
𝑥𝑥2 − 𝑥𝑥1 
 
 
(IX) 
 
B
 
 
 
𝐼𝐼𝐶𝐶50 = 𝑥𝑥1 −  𝑑𝑑1 − 0.5𝑚𝑚  
 
 
 
(X) 
Figure 3-3: Determination of IC50 value for cytotoxicity. 
A: Equations of next-neighbor method to determine IC50. B: Example graph of normalized cell viability. X-axis 
shows the antibody concentration, while Y-axis indicates the fraction of viable cells. m and IC50 are marked. 
For further data processing, reciprocal IC50 (rIC50) values were created (see formula XI) and 
normalized to one DM4 molecule per antibody (see formula XII). Finaly, normalization to WT 
nBT062-DM4 was performed.  
𝑓𝑓𝐼𝐼𝐶𝐶50 = 1𝐼𝐼𝐶𝐶50 (XI) 
 
𝑁𝑁𝑐𝑐𝑓𝑓𝑚𝑚𝑣𝑣𝑐𝑐𝑣𝑣𝑁𝑁𝑣𝑣𝑐𝑐𝑣𝑣𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐 𝐷𝐷𝐷𝐷4 𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =  𝑓𝑓𝐼𝐼𝐶𝐶50
𝐷𝐷𝐴𝐴𝐷𝐷 𝑐𝑐𝑓𝑓 𝑐𝑐𝑝𝑝𝑐𝑐𝑐𝑐𝑣𝑣𝑓𝑓𝑣𝑣𝑐𝑐 𝑐𝑐𝐵𝐵𝐵𝐵062 𝑣𝑣𝑣𝑣𝑓𝑓𝑣𝑣𝑣𝑣𝑐𝑐𝑐𝑐 (XII) 
 
For additional visualization of ADC concentration-dependent cell inhibition curves and 
statistical analysis using t-tests, GraphPad Prism was used.  
 
3.6 In vivo efficacy of nBT062-DM4 variants  
3.6.1 Evaluation of nBT062-DM4 variants in a xenograft mouse model 
To evaluate the antitumor activity of DM4-conjugated WT nBT062, stable nBT062, half 
nBT062 and bispecific nBT062-natalizumab in vivo, a study using a mammary cancer 
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xenograft mouse model was performed at Charles River Discovery Research Services 
GmbH (Freiburg).  
3.6.1.1 Xenograft mouse generation 
Tumor samples were derived from surgical specimens from cancer patients and implanted 
subcutaneously into immunodeficient mice. Patient-derived tumor xenografts (PDX) were 
subcutaneously passaged, until a stable growth pattern developed and master stocks were 
frozen after early passaging. In this study the MAXF (Mammary cancer xenograft Freiburg) 
1322 tumor model was used. This tumor model is derived from a metastasis of a 49 year old 
female patient suffering from a mammary adenocarcinoma. 
Immunodeficient female NMRI nu/nu mice (NMRI-Foxn1nu; NMRI nude) were delivered by 
Envigo RMS SARL (France) at the age of four to six weeks and were used for experiments 
after at least one week of acclimatization. Animals were kept under sterile and standardized 
conditions including a 14/10 h light/dark cycle, 25°C and a relative humidity between 40 and 
70%. Feed and water were provided ad libitum.  
MAXF 1322 tumors were raised in donor mice, extracted, cut into 3-4 mm length pieces and 
placed in PBS containing 10% penicillin/streptomycin. Recipient female NMRI nude mice 
were anesthetized by inhalation of isoflurane and were transplanted with tumor implants 
subcutaneously into one flank. Animals and tumors were monitored daily. When tumors 
reached a size between 50-250 mm³, preferably 80-200mm³ (see section 3.6.1.4), mice were 
separated into experimental groups, aiming at comparable median and mean group tumor 
volumes. The day of randomization was set as day 0.  
3.6.1.2 Study design and observation  
The four different model variants WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 
and bispecific nBT062-natalizumab-DM4 were administered intravenously (i.v.) into the tail 
vein either at a dose of 4 mg/kg or of 2 mg/kg. ADCs were given either as monotherapy or in 
combination with 10 ml/kg/dose of an intravenous human Ig preparation (IVIg, Intratect 10%, 
Biotest) to evaluate the influence of endogenous IgG4 on the therapeutic efficacy of nBT062-
DM4 variants. As negative controls, animals received the IVIg preparation or DPBS. ADCs 
were injected using a volume of 5 ml/kg, while the IVIg preparation was given in a volume of 
10 ml/kg. When dosed in combination, the IVIg preparation was given one hour before the 
ADCs. Each drug was injected once weekly for three consecutive weeks and the observation 
phase lasted up to day 86. The dosing schedule and individual groups are shown in Table 
3-13. The mortality was assessed daily, while mouse body weights and absolute tumor 
volumes were measured twice-weekly during the whole study.  
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Table 3-13: Study design for MAXF 1322 xenograft model. 
Group 
ID Therapy Total Daily Dose  
Schedule 
[Dosing days] 
Appl. 
Route 
No. of 
Animals 
1 Vehicle Control 10 ml/kg 1, 8, 15 (h:0) i.v. 5 
2 IVIg 10 ml/kg 1, 8, 15 (h:0) i.v. 5 
3 WT BT062-DM4 4 mg/kg 1, 8, 15 (h:1) i.v. 5 
4 Stable BT062-DM4 4 mg/kg 1, 8, 15 (h:1) i.v. 5 
5 Half BT062-DM4 4 mg/kg 1, 8, 15 (h:1) i.v. 5 
6 
Bispecific BT062-
natalizumab-DM4 
4 mg/kg 1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
7 
IVIg // 
WT BT062-DM4 
10 ml/kg // 
4 mg/kg 
1, 8, 15 (h:0) // 
1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
8 
IVIg //  
Stable BT062-DM4 
10 ml/kg // 
4 mg/kg 
1, 8, 15 (h:0) // 
1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
9 
IVIg // 
Half BT062-DM4 
10 ml/kg // 
4 mg/kg 
1, 8, 15 (h:0) // 
1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
10 
IVIg // 
Bispecific BT062-
natalizumab-DM4 
10 ml/kg // 
4 mg/kg 
1, 8, 15 (h:0) // 
1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
11 WT BT062-DM4 2 mg/kg 1, 8, 15 (h:1) i.v. 5 
12 Stable BT062-DM4 2 mg/kg 1, 8, 15 (h:1) i.v. 5 
13 Half BT062-DM4 2 mg/kg 1, 8, 15 (h:1) i.v. 5 
14 
Bispecific BT062-
natalizumab-DM4 
2 mg/kg 1, 8, 15 (h:1) i.v. 5 
15 
IVIg // 
WT BT062-DM4 
10 ml/kg // 
2 mg/kg 
1, 8, 15 (h:0) // 
1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
16 
IVIg //  
Stable BT062-DM4 
10 ml/kg // 
2 mg/kg 
1, 8, 15 (h:0) // 
1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
17 
IVIg // 
Half BT062-DM4 
10 ml/kg // 
2 mg/kg 
1, 8, 15 (h:0) // 
1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
18 
IVIg // 
Bispecific BT062-
natalizumab-DM4 
10 ml/kg // 
2 mg/kg 
1, 8, 15 (h:0) // 
1, 8, 15 (h:1) 
i.v. // 
i.v. 
5 
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3.6.1.3 Blood sampling 
Blood was taken by retro-orbital sinus puncture during isoflurane anesthesia and directly 
transferred into standard plasma vials containing lithium heparin as anticoagulant. The blood 
was incubated for 10 min at RT, centrifuged at 2875 x g for 10 min and plasma was 
collected. Heparin plasma samples were collected from all animals one week before therapy, 
24 h after the first and 24 h after the third injection. Plasma samples were stored at -80°C. 
3.6.1.4 Data Evaluation 
Tumor volumes were calculated using formula (XIII) and normalized relative to study day 0. 
𝑐𝑐𝑐𝑐𝑚𝑚𝑐𝑐𝑓𝑓 𝑣𝑣𝑐𝑐𝑐𝑐𝑐𝑐𝑚𝑚𝑐𝑐 = (𝐴𝐴 ∗ 𝐵𝐵2) ∗ 0.5 (XIII) 
A= largest tumor diameter 
B= perpendicular tumor diameter  
 
The test versus control value (T/C in %) was assessed as median relative tumor volume 
(RTV) of the test group compared to the control group according to formula II. Criteria for 
efficacy rating are shown in Table 3-14. 
𝐵𝐵 𝐶𝐶𝑚𝑚⁄ [%] = 𝑚𝑚𝑐𝑐𝑐𝑐𝑣𝑣𝑣𝑣𝑐𝑐 𝐷𝐷𝐵𝐵𝑅𝑅𝑚𝑚  𝑐𝑐𝑓𝑓𝑐𝑐𝑣𝑣𝑐𝑐𝑐𝑐𝑐𝑐 𝑔𝑔𝑓𝑓𝑐𝑐𝑐𝑐𝑝𝑝𝑚𝑚𝑐𝑐𝑐𝑐𝑣𝑣𝑣𝑣𝑐𝑐 𝐷𝐷𝐵𝐵𝑅𝑅𝑚𝑚  𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑓𝑓𝑐𝑐𝑐𝑐 𝑔𝑔𝑓𝑓𝑐𝑐𝑐𝑐𝑝𝑝 ∗ 100 (XIV) 
 
Table 3-14: Tumor control efficacy criteria. 
Classification T/C* 
Inactive >65% 
Borderline 50% – <65% 
Moderate 25% – <50% 
High 10% – <25% 
Very high 5% – <10% 
Complete remission <5% 
*T/C=median tumor volume in test group/median 
tumor volume in control group 
 
To illustrate tumor growth curves, tumor volumes of animals that were sacrificed due to their 
tumor load were further included using the Last-Observation-Carried-Forward methodology 
for as long as this increased the group’s median tumor volume.  
The non-parametric Kruskal-Wallis test followed by Dunn’s method for pairwise comparisons 
(Kruskal, Wallis 1952; Dunn 1964) was used to determine significance of the anti-tumor 
activity of applied antibodies. To evaluate the differences in time to tumor progression, the 
cut off of absolute tumor volume was set to 2000 mm² and Kaplan-Meier survival-style 
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statistics combined with the log-rank Mantel-Cox test for pairwise comparisons were 
employed (Kaplan, Meier 1958) using GraphPad Prism.  
 
3.6.2 Determination of bispecific antibody formation in xenografts 
Plasma samples obtained as described in section 3.6.1.3 from the MAXF 1322 xenograft 
mouse study were analyzed by a hybrid ligand binding assay (LBA)/LC-MS method at 
Triskelion, Netherlands. The aim was to determine the formation of bispecific antibodies in 
the different nBT062-DM4 model variants administered as monotherapy or in combination 
therapy with the IVIg preparation containing human IgG4 antibodies.  
In brief, DM4-conjugated nBT062 model variants were purified from murine plasma samples 
using an anti-BT062 idiotypic antibody immobilized to magnetic beads. nBT062-DM4 variants 
were eluted from beads, denatured, reduced, alkylated, and digested with trypsin. During 
method development the amino acid sequence TIYNEK was identified as signature peptide 
unique for nBT062. GLPSSIEK was obtained as a generic peptide for IgG4 antibodies. 
Prepared samples were analyzed by ultra-performance liquid chromatography - tandem 
mass spectrometry (UPLC-MS/MS) together with spiked stable isotope labeled internal 
standard peptides of TIYNEK and GLPSSIEK. Concentrations of nBT062-DM4 variants were 
calculated including the fraction of bispecific antibodies formed by calculating the ratio of 
TIYNEK to GLPSSIEK. 
3.6.2.1 Purification of nBT062 variants from murine plasma 
Prior to antibody loading, 50 µl Streptavidin beads (Merck Millipore) were washed with 200 µl 
PBS by removing the liquid with a pipette while the tube was placed into a magnetic rack 
attracting the beads to the tubes wall and subsequent addition of PBS. 10 µl of a 100 µg/ml 
concentrated biotinylated anti-BT062 antibody (Biotest) was added and immobilized onto the 
beads for 60 min at 1000 rpm on a shaker. The supernatant was removed and unconjugated 
binding sites on the beads were blocked with 200 µl of a 5% BSA/PBS solution for 15 min at 
1000 rpm. Beads were washed three times with 200 µl PBS and finally resuspended in 
200 µl PBS. 10 µl of murine lithium heparin plasma (sample) were added and specific 
nBT062 variant binding was carried out for 60 min at 1000 rpm on a thermoshaker at 22°C. 
Beads were washed three times with PBS and nBT062 variants were eluted by addition of 
50 µl 100 mM glycine –HCl pH 2.5 buffer followed by subsequent incubation at 95°C for 
10 min and 1000 rpm. The liquid containing the purified nBT062 variant was transferred into 
a new vial and 10 µl of stable isotope labeled internal standard peptides TIYNEK-13C615N2 
and GLPSSIEK-13C615N2 (50 ng/ml) were added. To denature and reduce the protein 
samples, 10 µl of 1% Rapigest (in 100 mM ammonium bicarbonate buffer) and 6 µl of 0.2 M 
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DTT were added into the vial. Incubation was performed for 10 min at 1000 rpm. Samples 
were alkylated with 35 µl of 0.1 M Iodoacetic acid (IAA, in 100 mM ammonium bicarbonate 
buffer) incubated for 30 min in the dark. The reaction was quenched by adding 3 µl 0.2 M 
DTT followed by subsequent incubation for 20 min at 37°C and 1000 rpm shaking. Protein 
digestion was achieved by adding 70 µl of a 100 µg/ml trypsin solution (in 100 mM 
ammonium bicarbonate buffer) into the vial and incubation was performed for 150 min at 
37°C and 1000 rpm. Trypsin specifically cleaves the protein primary structure C-terminally of 
each lysine (K) and arginine (R). The digestion reaction was terminated by adding 18 µl of 
acetonitrile solution containing 5% TFA and 10% formic acid (FA), incubated for 10 min at 
37°C and 1000 rpm.  
3.6.2.2 UPLC-MS/MS analysis of prepared nBT062 variant samples 
Prepared nBT062 variant samples were quantitatively analyzed with respect to the presence 
of the signature peptide TIYNEK of nBT062 and of the generic GLPSSIEK peptide specific 
for IgG4 antibodies using a UPLC-MS/MS method. 0.1% FA in milliQ water and 0.1% FA in 
acetonitrile were applied to an Acquity UPLC system (Micromass Waters) as mobile phase A 
and B, respectively. The autosampler was set to 10°C. 10 µl of a prepared sample (see 
section 3.6.2.1) were injected into the system and separated on an Acquity HSS T3, 100 x 
2.1 mm, 1.8 μm column (Waters) using the phase gradient as depicted in Table 3-15. The 
flow rate was set to 500 µl/min and a column temperature of 50°C was applied. Samples 
were injected into the connected XEVO TQS (Micromass Waters) mass spectrometer using 
an electrospray ionization (Positive mode) and a capillary of 0.7 kV. The source temperature 
was set to 150°C, the desolvation temperature to 600°C. A cone gas flow of 150 L/h and 
desolvation gas flow of 1200 L/h was used.  
 
Table 3-15: UPLC phase gradient for bispecific antibody detection via UPLC-MS/MS. 
Time (min) Mobile phase A (%) Mobile Phase B (%) Divert valve 
0 95 5 Waste 
0.25 95 5  
1   LC 
3.9 65 35  
5 0 100  
6 0 100 Waste 
6.5 95 5  
8 95 5  
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3.6.2.3 Data evaluation 
A BT062-DM4 reference standard (50 - 0.1 µg/ml) was added directly into pooled murine 
heparin plasma and used as calibration within each run. For data evaluation, Masslynx 
software was used to determine the peak areas and the calibration curve equation was 
calculated in Microsoft Excel. The resulting calibration curve was used to calculate the 
concentrations in all samples. Outlying results as determined by the Dixon's Q test were 
excluded. The ratios of both signature peptides GLPSSIEK and TIYNEK were calculated and 
processed as follows: ratio GLPSSIEK:TIYNEK≤1 matches 0% of IgG4 shuffling, while a 
ratio GLPSSIEK:TIYNEK=2 matches 100% half-antibody exchange. Graphical display and 
statistical t test was performed using GraphPad Prism. 
 
3.6.3 Anti-CD138 antibody detection using an electrochemiluminescence 
assay 
For quantitative detection of anti-CD138 antibodies in supernatants from nBT062 variant 
expressing cells or IVIg preparations, Meso Scale Discovery's (MSD) 
electrochemiluminescence (ECL) platform was used. This platform uses a Sulfo-Tag marker 
molecule, which is a derivate of Tris(2,2-bipyridyl)-ruthenium(II)-chloride (Ru(bpy)3) for 
detection. When applying a voltage to the graphite electrode at the bottom of a multi-array 
plate, Ru(bpy)3 is oxidized. Simultaneously, the buffer ingredient tripropylamine (TPA) is 
oxidized by creating a radical. The reaction of both molecules leads to a complex with an 
excited energy state. Due to the emission of light at 620 nm, this complex passes back to 
ground state (see Figure 3-4A).  
This detection strategy used for anti-CD138 antibody quantification is shown in Figure 3-4B: 
Soluble CD138 proteins were coated to a surface and solutions containing potential 
anti-CD138 antibody variants were added for binding. To detect bound CD138-specific 
antibodies, biotin-conjugated anti-human antibodies were used (see section 3.8.13). 
Visualization was achieved by adding a Streptavidin-conjugated marker. 
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Figure 3-4: Detection of anti-CD138 antibodies by electrochemiluminescence  
A: Detection principle of Meso Scale Discovery’s electrochemiluminescence plattform. Ru(bpy)3 attached to the 
protein of interest forms a complex with tripropylamine (TPA) when applying a voltage. A subsequent complex-
decay results in the emission of detectable light (adapted from Meso Scale Diagnostics 2013). B: Schematic 
assay design: soluble CD138 is coated onto a Multi-Array plate. Anti-CD138 antibodies within a test solution are 
captured and subsequently detected by an biotinylated anti-human antibody itself captured by a streptavidin-
conjugated Sulfo-Tag (Ru(bpy)3). 
 
3.6.3.1 Procedure 
Coating of plates 
Freeze-dried soluble CD138 (sCD138, R&D Systems) was reconstituted according to the 
manufacturer’s instructions. A coating solution containing 1 µg/ml sCD138 in PBS was 
prepared and 50 µl were transferred into each well of a 96-well standard multi array plate 
(MSD). Soluble CD138 was coated during an incubation of 4 h at RT and 600 rpm shaking 
conditions. Uncoated proteins were washed away with three cycles of liquid aspiration and 
subsequent addition of 150 µl washing solution (see section 3.8.13) into each well using the 
automated Tecan plate washer (Tecan). After the last washing cycle the supernatant was 
aspirated. 
Preparation of test- and standard samples 
Natalizumab was used as negative control and nBT062 was used as positive control. Both 
antibody standards were diluted with PBST-KS blue (Biotest) to an initial concentration of 
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100 µg/ml and 10-times serial dilutions up to 0.01 ng/ml were prepared. IVIg preparations 
and cell culture supernatants were also prepared in 10-times serial dilutions. 200 µl of 
standards and test samples were transferred into respective wells of the sCD138-coated 
plate. All approaches were measured in triplicates. For homogenization, the plate was 
shaken for 1 min at 600 rpm and incubated for approx. 16 h stationary. 
Detection of anti-CD138 antibodies 
The plate was washed as described above. 50 µl of a biotinylated goat anti-human IgG 
antibody (Jackson ImmunoResearch, 15 ng/ml in PBST-KS blue) were added into each well 
and the multi array plate was incubated for 60 min at 600 rpm to enable antibody binding. 
Unbound detection antibodies were removed by applying the washing program. Streptavidin-
conjugated SulfoTag (MSD) was diluted with PBST-KS blue to a concentration of 0.5 ng/ml 
and 50 µl were transferred to each well. After an incubation of 20 min at 600 rpm, the plate 
was washed. Read buffer T (MSD) was diluted 1:4 with water and each well was filled with 
150 µl of the solution. After 2 min of incubation at 600 rpm, the ECL signal was detected 
using a MSD Sector Imager 6000. Data evaluation was done using GraphPad Prism 6. 
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3.7 General reagents and kits 
Reagent Manufacturer/ Supplier Cat.-No. 
2-propanol Merck 1070222511 
BT062 Biotest AG  
BT062 formulation buffer Biotest  
DM4 Immunogen Inc.  
Dulbecco's Balanced Salt Solution (DPBS) Thermo Fisher Scientific 14190136 
Ethanol 100% Merck 1009831000 
Hydrochloric acid (HCl), 5 mol/L Merck 4807915000 
nBT062 Biotest AG  
Sodium hydroxide (NaOH) Solution, 5 mol/L Merck 1099130001 
Tysabri (natalizumab) Biogen Idec  
   
 
Kits 
  
Dylight 488 Amine-Reactive  
Labeling Kit 
Pierce / 
Thermo Scientific 
53024 
   
 
3.8 Approach specific reagents, buffers and solutions 
3.8.1 Cell cultivation 
Cell line Manufacturer/ Supplier 
FreeStyle CHO-S Thermo Fisher Scientific (R80007) 
Jurkat ATCC (TIB-152) 
NCI-H929 ATCC (CRL-9068) 
Ba/F3 DSMZ (ACC 300) 
Ba/F3-hCD138 Sirion Biotech GmbH / Biotest AG 
 
 Final concentration Total addition 
FreeStyle CHO-S medium 
FreeStyle™ CHO Expression Medium (Thermo 
Fisher Scientific, 12651014) 
 1000 ml 
For Selection: Puromycin (Thermo Fisher Scientific, 
A1113803) and MTX (Sigma-Aldrich, M8407) as 
described in Section 3.2.2.2 
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Jurkat medium   
RPMI 1640 with L-glutamine (Lonza, BE12-702F)  500 ml 
Fetal Bovine Serum (PAA, A15-105) 10% 55 ml 
L-glutamine (100x, Lonza, BE17-605E) 2 mM 5.5 ml  
HEPES Puffer (100x, Gibco, 15630-056) 10 mM 5.5 ml 
sodium pyruvate (100x, Gibco, 11360-039) 1 mM 5.5 ml 
   
NCI-H929 medium   
RPMI 1640 with L-glutamine (Lonza, BE12-702F)  500 ml 
Fetal Bovine Serum (PAA, A15-105) 10% 55 ml 
L-glutamine (100x, Lonza, BE17-605E) 2 mM 5.5 ml 
   
Ba/F3 medium   
RPMI 1640 with L-glutamine (Lonza, BE12-702F)  500 ml 
Fetal Bovine Serum (PAA, A15-105) 10% 55 ml 
L-glutamine (100x, Lonza, BE17-605E) 2 mM 5.5 ml 
Murine Interleukin-3 (R&D Systems, 403-ML-010),      
directly added to flask 
10 ng/ml 20 µl per  
20 ml cells 
   
Ba/F3-hCD138   
RPMI 1640 with L-glutamine (Lonza, BE12-702F)  500 ml 
Fetal Bovine Serum (PAA, A15-105) 10% 55 ml 
L-glutamine (100x, Lonza, BE17-605E) 2 mM 5.5 ml 
Puromycin (Gibco, A11138-03) 0.375 ng/ml 21 µl 
Murine Interleukin-3 (R&D Systems, 403-ML-010),      
directly added to flask 
10 ng/ml 20 µl per  
20 ml cells 
   
 
3.8.2 Expression of Antibodies 
 
 
 
  
Reagent Manufacturer/ Supplier Cat.-No. 
SG Cell Line 4D-Nucleoctor X Kit Lonza V4XC-3024 
Complex feed #1 Biotest n/a 
Mini Kleenpak Fluorodyne II 0.2µm filter Pall KA02DFLP8G 
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3.8.3 Antibody affinity purification 
 Final concentration Total addition 
0.1 M citrate buffer pH 3.75   
Citric acid (Merck, #100247 0.1 M 19.21 g 
Adjust pH to 3.75   
MilliQ-H2O  Ad 1000 ml 
   
0.1 M citrate buffer pH 2.7   
Citric acid (Merck, #100247) 0.1 M 19.21 g 
Adjust pH to 2.7   
MilliQ-H2O  Ad 1000 ml 
   
1M Tris-base pH 8.0   
Tris-base (Prolabo, #103156X) 1 M 12.11 g 
Adjust pH to 8.0   
MilliQ-H2O  Ad 100 ml 
 
3.8.4 SDS-PAGE 
 Final concentration Total addition 
Fixation solution    
Methanol (Merck, 1.06009.2511) 37.2% 372 ml 
Acetic acid 100% (VWR, 20102.292) 7% 70 ml 
MilliQ-H2O  Ad 1000 ml 
   
Staining solution   
Reagent 1   
Coomassie Brilliant Blue (Sigma, B0770) 1 g/L (in final solution) 0,5 g 
MilliQ-H2O  Ad 10 ml 
Material/Reagent Manufacturer/ Supplier Cat.-No. 
HiTrap MabSelect 5 ml Protein A column GE Healthcare 28-4082-55 
Slide-A-Lyzer dialysis cassettes, 10kDa MWCO Thermo Fisher Scientific 66807 
   
Reagent Manufacturer/ Supplier Cat.-No. 
Novex 4-12% Tris-Glycine Gel Thermo Fisher Scientific NP0335PK2 
NuPAGE LDS Sample buffer, 4x Thermo Fisher Scientific NP0007 
NuPAGE Sample reducing agent, 10x Thermo Fisher Scientific NP0009 
NuPAGE  MOPS SDS Running buffer, 20x Thermo Fisher Scientific NP0001 
SeeBlue Plus2 Protein Standard Thermo Fisher Scientific LC5925 
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Reagent 2 
  
Orthophosphoric acid 85% (Merck, 1.00552.0250) 20 g/L 10 g 
Ammonium sulfate (Merck, 1.01211.1000) 150 g/L 75 g 
MilliQ -H2O  Ad 500 ml 
Stock staining solution 
  
Reagent 1 2% 10 ml 
Reagent 2 98% 490 ml 
Final staining solution   
Stock staining solution 80% 40 ml 
Methanol (Merck, 1.06009.2511) 20% 10 ml 
   
Fast-destaining solution   
Methanol (Merck, 1.06009.2511) 25% 250 ml 
Acetic acid 100% (VWR, 20102.292) 10% 100 ml 
MilliQ -H2O  Ad 1000 ml 
   
Slow-destaining solution   
Methanol (Merck, 1.06009.2511) 25% 250 ml 
MilliQ -H2O  Ad 1000 ml 
   
Glycerol solution   
Glycerol (VWR, 444482V) 1% 1 g 
MilliQ -H2O  Ad 100 ml 
   
400 mM NEM solution   
N-Ethylmaleimide (Merck, 34115) 0.4 M 0.05g 
MilliQ -H2O  1 ml 
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3.8.5 Isoelectric focusing 
 
 
 Final concentration Total addition 
Fixation solution 
Trichloroacetic acid (Merck, 1.00807.1000) 120 g/l 120 g 
Sulfosalicylacid dihydrat (Merck, 8.00691.0250) 35 g/l 35 g 
MilliQ -H2O  Ad 1000 ml 
   
 
3.8.6 Size exclusion Chromatography 
 
 Final concentration Total addition 
nBT062 SEC buffer 
Reagent A 
Na2HPO4 (Merck, 1.06580) 0.2 M 35.6 g 
MilliQ -H2O  Ad 1000 ml 
   
Reagent B   
NaH2PO4 (Merck, 1.06345) 0.2 M 31.2 g 
MilliQ -H2O  Ad 1000 ml 
   
Add Reagent B into A until pH 7.0 is obtained   
  
Reagent Manufacturer/ Supplier Cat.-No. 
Novex IEF Sample Buffer pH 3-10 (2X) Thermo Fisher Scientific LC5311 
IEF Marker 3-10 Serva 39212.01 
Novex pH 3-10 IEF Protein Gels Thermo Fisher Scientific 56015 
Novex IEF Cathode Buffer pH 3-10 (10X) Thermo Fisher Scientific LC5310 
Novex IEF Anode Buffer (50X) Thermo Fisher Scientific LC5300 
PVDF Transfer Membrane, 0.45 µm Thermo Fisher Scientific 88585 
Novex Tris-Glycine Transfer Buffer (25X) Thermo Fisher Scientific LC3675 
Odyssey Blocking Buffer (PBS) Licor 927-40000 
Anti-natalizumab-HRP, IgG1 Bio-Rad HCA249P 
Biotinylated Anti-BT062 idyotype antibody Biotest  
Anti-HRP-800CW (Chemi-IR Detection Kit) Licor 926-32236 
Streptavidin-680RD Licor 926-68079 
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Denaturing SEC buffer   
K2HPO4 (Merck, 1.05104) 0.1 M 11.12 g 
KH2PO4 (Merck, 1.04877) 0.1 M 8.72 g 
KCl (Merck, 1.04936) 0.25 M 11.92 g 
Adjust pH to 7.0   
MilliQ -H2O  Ad 800 ml 
2-propanol (Merck, 1.00995) 20% 200 ml 
   
 
3.8.7 In vitro half-antibody exchange analysis 
 
 Final concentration Total addition 
GSH solution 
Reduced glutathione (Sigma, G6013) 100 mM 30.73 mg 
MilliQ -H2O  1 ml 
   
GSSG solution   
Oxidized glutathione (Sigma, G4376) 100 mM 61.26 mg 
MilliQ -H2O  1 ml 
 
3.8.8 Fluorescence microscopy 
 
 
 Final concentration Total addition 
0.02% Saponin 
Saponin (Merck, ) 0.02% 20 mg 
DPBS  Ad 100 g 
   
1x BMB/PBS   
Reagent A   
Maleic acid (Sigma-Aldrich, M0375-500G) 100 mM 11.6 g 
NaCl (Merck, 1064045000) 250 mM 14.61 g 
MilliQ -H2O  Ad 1000 ml 
Reagent Manufacturer/ Supplier Cat.-No. 
Paraformaldehyde, 4% in PBS Santa Cruz 30525-89-4 
Rabbit anti-LAMP1 antibody Abcam ab24170 
Cy3-labeled goat anti-rabbit H+L Jackson 
ImmunoResearch 
111-165-003 
Prolong Gold Antifade Mountant with DAPI Thermo Fisher Scientifc P36935 
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Reagent B (BMB 10x Stock)   
Blocking Reagent (BMB, Roch, 11096176001) 10 % 10 g 
Reagent A  Ad 100 g 
   
1xBMB/PBS (final solution)   
Reagent B 10 % 10 ml 
DPBS  Ad 100 ml 
 
3.8.9 DM4-conjugation of antibodies 
 
 
 Final concentration Total addition 
Buffer A 
KH2PO4  (Merck, 1.04877) 50 mM 6.8 g 
NaCl (Merck, 1064045000) 50 mM 2.922 g 
EDTA (Sigma-Aldrich, 34103-500GM) 2 mM 0.744 g 
Adjust pH to 6.5   
MilliQ -H2O  Ad 1000 ml 
 
3.8.10 DM4 distribution analysis by LC-MS 
 Final concentration Total addition 
Eluens C    
Isopropanol (Merck, 1096341011) 2% 20 ml 
Trifluoroacetic acid (Merck, 8082600500) 0.1% 1 ml 
MilliQ-H2O  Ad 1000 ml 
   
Eluens D    
Acetonitrile (Merck, 1000032500) 10% 100 ml 
Isopropanol (Merck, 1096341011) 20% 200 ml 
Trifluoroacetic acid (Merck, 8082600500) 0.1% 1 ml 
MilliQ-H2O  Ad 1000 ml 
 
Reagent Manufacturer/ Supplier Cat.-No. 
SPDB Linker Immunogen n/a 
DM4 Immunogen n/a 
Dimethylacetamid (DMA) Merck 8032351000 
Reagent Manufacturer/ Supplier Cat.-No. 
Zorbax RRHD 300-Diphenyl, 1.8 μm, 2.1x100mm Agilent 858750-944 
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3.8.11 DM4 conjugation site mapping by LC-MS 
 Final concentration Total addition 
Denaturing buffer   
Guanidine HCl 6 M  
Tris-HCl 1.2 M  
Adjust pH to 7.74   
MilliQ Water  Ad 1000 ml 
   
Digestion buffer   
Tris-HCl 50 mM  
CaCl2 1 mM  
pH 8.0   
MilliQ water  Ad 1000 ml 
   
Eluent A    
Acetonitrile (Merck,1000032500) 2% 20 ml 
Trifluoroacetic acid (Merck, 8082601000) 0.05% 0.5 ml 
MilliQ-H2O  Ad 1000 ml 
   
Eluent B   
Acetonitrile (Merck, 8082601000) 80% 800 ml 
Trifluoroacetic acid 0.05% 0.5 ml 
MilliQ-H2O  Ad 1000 ml 
 
3.8.12 Cytotoxcity Assay 
 Final concentration Total addition 
Assay buffer   
Bovin serum albumin  0.1% 0.5 g 
DPBS  Ad 500 ml 
Adjust pH to 7.74   
   
 
Reagent Manufacturer/ Supplier Cat.-No. 
1 M DTT Merck 20-265 
Trifluoroacetic acid Merck 8082601000 
Reagent Manufacturer/ Supplier Cat.-No. 
WST-1 Roche 11 644 807 001 
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3.8.13 Anti-CD138 antibody detection assay 
 Final concentration Total addition 
Washing solution   
Bovin serum albumin  0.1% 0.5 g 
PBS  Ad 500 ml 
Adjust pH to 7.74   
 
3.9 Laboratory equipment 
Equipment Manufacturer Type 
96-Well plate, U-bottom Greiner  CellStar , No. 650180 
Äkta chromatography system GE Healthcare Äkta Avant 150 
Illustra NAP-25 columns GE Healthcare 17-0852-01 
Illustra NAP-5 columns GE Healthcare 17-0853-01 
Amicon Ultra 0.5 ml 30 kDa Merck UFC503096 
Sterile filter 0.2 µm VWR 514-0064 
Peristaltic pump Watson Marlow 323 
12-Well plate, F-bottom VWR No. 734-2778 
Blotting Paper Sigma-Aldich Whatman 3MM papers 
Nucleofector Lonza Lonzas 4D-Nucleofector 
Cell count chamber Neubauer; VWR 631-1131 
Cell culture flask Sarstedt 25 cm³; 75 cm³ 
Cell culture cryogenic tubes Nunc / Thermo Scientific 1.8 ml, No. 377267 
Cell culture shaking flask Corning 125 ml, 250 ml, 500 ml, 1 L 
Cell freezing container Nalgene / Thermo Scientific Mr. Frosty, No. 5100-0001 
Centrifuge Thermo Scientific Heraeus Multifuge 3L-R 
rotor: 75006445 
Centrifuge tube VWR 50 ml, No. 525-0224 
CO2 incubator, static Thermo Scientific HeraCell 240i 
CO2 incubator, shaking Kuhner Climo-Shaker ISF1-X 
Dialysis Devices, 500 µl,  
    10K MWCO 
Pierce / Thermo Scientific Slide-A-Lyzer MINI Dialysis; 
No. 88401 
Reagent Manufacturer/ Supplier Cat.-No. 
sCD138 R&D Systems 2780-SD-050 
biotinylated goat anti-human IgG antibody Jackson 
ImmunoResearch 
109-066-097 
Streptavidin SULFO-TAG Labeled Meso Scale Discovery R32AD-1 
Read Buffer T (4x) Meso Scale Discovery R92TC 
PBST-KS blue Biotest 1081 
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Electrophoresis chamber Thermo Scientific XCell SureLock Mini-Cell 
Flow cytometer Becton & Dickinson FACSCanto II Flow Cytometer 
Fluorescence imaging system Licor Odyssey CLx imager 
SEC column Tosoh Bioscience TSKgel G3000SW, No. 05789 
Nano HPLC System Dionex Ultimate 3000 
IEF System GE Healthcare Life Science Multiphor II 
Laminar flow Thermo Scientific HeraSafe KS15 
Micro centrifuge Thermo Scientific Heraeus Biofuge fresco 
Microscope Carl Zeiss Axiovert 40C 
Orbital Shaker Heidolph Polymax 1040 
pH-Meter WTW InoLab pH 730 
Plate photometer BMG Labtech POLARstar Omega 
Cuvette photometer Amersham Biosciences Ultrospec 2100 pro 
Plate Shaker IKA MTS 2/4 digital microtiter 
shaker 
96-Well Plate Washer Tecan Power Washer PW96 
Pipetboy IBS Integra Biosciences Pipetboy comfort 
Pipette 0,5-10 µl Brand Transferpette 
Pipette 100-1000 µl Brand Transferpette 
Pipette 10-100 µl Brand Transferpette 
Scanner Epson Perfection V700 Photo 
SDS-PAGE Power Supply Life technologies PowerEase 90W Power 
Supply 
MSD ECL Reader  Meso Scale Discovery Sector Imager 6000 
Thermoshaker VWR PHMT-PSC24N 
Vortexer IKA MS2 Minishaker 
Water bath Grant SUB Aqua 18 
 
 
 
Software 
  
CellSens Olympus Version 1.9 
Chromeleon Dionex Version 6.8 
Discovery Workbench 2006 MSD 3.0.18 
Excel Microsoft Microsoft Office 2007 
FACSDiva Software Becton&Dickinson Version 6.1.3 
Flowjo Treestar Inc. Mac Version 9.3 
GraphPad Prism  GraphPad Software Inc. Version 6 
Image Studio Licor Version 1.0.11 
Unicorn  GE Healthcare Version 6.2 
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4 Results 
4.1 Generation and characterization of nBT062 model variants by 
SDS-PAGE, IEF and SEC 
In 2009 Labrijn and colleagues reported that the therapeutic monoclonal antibody 
natalizumab undergoes half-antibody exchange with endogenous IgG4 in humans (Labrijn et 
al. 2009). In this thesis, IgG4-related half-antibody exchange and its potential effect on the 
antibodies functionality and efficacy was investigated for the anti-CD138 antibody-drug 
conjugate BT062. Therefore, four model variants as shown in Figure 4-1 were generated: (I) 
WT nBT062, comprises the backbone of an unmodified human IgG4 antibody. (II) Stable 
nBT062 was generated by introducing stabilizing mutations within the hinge and CH3 
domains into the WT nBT062 sequence to prevent half-antibody exchange. (III) By 
exchanging the cysteines at position 226 and 229 in the hinge region to serines in WT 
nBT062, covalent dimerization of the heavy chains was inhibited resulting in nBT062 half-
antibodies (half nBT062). (IV) To study effects of bispecific antibodies derived by half-
antibody exchange with endogenous IgG4, a stabilized, bispecific nBT062-natalizumab was 
designed as described in section 3.1. All variants were expressed in FreeStyle CHO-S cells 
using an 8-day batch cultivation. Supernatants were 0.2 µm filtered and frozen until 
purification (see section 3.2.2). nBT062 variants were purified by Protein A affinity 
chromatography as exemplarily demonstrated for WT nBT062 in Figure 4-2 followed by a 
buffer exchanging step (see section 3.2.3). 
 
 
 
Figure 4-1: Schematic representation of nBT062 model antibodies.  
The generated nBT062 model antibodies wild type (WT) nBT062, stable nBT062, half nBT062 and bispecific 
nBT062-natalizumab are shown. The different variants mimic antibody species produced by in vivo IgG4 half-
antibody exchange. Different modifications are indicated.  
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Figure 4-2: Exemplary chromatogram of WT nBT062 affinity chromatography.  
Purification of nBT062 variants was performed by affinity chromatography using a mabSelect protein A column 
connected to an Äkta Avant 150 system. Purification included sample loading, washing steps of column-bound 
antibodies with DPBS and DPBS + 1M NaCl and elution with glycin-HCl pH 3.5 followed by neutralization and 
buffer exchange. This chromatogram demonstrates purification of WT nBT062 as example.  
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To examine correct expression and purification of model antibodies, SDS-PAGE analysis, 
IEF, and SEC were used for a first characterization. Reducing and non-reducing SDS-PAGE 
analysis was performed as described in section 3.3.1 and results are shown in Figure 4-3. By 
applying reducing conditions, all four nBT062 model variants were separated in two bands, 
one at approx. 25 kDa and one at approx. 50 kDa of molecular weight, representing the 
antibodies L and H chains, respectively. Within the bispecific nBT062-natalizumab sample, 
two H chain bands with minimal different molecular weights were obtained, indicating 
separate nBT062 and natalizumab H chains with calculated weights of 49.7 and 49.3 kDa, 
respectively (calculated using ProtParam webservice). An additional band at approx. 85 kDa 
was observed for the stable nBT062 antibody indicating a small fraction of dimerized H 
chains (H2). By applying non-reducing conditions, WT nBT062, stable nBT062, and 
bispecific nBT062-natalizumab demonstrated each a high-intensity band at approx. 150 kDa 
representing full lengh antibodies (H2L2). For WT nBT062 a low-intensity band at approx. 
70 kDa was additionally observed, indicating a half antibody fraction which was not detected 
in stable nBT062 and bispecific nBT062-natalizumab samples. This half antibody fraction at 
approx. 70 kDa was identified as the only high-intensity band within the half nBT062. Full 
lenght H2L2 antibodies were lacking in this sample. These SDS-PAGE results indicate that 
the different nBT062 variants were expressed correctly and each variant demonstrated the 
specific properties for half antibody occurance as expected. Further, no undefined bands 
were observed, e.g. host cell proteins, demonstrating a high purify of the antibody samples. 
 
 
  
 
Figure 4-3: Reducing and non-reducing 
SDS-PAGE of WT, stable, half nBT062 
and bispecific nBT062-natalizumab. 
Non-reduced analyzed antibodies were 
diluted with NuPAGE LDS sample 
buffer/100 nM NEM solution and heated 
30s at 70°C. Reduced analyzed antibodies 
were treated with NuPAGE LDS sample 
buffer/NuPAGE Sample Reducing Agent 
and heated for 10 min at 70°C. 10 µg of 
each antibody was loaded onto a NuPAGE 
Novex 4-12% Bis-Tris Gel. Coomassie 
staining was used for visualization and 
SeeBlue Plus 2 Protein Standard for size 
identification (indicated in kDa). Antibody 
subunits are marked on the right: H= heavy 
chain; L= light chain. 
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IEF was performed to assess the isoelectric points (pIs) of WT nBT062, stable nBT062, half 
nBT062, and bispecific nBT062-natalizumab and demonstrate differences based on the 
individually introduced mutations of each variant (see section 3.3.2). Results are shown in 
Figure 4-4. nBT062 variants were stained by Coomassie blue staining and by immuno-
detection after western blotting. The Coomassie stained gel revealed that WT nBT062 was 
separated in 7 bands ranging from approx. pH 6.5 to 7.3, including one band with the highest 
intensity nearly at pH 6.8. The pIs of stable nBT062 were ranging from approx. pH 6.4 to 7.0, 
also separated into 7 bands. The band patterns of WT nBT062 and stable nBT062 were 
similar with a slightly acidic shift for stable nBT062. For half nBT062 4 bands between pH 6.1 
and 6.8 with two high intensity and two low intensity bands were detected. Natalizumab was 
also divided into 4 bands, two high intensity bands at approx. pH 7.7 and two low intensity 
bands at approx. pH 7.6 and 7.8. The bispecific nBT062-natalizumab demonstrated 10 
bands separated from approx. pH 7.3 to 8.0, including one high intensity band at pH 7.4. This 
analysis clearly demonstrated a basic pI shift for bispecific nBT062-natalizumab compared to 
the other nBT062 variants through the introduced mutations. This is most probably based on 
the introduced natalizumab CDR region rather than the stabilizing and chain-pairing 
mutations as natalizumab itself has also a basic pI. Multicolor western blotting of an 
isoelectric focusing gel was performed to identify monospecific antibodies within the 
bispecific nBT062-natalizumab fraction (Figure 4-4 B). Anti-idiotypic antibodies against 
nBT062 (green) and natalizumab (red) were used for visualization. The staining revealed that 
WT nBT062, stable nBT062 and half nBT062 were only detected by the anti-nBT062 
idiotypic antibody, while natalizumab was exclusively detected by the anti-natalizumab 
idiotypic antibody. For bispecific nBT062-natalizumab it was observed that 8 out of 10 bands 
were stained by both anti-idiotypic antibodies. Two bands were exclusively stained by the 
anti-natalizumab idiotypic antibody within this fraction. This experiment demonstrated that the 
bispecific nBT062-natalizumab sample did not contain any monospecific nBT062 antibodies 
which could interfere with further analysis.  
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Figure 4-4: Isoelectric focusing of WT, stable, half nBT062 and bispecific nBT062-natalizumab. 
10 µg of each untreated antibody was loaded onto an IEF Gel, pH 3- 10 for isoelectric point separation. (A) Serva 
IEF Marker 3-10 was used for pH identification and Coomassie staining was done for protein visualization. pH 
values are assigned on the left. (B) After isoelectric focusing, indicated nBT062 model variants were blotted onto 
a PVDF membrane. Selective nBT062 and natalizumab specificities were detected by anti-idiotypic antibodies 
visualized in green and red, respectively.  
 
WT nBT062, stable nBT062, half nBT062, and bispecific nBT062-natalizumab were analyzed 
by SEC using either native running buffer or denaturing running buffer containing 10% 2-
propanol (see section 3.3.3). The latter conditions were mainly applied to observe half-
antibody formations, while native running buffer was used to focus on aggregates and protein 
fragments. Detection occurred at 280 nm. Bigger proteins were released earlier from the 
column than small molecules, which were retained by porous particles of the column 
material. As demonstrated in Figure 4-5 A, under native conditions main peaks were 
detected between approx. 29.5 min and 35 min representing the full-length antibodies of all 
nBT062 variants. Within this time frame, half nBT062 and bispecific nBT062-natalizumab 
showed a shorter retention time (31.8 min and 32.1 min, respectively). Additionally, the main 
peak of bispecific nBT062-natalizumab comprises a shoulder at 31.1 min. On the contrary, 
WT and stable nBT062 demonstrated nearly identical retention times for their peak maxima 
at 32.5 min. Aggregates were observed for all nBT062 antibody variants, but with different 
proportions as identified by peak integration: Half nBT062 contained less than 4.5%, WT 
nBT062 contained 7.4%, and bispecific nBT062-natalizumab showed 7.1%.Suprisingly, most 
aggregates (25%) were detected in stable nBT062, indicating the BT062 formulation buffer is 
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not optimal for stable nBT062. However, nearly no antibody-related protein fragments could 
be observed in the LC spectrum at 280 nm of each nBT062 variant.  
Under denaturing conditions, main peaks representing full length antibodies of WT nBT062, 
stable nBT062, and bispecific nBT062-natalizumab demonstrated comparable retention 
times at 39.1 min, 39.0 min, and 38.9 min, respectively (Figure 4-5 B). In contrast to that, the 
main peak of half nBT062 was observed after 42.1 min, indicating a smaller molecule size 
and, thus, the presence of half-antibodies. Within this sample no full length antibody peak at 
approx. 39 min was detected. In addition to the main peaks of WT nBT062 and bispecific 
nBT062-natalizumab, both samples showed small half antibody peaks at 43.1 min and 
42.6 min representing 6.1% and 2.3% half-antibodies, respectively. For stable nBT062, no 
half antibody peak was observed. Even under denaturing conditions in the presence of 10% 
2-propanol, aggregate peaks occurred within stable nBT062 with fractions of 7.5%. 
Interestingly, bispecific nBT062-natalizumab revealed an aggregate fraction of 32.2%. 
Taken together, the SEC analysis demonstrated only minor amounts of aggregates for WT 
nBT062, half nBT062, and bispecific nBT062-natalizumab, while the fraction of aggregates 
was higher in stable nBT062. The analysis revealed that the presence of half-antibodies 
seems to depend on the surrounding buffer conditions: Half nBT062 was detected as half-
antibodies (HL) only using denaturing running buffer. In native running buffer, half nBT062 
molecules seem to dimerize despite the lack of covalent H -H pairing. 
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Figure 4-5: Size exclusion chromatography of nBT062 model variants. 
WT nBT062, stable nBT062, half nBT062, and bispecific nBT062-natalizumab were separated under native (A) or 
denaturing (B) conditions using a TSKgel G3000 column (Tosoh Bioscience) connected to a nano HPLC system. 
Detection was done at 280 nm and different antibody-related species are indicated. H= Heavy chain, L= light 
chain. 
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To investigate if the incorporation of the stabilizing mutations S228P and R409K within stable 
nBT062 (and bispecific nBT062-natalizumab) can successfully prevent the formation of 
bispecific antibodies, an in vitro assay was performed. WT nBT062 and stable nBT062 were 
treated in the presence of identical amounts natalizumab with 10 mM GSH to potentially 
reduce the disulfide bonds of the hinge region for half-antibody formation. GSH was removed 
and subsequent reoxidation was enabled by GSSG addition (see section 3.3.4). The 
formation of bispecific antibodies was determined by IEF as shown in Figure 4-6. While 
untreated control antibodies, WT nBT062 and stable nBT062 separately loaded onto the gel, 
demonstrated pIs of approx. 6.2 to 6.8, natalizumab bands were more basic in the pH range 
of approx. 7.5 to 7.7. These bands of all individual antibodies were also observed in the 
respective mixtures of reoxidized WT nBT062/natalizumab and stable nBT062/natalizumab. 
However, 4 additional bands in the intermediate pH range of 6.9 to 7.4 were detected in the 
reoxidized mixture of WT nBT062/natalizumab representing generated bispecific antibodies 
(red line). Those bispecific antibody bands were lacking in the reoxidized mixture of stable 
nBT062/natalizumab. Thus, it can be concluded that stabilizing mutations S228P and R409K 
could successfully prevent the half-antibody exchange under the applied reducing conditions 
in this experiment. 
 
Figure 4-6: Evaluation of in vitro half-antibody exchange.  
WT nBT062 or stable nBT062 was mixed with natalizumab and treated with 10 mM GSH and after dialysis 
subsequently with 5 mM GSSG. 10 µg of each treated or untreated control antibody solution was loaded as 
indicated onto an IEF Gel, pH 3-10 for IEF. Coomassie staining was done for protein visualization. pH values 
based on the Serva IEF Marker 3-10 are assigned on the left and pH range of bispecific antibodies are indicated 
in red. 
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4.2 Antigen-binding of nBT062 model variants 
Specific binding of WT nBT062, stable nBT062, half nBT062 and bispecific nBT062-
natalizumab to CD138 and CD49d was investigated by flow cytometry according to 
section 3.4.2. Murine, transgenic Ba/F3-hCD138 cells (CD138+/ CD49d-) and human T 
lymphocyte Jurkat cells (CD138-/ CD49d+) were incubated with serial dilutions of nBT062 
model antibodies and natalizumab (5x10-7 - 2.82x10-12 M). Detection was done using an 
Alexa Fluor 647 conjugated anti-human secondary antibody. nBT062 and natalizumab were 
mutually used as isotype controls and cells stained only with the secondary antibody 
functioned as a further negative control. Cell gating was performed in the forward-sideward 
scatter (FSC-SSC) of unstained cells. An example for the gating strategy is shown in Figure 
4-7 A, including a histogram overlay of cells incubated with different WT nBT062 
concentrations demonstrating concentration-dependent staining (see Figure 4-7 B). Median 
fluorescence intensities (MFIs) were plotted against the corresponding antibody 
concentrations. As demonstrated in Figure 4-8 A, WT nBT062, stable nBT062 and half 
nBT062 demonstrated comparable binding to CD138+ Ba/F3-hCD138 cells with avidities of 
5.5x10-10, 7.1x10-10 and 11.2x10-10 M, respectively (see Table 4-2). Binding of bispecific 
nBT062-natalizumab to CD138 was slightly reduced. However, the affinity of nBT062-
natalizumab against CD138 was still in the nanomolar range (~23x10-9 M, Table 4-2). 
Natalizumab was not able to bind those CD138+/CD49d- Ba/F3-hCD138 cells. 
CD49d-expressing, CD138- Jurkat cells were bound by natalizumab and bispecific nBT062-
natalizumab with binding activities of 4x10-10 M and 21x10-10 M, respectively, indicating that 
both antigens were recognized by the bispecific model variant. The other nBT062 variants 
did not show any binding to these CD138- cells. In conclusion, it was demonstrated that all 
nBT062 variants were able to bind CD138 with low nanomolar avidity, despite the binding of 
bispecific nBT062-natalizumab was slightly reduced. 
 
Figure 4-7: Exemplary FACS staining and gating strategy using Ba/F3-hCD138 cells  
Ba/F3-hCD138 cells were stained with different concentrations of nBT062 variants and natalizumab. An Alexa 
Fluor 647-labeled anti-human antibody was used for detection. A: Gating of Ba/F3-hCD138 cells in the forward-
/sideward scatter. Gating was adjusted for Jurkat cells. B: Exemplary overlay histogram of Ba/F3-hCD138 cells 
incubated with indicated concentrations of WT nBT062 and stained with an Alexa Fluor 647 secondary antibody.  
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Figure 4-8: nBT062 model variants selectively bind to CD138+ cells in a concentration-dependent manner. 
Ba/F3-hCD138 cells, positive for nBT062 antigen and negative for natalizumab antigen (A), and Jurkat cells, 
negative for nBT062 antigen and positive for natalizumab antigen (B), were incubated with different 
concentrations (5x10-7–2.82x10-12 M) of WT nBT062, stable nBT062, half nBT062 and bispecific nBT062-
natalizumab antibodies. Data were obtained by flow cytometry using a secondary anti-human antibody for 
detection. Binding curves demonstrate one representative experiment out of three, each measured in triplicates. 
MFI= Median Fluorescence Intensity. 
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4.3 Internalization analysis of nBT062 model antibodies 
As cellular antibody internalization is one of the most critical parameters of ADCs, uptake of 
WT nBT062, stable nBT062, half nBT062 and bispecific nBT062-natalizumab was 
investigated by flow cytometry and fluorescence microscopy. For both assays, nBT062 
model variants directly labeled with Dylight-488 (Dy488) fluorescent dyes according to 
section 3.4.1 were used.  
4.3.1 Internalization by flow cytometry 
For flow cytometric analysis, human multiple myeloma derived NCI-H929 (CD138+/CD49d+) 
and transgenic Ba/F3-hCD138 (CD138+/CD49d-) cells were incubated with Dy488-labeled 
WT nBT062, stable nBT062, half nBT062 or bispecific nBT062-natalizumab for either 0.5 h at 
4°C for surface staining or 24 h at 37°C to enable antibody internalization. CD49d expressed 
on NCI-H929 cells was blocked with an excess of unlabeled natalizumab. To distinguish and 
verify surface bound or internalized antibodies, CD138 was cleaved of by trypsin. The results 
of three individual experiments, each measured in triplicates are shown in Figure 4-9 as MFI 
values. For NCI-H929 cells, highest and similar staining intensities of the different nBT062 
variants were observed after 24 h of incubation without trypsin digestion at absolute MFI 
values of approx. 10,700. Subsequent treatment with trypsin decreased the fluorescence 
intensities of WT nBT062, stable nBT062 and half nBT062 by approx. 62%, while the 
intensity of bispecific nBT062-natalizumab was only decreased by 42% (Figure 4-9 A). Thus, 
the MFI values detected after 24, indicating higher amounts of internalized nBT062-
natalizumab compared to the other variants. A shorter incubation period of 0.5 h led to MFIs 
for WT nBT062, stable nBT062 and half nBT062 which were approx. 67% of the values after 
24 h incubation. On the contrary, surface staining of bispecific nBT062-natalizumab reached 
only 38% of the 24 h incubation, which was significantly different from the monospecific 
variants. Trypsin treatment after this 0.5 h incubation revealed fluorescence intensities of 
similar values as unstained cells and negative control staining (natalizumab). Similar findings 
were observed with Ba/F3-hCD138 cells: The highest MFI values for all nBT062 variants 
were found after 24 h of antibody incubation without subsequent trypsin digestion. The 
average MFI was 4460 (Figure 4-9 B). Fluorescence intensities decreased after proteolytic 
treatment to 73%, 69%, 72% and 77% for WT nBT062, stable nBT062, half nBT062 and 
bispecific nBT062-natalizumab, respectively. CD138-surface binding (0.5 h incubation) with 
WT nBT062 led to 24% fluorescence intensity compared to the 24 h incubation without 
trypsin. Similar to that, stable nBT062 and half nBT062 reached 27%, while only 14% cell 
surface staining were observed with bispecific nBT062-natalizumab, demonstrating a 
significant difference between the monospecific variants and the bispecific one. In summary, 
it was observed that WT nB062, stable nBT062 and half nBT062 demonstrated similar 
surface binding and internalization on both tested cell lines. In contrast, bispecific nBT062-
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natalizumab demonstrated a reduced surface binding in both cell lines, but similar or even 
higher MFI values for internalization.  
 
 
Figure 4-9: Internalization analysis of nBT062 model variants due to CD138 binding. 
Dy488 conjugated WT nBT062, stable nBT062, half-nBT062 and bispecific nBT062-natalizumab were incubated 
for 0.5 h at 4°C or 24 h at 37°C in the presence of an excess of unlabeled natalizumab with NCI-H929 cells (A) or 
without natalizumab on Ba/F3-hCD138 cells (B). To distinguish and verify surface bound or internalized 
antibodies, CD138 was cleaved off by trypsin incubation prior to flow cytometric analyses. The median 
fluorescence intensity (MFI) for Dylight-488 is shown on the Y-axis. Data are obtained from three individual 
experiments, each measured in triplicates and statistical analysis was done using t-students test. **p<0.01; 
***p<0.001; ****p<0.0001. 
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4.3.2 Internalization by fluorescence microscopy 
To further investigate nBT062 variant internalization and analyze the mechanism of antibody 
uptake, fluorescence microscopy was used. Dy488-labeled WT nBT062, stable nBT062, half 
nBT062 or bispecific nBT062-natalizumab was incubated for 0.5h at 4°C with Ba/F3-hCD138 
(CD138+/CD49d-) cells to enable surface binding. Dy488-conjugated natalizumab and Ba/F3 
(CD138-/CD49d-) cells were used as negative controls. After removing unbound antibodies, 
internalization of surface-bound nBT062 variants was accomplished by a 3 h incubation 
period at 37°C. Trypsin treated, fixed and permeabilized cells were co-stained with an anti-
LAMP1 antibody to mark lysosomes; nuclei were stained with DAPI. Results of fluorescence 
microscopy are shown in Figure 4-10. For all nBT062 variants, internalization was observed 
in Ba/F3-hD138 cells. Cells incubated with WT nBT062 and stable nBT062 additionally 
demonstrated a faint surface staining. This staining was even lower or absent on cells 
incubated with half nBT062 or bispecific nBT062-natailzumab, respectively. Observations for 
negative controls were as expected: Neither Ba/F3-hCD138 cells incubated with Dy488-
labeled natalizumab (V) showed any green staining, nor CD138- Ba/F3 cells incubated with 
WT nBT062-Dy488 (VI). Lysosomes visualized by the anti-LAMP1 antibody were detected as 
small red dots in each cell (b). Overlay pictures (d) of the three fluorescence channels 
demonstrated a clear merged staining of each nBT062 variant and anti-LAMP1 antibody 
indicated by the white arrows.  
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Figure 4-10: Internalization of nBT062 model variants analyzed by fluorescence microscopy. 
Ba/F3-hCD138 cells were incubated with Dy488-labeled WT nBT062 (I), stable nBT062 (II), half nBT062 (III), 
bispecific nBT062-natalizumab (IV) or natalizumab (V, green). As negative control, Ba/F3 cells were incubated 
with Dy488-labeled WT nBT062 (VI). Lysosomal staining was performed with an anti-LAMP1 antibody (b, red) 
and cell nuclei were stained with DAPI (c, blue). Pictures of merged channels are shown in the lower right (d). 
White arrows indicate co-staining of nBT062 antibodies and anti-LAMP1 antibody (yellow). Pictures are taken 
from one representative experiment out of three individuals.  
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4.4 DM4-conjugation of nBT062 models and characterization of the 
derived nBT062 ADC variants 
According to section 3.5.1, WT nBT062, stable nBT062, half nBT062 and bispecific nBT062-
natalizumab were conjugated with the maytansine DM4, a tubulin inhibiting agent, to 
generate respective ADCs. The conjugation was performed in two steps: In a first reaction, 
the SPDB linker was attached to the nBT062 variant and, in a second step, DM4 was added 
to react with the pyridyldithio group of the SPDB linker. During the conjugation process, 
antibody and DM4 concentrations were monitored based on OD280 and OD252 absorptions, 
respectively. WT nBT062, stable nBT062 and half nBT062 were conjugated with 100% of 
SPDB linker and DM4 to aim for a DAR of 3.5. As shown in Table 4-1, for WT nBT062-DM4 
a DAR of exactly 3.5 was reached and the conjugation of stable nBT062-DM4 led to a DAR 
of 3.4. Half nBT062 was conjugated identical to full length WT nBT062 and stable nBT062 as 
it was seen in the SEC analysis that half antibody occurrence seems to depend on 
surrounding buffer conditions and half nBT062 molecules were dimerized under native 
conditions (see section 4.1). Therefore, for dimerized half nBT062 molecules a DAR of 3.2 
was observed, meaning that in average 1.6 DM4 molecules were attached to each HL 
fragment of half nBT062-DM4. To mimic potential in vivo derived bispecific nBT062-DM4 
antibodies with diminished DM4 payload, the molar concentration of SPDB and DM4 to 
bispecific nBT062-natalizumab was reduced. The use of 70% SPDB and DM4 led to a DAR 
of 2.6, while 50% SPDB and DM4 result in a final ADC having a DAR of 1.7. The final yield of 
the conjugation reactions ranged from approx. 8.5 mg (55% of initial amount) for bispecific 
nBT062-natalizumab-DM4 to approx. 15.9 mg (65% of initial amount) for WT nBT062-DM4. 
Final ADC concentrations were between approx. 2 mg/ml and 3 mg/ml. For further analysis, 
the bispecific nBT062-natalizumab-DM4 with a DAR of 1.7 was used as this version reflects 
better a potentially in vivo arisen bispecific nBT062-DM4 species. 
 
Table 4-1: DM4-conjugated nBT062 variant batches. DAR= DM4 to antibody ratio. 
Sample 
Used SPDB/ DM4 
[%] 
Final conc. 
[mg/ml] 
Total amount 
[mg] 
DAR 
Yield 
[%] 
WT nBT062-DM4  100 2.89 15.87 3.5 65 
Stable nBT062-DM4  100 2.48 13.14 3.4 60 
Half nBT062-DM4 (H2L2)  100 2.49 12.45 3.2 63 
Bs nBT062-natalizumab-DM4  70 2.18 10.45 2.6 63 
Bs nBT062-natalizumab-DM4  50 1.96 8.45 1.7 55 
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4.4.1 DM4 distribution in nBT062-DM4 model antibodies  
To characterize the produced nBT062 ADCs, the different DAR species of WT nBT062-DM4, 
stable nBT062-DM4, half nBT062-DM4 and bispecific nBT062-natalizumab-DM4 were 
analyzed by LC-MS analysis (see section 3.5.3). Results from deconvoluted MS spectra are 
shown in Figure 4-11. Among the ADC variants, WT nBT062-DM4, stable nBT062-DM4 and 
half-nBT062-DM4, a small fraction of unconjugated antibodies was observed (DAR 0). The 
detected mass of unconjugated WT nBT062 and stable nBT062 was 148674 Da for both 
variants. For half nBT062-DM4, eight DAR 0 peaks were observed representing different 
glycosylation species with masses from 74304 Da to 75125 Da. The main glycosylation 
species had a mass of 74963 Da. No DAR 0 species was detected for nBT062-natalizumab-
DM4 as determined by measuring an unconjugated nBT062-natalizumab sample having a 
main glycosylation species with a mass of 148805 Da (data not shown). Each SPDB-DM4 
complex adds approx. 880 Da to each antibody backbone.  
Deconvoluted MS spectra of WT nBT062-DM4 and stable nBT062-DM4 were similar as both 
demonstrate DAR species from DAR 0 to DAR 6 with main species of DAR 2 to DAR 4 as 
determined by the area under the curve. For each of these DAR species, from one up to five 
peaks were observed and identified as different antibody glycosylation forms. The half 
nBT062-DM4 variant comprised fractions having zero to four DM4 molecules per antibody 
molecule while DAR 0, DAR 1 and DAR 2 species were the most potent ones. Compared to 
WT nB062-DM4, stable nBT062-DM4 and bispecific nBT062-natalizumab-DM4, the half 
nBT062-DM4 demonstrated a more complex glycosylation pattern as up to 14 different 
glycosylation species could be observed. For bispecific nBT062-natalizumab-DM4, DAR 1, 
DAR 2 and DAR 3 species were detected, separated in two different glycosylation species. 
Taken together, this analysis demonstrated that there were several DAR species for each 
nBT062-DM4 variant beside the mean DAR species as calculated by the OD280/252 absorption 
method. However, only marginally amounts of unconjugated antibodies and no more than 6 
DM4 molecules per antibody were detected indicating an even conjugation reaction.  
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Figure 4-11: Deconvoluted MS spectra of DM4-conjugated nBT062 variants. 
WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 and bispecific nBT062-natalizumab-DM4 were 
separated by reversed phase LC and antibody peaks were directly analyzed by mass spectroscopy. The 
deconvoluted MS spectra are shown. The mass is indicated on the X-axis and relative intensity on the Y-axis. 
DAR= DM4 to antibody ratio.  
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4.4.2 Mapping of DM4-conjugation sites 
IgG4 H chains contain approx. 30 lysines, while L chains have approx. 12 lysines. 
Conjugation of SPDB-DM4 is achieved by random acylation of lysine amino groups.  To 
study the effects of the introduced mutations in stable nBT062 (S228P, L235E and R409K) 
or half nBT062 (C226S and C229S) on the conjugation sites, a LC-MS analysis of denatured, 
alkylated and digested samples was performed (see section 3.5.4). Based on the low amount 
of DM4-conjugated material, bispecific nBT062-natalizumab-DM4 could not be analyzed by 
this method. Figure 4-12 schematically depicts the results of individual H and L chain 
conjugated sites. It is shown that no differences were observed between the L chains of WT 
nBT062-DM4, stable nBT062-DM4 and half nBT062-DM4 as the 10 identical lysines were 
partly found to be SPDB-conjugated in each of those variants. Additionally, for all of the three 
variants a SPDB-DM4 conjugation was detected on the N-terminal amino group. Within the H 
chains of WT nBT062-DM4, stable nBT062 and half nBT062-DM4, 14 identical lysines were 
partly found to be conjugated with SPDB. However, no further conjugation site was obtained 
in half nBT062-DM4, while K250 was additionally available for conjugation in stable nBT062-
DM4 and WT nBT062-DM4. Even further, WT nBT062-DM4 was the only antibody variant 
which had K223 conjugated with SPDB-DM4. These results indicate that the introduced 
mutations did only marginally influence the availability of lysines for SPDB-DM4 conjugation. 
 
 
Figure 4-12: SPDB-DM4 conjugation sites of WT nBT062-DM4, stable nBT062-DM4 and half-nBT062-DM4. 
WT nBT062-DM4, stable nBT062-DM4 and half nBT062-DM4 were denatured, alkylated, digested and analyzed 
by LC-MS to identify SPDB-DM4 conjugated amino groups. Identical conjugated lysines are shown in black, 
differences or N-terminal conjugation is shown in color as indicated. HC= heavy chain; LC= light chain.   
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4.4.3 Influence of DM4 conjugation on CD138-specific binding activity 
In line with the CD138-binding analysis shown in section 4.2, the influence of DM4 
conjugation on the CD138-binding activity of nBT062-DM4 model variants was investigated. 
Ba/F3-hCD138 cells (CD138+/CD49d-) and NCI-H929 cells (CD138+/CD49d+) were incubated 
with unconjugated or DM4-conjugated WT nBT062, stable nBT062, half nBT062 and 
bispecific nBT062-natalizumab. Each variant was tested in a concentration series ranging 
from 2.82x10-12 to 5x10-7 mol/L. Binding of the nBT062 variants to target cells was detected 
by flow cytometric analysis using an Alexa Fluor 647 conjugated anti-human IgG (see section 
3.4.2). Binding curves from three experiments, each measured in triplicates, were merged 
and are shown in Figure 4-13. Corresponding KD values were calculated by non-linear fitting 
using GraphPad Prism and KD values are listed in Table 4-2 (see Annex 7.3 for individual 
values). Absolut detection maxima were different in both cell lines: Ba/F3-hCD138 cells 
reached MFIs of approx. 11,000, while MFI values of approx. 60.000 were obtained on NCI-
H929 cells. These findings indicate a higher surface expression of CD138 on the NCI-H929 
cells. In accordance with results in section 4.2, WT nBT062, stable nBT062 and half nBT062 
demonstrated nearly identical binding curves within each cell line tested, Ba/F3-hCD138 and 
NCI-H929. Binding of bispecific nBT062-natalizumab was slightly reduced compared to the 
monospecific variants. The CD138-binding activities of unconjugated and respective 
DM4-conjugated nBT062 variants were comparable. Based on nonlinear regression fitting of 
normalized results including best-fit statistical comparison of EC50 values, there was no 
difference in CD138-binding avidity of unconjugated WT nBT062, stable nBT062, half 
nBT062 and bispecific nBT062-natalizumab compared to their respective DM4-conjugated 
variants (see appendix 7.3). Binding of WT nBT062, stable nBT062 and half nBT062 either 
DM4-conjugated or naked to NCI-H929 cells was between 1- 2x10-9 M, while bispecific 
nBT062-natalizumab binds with approx. 8-9x10-9 M (combined binding of CD138 and 
CD49d). Binding avidity to Ba/F3-hCD138 cells was slightly higher with 0.5- 1x10-9 M for the 
monospecific nBT062 variants and approx. 20x10-9 M for bispecific nBT062-natalizumab, 
either conjugated or not. Taken together, these results indicate that the DM4 conjugation did 
not influence the binding activity of any nBT062 variant.  
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Table 4-2: Binding avidities of DM4 conjugated or unconjugated nBT062 model variants. 
Cells 
DM4-
conjugate 
WT 
nBT062 
[M] 
Stable 
nBT062 
[M] 
Half 
nBT062 
[M] 
bispecific nBT062-
natalizumab 
[M] 
NCI-H929 No 1.16E-09 1.57E-09 1.88E-09 9.25E-09* 
NCI-H929 Yes 1.68E-09 1.79E-09 2.02E-09 7.89E-09* 
Ba/F3-hCD138 No 5.46E-10 7.05E-10 1.12E-09 2.26E-08 
Ba/F3-hCD138 Yes 7.28E-10 7.00E-10 9.00E-10 1.79E-08 
*Bispecific nBT062-natalizumab is capable of CD49d binding on NCI-H929 cells. 
 
 
Figure 4-13: Binding of unconjugated and DM4 conjugated nBT062 variants. 
Ba/F3-hCD138 cells (CD138+/CD49d-; A) and NCI-H929 cells (CD138+/CD49d+; B) were incubated with different 
concentrations (5x10-7–2.82x10-12 M) of unconjugated or DM4-conjugated WT nBT062, stable nBT062, half 
nBT062 and bispecific nBT062-natalizumab antibodies. Data were obtained via flow cytometry using a secondary 
anti-human antibody for detection. Binding curves demonstrate mean values of three individual experiments, each 
measured in triplicates, and non-linear fitting with GraphPad Prism. R²= 0.91- 0.97. MFI= Median Fluorescence 
Intensity. 
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4.5 In vitro cytotoxicity of nBT062-DM4 variants on NCI-H929 cells 
To investigate the cytotoxic activity of generated nBT062-DM4 variants, NCI-H929 cells 
(CD138+/CD49d+) were incubated with different concentrations of either WT nBT062-DM4, 
stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4 and the cells’ 
viability was tested after 5 days. To block CD49d binding of bispecific nBT062-natalizumab-
DM4, this antibody variant was additionally incubated with a 50x excess of natalizumab. As 
control, the influence of 50x natalizumab was also tested in combination with WT nBT062-
DM4. WST-1 substrate turnover of viable cells was determined and IC50 values were 
calculated as described in section 3.5.1. The IC50 value is defined as the drug concentration 
at which the proliferation rate of the cells is 50% compared to untreated cells. This value is 
also represented in normalized, non-linear fitted concentration-dependent inhibitory curves 
as point of inflection. The mean inhibition curves of three experiments, each measured in 
triplicates, are shown in Figure 4-14 A. It was observed that curves of WT nBT062-DM4, 
stable nBT062-DM4 and half nBT062-DM4 were similar with points of inflection near 10-10 M. 
In contrast, the point of inflection of bispecific nBT062-natalizumab-DM4 was shifted to 
approx. 10-9 M. Paired t test analysis revealed that this shift was significant against WT and 
stable nBT062-DM4.  
WT nBT062-DM4, stable nBT062-DM4 and half nBT062-DM4 demonstrated mean IC50 
values of 0.105, 0.085, and 0.137 nM, respectively. These differences were not significant. 
The IC50 of bispecific nBT062-natalizumab-DM4 was significantly reduced to 0.456 nM. IC50 
results were further processed and are shown as relative cytotoxicity normalized to WT 
nBT062-DM4 in Figure 4-14 B. Relative to WT nBT062-DM4, stable nBT062-DM4 and half 
nBT062-DM4 variants demonstrated cytotoxicities of 127% and 85%, respectively. These 
differences were not significant at all. Bispecific nBT062-natalizumab-DM4 demonstrated a 
relative cytotoxicity of 52% in the absence of natalizumab. This inhibitory potency was even 
further reduced to 32% in the presence of natalizumab. Significant differences between the 
monospecific variants and nBT062-natalizumab-DM4 we only observed to the group with 
additional natalizumab. Natalizumab itself did not mediate any cytotoxic effect. Nevertheless, 
there was a trend to decrease the efficacy of bispecific nBT062-natalizumab-DM4 but also 
slightly influenced the cytotoxicity of WT nBT062-DM4 in terms of variability. No unspecific 
cytotoxicity of nBT062-DM4 variants was detected on CD138- Jurkat cells in concentrations 
ranging from 0.01 - 4 nM (see Appendix 7.4). In conclusion, it was demonstrated that all 
nBT062-DM4 variants were capable to mediate CD138-specific cytotoxicity in the nanomolar 
range.  
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Figure 4-14: Cytotoxic effect of nBT062-DM4 variants on NCI-H929 cells. 
NCI-H929 cells (CD138+/CD49d+) were incubated with different concentrations of WT nBT062-DM4, stable 
nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4, as indicated in the presence or absence 
of an excess of natalizumab. After 5 days of incubation, a WST-1 assay was used to determine the viability. 
Exemplary concentration dependent inhibition curves are shown in A. Reciprocal IC50 values of each nBT062-
DM4 variant were normalized to WT nBT062-DM4 and one DM4 molecule per antibody. Results are shown in B 
from three separate experiments each measured in triplicates. N/A= not available; no cytotoxic activity was 
obtained. *p<0.05, **p<0.01. 
 
4.6 In vivo assessment of nBT062-DM4 model variants 
4.6.1 Efficacy of nBT062-DM4 variants in a xenograft mouse model 
In addition to in vitro cytotoxicity assays, the efficacy of WT nBT062-DM4 and generated 
corresponding model variants, mimicking ADC species potentially arisen in vivo, was 
assessed in a xenograft mouse model. Immunodeficient NMRI nude mice were inoculated 
with the patient-derived mammary cancer MAXF 1322 known for CD138 expression. Mice 
were treated three times with either 4 or 2 mg/kg/week of WT nBT062-DM4, stable nBT062-
DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4. The influence of 
endogenous IgG4 on the efficacy of the therapeutic ADCs was investigated by administering 
the nBT062-DM4 model variants either alone or in combination with 10 ml/kg/week of a 10% 
IVIg preparation containing also the IgG4 subtype.  
Results are summarized in Table 4-3 and tumor growth curves are shown in Figure 4-15. WT 
nBT062-DM4, stable nBT062-DM4 and half nBT062-DM4 monotherapy at both dose levels 
of 4 mg/kg/week and 2 mg/kg/week all induced complete remission of tumors with a 
minimum T/C value (see section 3.6.1.4) of 0.0% in all groups. Additionally, no tumor 
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regrowth was detected in the treatment-free observation period up to day 86. For bispecific 
nBT062-natalizumab-DM4 monotherapy a borderline efficacy was observed at 4 mg/kg/week 
(min. T/C: 62.1%) while one treated animal out of five within this group showed a very good 
response (opt. T/C: 8.2). However, the treatment was inactive at 2 mg/kg/week (min. T/C: 
97.5%). In addition, no tumor inhibition was detected by co-administration of the human IVIg 
preparation at both dose levels (min. T/C values ≥ 98.5%). In the presence of IgG antibodies, 
WT nBT062-DM4, stable nBT062-DM4 and half nBT062-DM4 also led to complete tumor 
remissions at dosing of 4 mg/kg/week (all min. T/C 0.0%). At a dosage of 2 mg/kg/week, a 
decrease in efficacy by the co-administration of the IVIg preparation was observed: Half 
nBT062-DM4 demonstrated a moderate efficacy (min. T/C 45.3%) and WT nBT062-DM4 
reached a borderline effect (min. T/C 58.9%). This decrease was significant in both cases. 
Compared to that, stable nBT062-DM4 was only minor influenced by the human IgG 
antibodies as complete remission of tumors and survival was seen in 3 of 5 mice (min. T/C: 
0.0%). 
Kaplan-Meier survival curves are shown in Figure 4-16. As mice with tumors larger than 
2000 mm³ were excluded from the experiment, this analysis is also an indicator of a delay in 
tumor growth. It was observed that WT nBT062-DM4, stable nBT062-DM4 and half nBT062-
DM4 at 4 mg/kg/week both alone and in the presence of human IgG antibodies 
demonstrated a significant delayed tumor growth and extended survival compared to the 
control group. In combination with the IVIg preparation, survival was not significantly different 
to the corresponding nBT062-DM4 variant monotherapies but was significantly extended 
compared to the IVIg alone for all three variants at 4 mg/kg/day. Tumor growth compared to 
the vehicle control was also significantly delayed by monotherapy with 2 mg/kg/week of WT 
nBT062, stable nBT062-DM4 and half nBT062-DM4 (p≤0.013). When given with the IVIg 
preparation, tumor growth was only significantly delayed compared to the vehicle control for 
stable nBT062-DM4 treatment (p=0.0277) but not for WT nBT062-DM4 and half nBT062-
DM4. Indeed, based on the Mantel-Cox test the IVIg preparation had a significant negative 
effect on the 2 mg/kg/week treatment with half nBT062-DM4 (p=0.0018) but a lower effect on 
treatment with WT nBT062-DM4 (p=0.0251). Direct comparison of stable nBT062-DM4 at 
2 mg/kg/week with and without the IVIg did not lead to a significant difference in tumor 
growth delay. Treatment with bispecific nBT062-natalizumab-DM4 did not significantly 
prolong survival compared to the vehicle control in any of tested dosage and combinations.  
In summary, these data demonstrate that nBT062-DM4 and the models mimicking potentially 
related IgG4 species are all capable of CD138+ tumor cell killing in vivo. Indeed, the 
bispecific nBT062-natalizumab-DM4 was the least potent variant. However, at low doses WT 
nBT062-DM4 and half nBT062-DM4 were reduced in their efficacy in the presence of human 
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IgGs, which was hardly seen for the stable nBT062-DM4. This indicates that the stabilizing 
mutations S228P and R409K might be able to prevent IgG4-based ADCs from a half-
antibody exchange mediated loss in efficacy. 
Table 4-3: Overview of the antitumor efficacy in the different treatment groups.  
Group 
ID 
Therapy1 Dose Level Minimum T/C* 
[%] (Day)2 
Efficacy 
Rating 
Td** 
[Days] 
1 Vehicle Control 10 ml/kg/week n/a n/a 3.0 
2 IVIg 10 ml/kg/week 100.0 (0) - 2.1 
3 WT nBT062-DM4 4 mg/kg/week 0.0 (27) ++++ n.r. 
4 Stable nBT062-DM4 4 mg/kg/week 0.0 (27) ++++ n.r. 
5 Half nBT062-DM4 4 mg/kg/week 0.0 (27) ++++ n.r. 
6 Bispecific nBT062-natalizumab-DM4 4 mg/kg/week 62.1 (27) +/- 2.4 
7 IVIg // WT nBT062-DM4 
10 ml/kg/week // 
4 mg/kg/week 0.0 (27) ++++ 1.8 
8 IVIg //  Stable nBT062-DM4 
10 ml/kg/week // 
4 mg/kg/week 0.0 (27) ++++ n.r. 
9 IVIg // Half nBT062-DM4 
10 ml/kg/week // 
4 mg/kg/week 0.0 (27) ++++ n.r. 
10 
IVIg // 
Bispecific nBT062-
natalizumab-DM4 
10 ml/kg/week // 
4 mg/kg/week 100.0 (0) - 1.9 
11 WT nBT062-DM4 2 mg/kg/week 0.0 (23) ++++ n.r. 
12 Stable nBT062-DM4 2 mg/kg/week 0.0 (27) ++++ 2.0 
13 Half nBT062-DM4 2 mg/kg/week 0.0 (27) ++++ n.r. 
14 Bispecific nBT062-
natalizumab-DM4 
2 mg/kg/week 97.5 (6) - 2.8 
15 IVIg // 
WT nBT062-DM4 
10 ml/kg/week // 
2 mg/kg/week 
58.9 (27) +/- 1.7 
16 IVIg //  
Stable nBT062-DM4 
10 ml/kg/week // 
2 mg/kg/week 
0.0 (23) ++++ 1.5 
17 IVIg // 
Half nBT062-DM4 
10 ml/kg/week // 
2 mg/kg/week 
45.3 (27) + 1.7 
18 
IVIg // 
Bispecific nBT062-
natalizumab-DM4 
10 ml/kg/week // 
2 mg/kg/week 
98.5 (9) - 1.7 
*T/C= median tumor volume in test group/median tumor volume in control group  
**Td: Tumor volume doubling time;  
Efficacy rating: ++++, T/C <5%; +++, T/C 5 - <10%; ++, T/C 10 - <25%; +, T/C 25 - <50%; +/-, T/C 50-65%; 
            -, T/C ≥ 65% 
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Figure 4-15: Relative tumor growth curves demonstrating in vivo efficacy of nBT062-DM4 variants 
Immunodeficient NMRI nude mice bearing MAXF 1322 mammary cancer xenografts were treated with 2 or 
4 mg/kg/week of WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-
DM4 as indicated. ADCs were administered either alone or in combination with 10 ml/kg/week of a 10% human 
IVIg preparation containing endogenous IgG4 antibodies. Three intravenous injections were administered as 
specified by the arrows. PBS was used as control vehicle and the IVIg preparation was also tested as 
monotherapy. Curves demonstrate median of relative tumor volumes over time. 
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Figure 4-16: Kaplan-Meier survival plots from MAXF 1322 xenograft mouse model testing nBT062 
variants. 
Immunodeficient NMRI nude mice bearing MAXF 1322 mammary cancer xenografts were treated with 2 or 
4 mg/kg/week of WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-
DM4 as indicated. ADCs were administered either alone or in combination with 10 ml/kg/week of a 10% human 
IVIg preparation containing endogenous IgG4 antibodies. Intravenous injections were administered on day 1, 8 
and 15 as specified by the arrows. PBS was used as control vehicle and the IVIg preparation was also tested as 
monotherapy. Curves demonstrate survival of individual treated groups over time until day 86 after randomization 
of mice.  
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4.6.2 Body weight changes of nBT062-DM4 variant treated mice 
During preclinical mouse studies, body weight changes of the treaded mice are used as 
indicator for drug tolerability. Median of relative body weights from mice of this study are 
presented in Figure 4-17. Group median body weight loss (BWL) was not observed in seven 
groups (Group IDs 5, 6, 9, 11, 12, 13, 14 according Table 4-3). All other groups 
demonstrated BWL of less than 1.9%. In the group that received 2 mg/kg/day half nBT062-
DM4 with the IVIg preparation BWL was 9.4% on day 41, since one of the two remaining 
animals showed weight loss below 20%. There was a second drop in group median BWL 
within this group on day 58 when one of the two remaining mice was excluded from the 
experiment for tumor burden. However, the mice treated with half nBT062-DM4 in 
combination with the IVIg preparation and which had once a BWL of more than 20% was the 
one survived the longest in this group. Taken together, these data demonstrate that all 
nBT062-DM4 variants and also the IVIg preparation were tolerated at the dosages 
administered.  
 
Figure 4-17: Impact of nBT062-DM4 variant treatments on body weights of mice. 
Immunodeficient NMRI nude mice bearing MAXF 1322 mammary cancer xenografts were treated with 2 or 
4 mg/kg/week of WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-
DM4 as indicated. ADCs were administered either alone or in combination with 10 ml/kg/week of a 10% human 
IVIg preparation containing IgG4 antibodies. PBS was used as control vehicle and the IVIg preparation was also 
tested as monotherapy. Median of relative body weights are mapped by the curves.  
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4.6.3 Detection of bispecific antibodies in plasma of mice treated with nBT062-
DM4 variants 
It was observed in the MAXF 1322 xenograft model that the antitumor efficacy of 
nBT062-DM4 variants was decreased when coadministered with an IVIg preparation. This 
loss of efficacy was more pronounced for WT nBT062-DM4 and half nBT062-DM4. To 
investigate if this attenuated anti-tumor effect was based on an IgG4 shuffling related 
phenomenon, heparin plasma samples from mice of the in vivo study described in section 
4.6.1 were analyzed. Blood samples were taken one week prior treatment (predose samples) 
and 24 h after the first and third treatment with nBT062-DM4 variants either with or without 
administration of the IVIg preparation and analyzed by LBA/LC-MS (see section 3.6.2). This 
method uses a magnetic CD138-bead pull down assay to isolate CD138-specific antibodies. 
Those antibodies were trypsinated and analyzed by LC-MS regarding a specific nBT062 
signature peptide sequence and a generic human IgG4 peptide sequence. The amount of 
shuffled antibodies was then calculated by the ratio of the specific nBT062 signature peptide 
to the IgG4 generic peptide. The predose samples were taken as negative controls and, 
indeed, none of both signature peptides neither specific for nBT062 nor human IgG4 in 
general were found. As a second negative control, plasma from mice treated with the IVIg 
preparation alone was also tested. Within these samples nearly no amounts of signature 
peptides were detected demonstrating that the upstream CD138 pull down assay worked 
well. Results of the half-antibody exchange analysis on WT nBT062-DM4, stable nBT062-
DM4 and half nBT062-DM4 are shown in Figure 4-18. Without the co-administration of the 
IVIg preparation the three nBT062-DM4 variants did not display any nBT062-related IgG4 
shuffled fraction. Samples from the IVIg combination therapy exhibited IgG4 shuffling of 53% 
and 67% for WT nBT062-DM4 at dosages of 4 and 2 mg/kg/week, respectively while half 
nBT062-DM4 combination treatment led to half-antibody exchange fractions of 7% and 10% 
at identical dosing. Compared to each respective monotherapy, these increases in IgG4 
shuffling were significant. No half-antibody exchange was observed in samples containing 
stable nBT062-DM4 in combination with human IgGs. However, the extent of shuffling was 
significantly higher in WT nBT062-DM4 combination treatment compart to IVIg combinations 
with either stable nBT062-DM4 or half nBT062-DM4. These results indicate that the 
stabilizing mutations S228P and R409K incorporated into stable nBT062 were successfully 
able to prevent monoclonal antibodies from undergoing the IgG4 half-antibody exchange in 
vivo.  
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Figure 4-18: In vivo half-antibody exchange in MAXF 1322 xenografts treated with nBT062 variants. 
Heparin plasma samples from MAXF 1322 xenograft mice treated with WT nBT062-DM4, stable nBT062-DM4 or 
half nBT062-DM4 alone or in combination with an IVIg preparation were analyzed by LC-MS analysis after 
excluding non-CD138-binding antibodies using a magnetic bead pull down assay. Signature peptides specific for 
nBT062 and human IgG4 antibodies were used to identify the frequency of half-antibody exchange. Three mice 
from each treatment were analyzed, while each mouse provided a predose sample (negative control) and 
samples 24 h after the first and third drug injection (combined). T test was used for statistical analysis. *p<0.05; 
**p<0.01; ***= p<0.001; ****p<0.0001. 
 
4.6.4 Analysis of the IVIg preparation 
The 10% human IVIg preparation used in this xenograft mouse study was analyzed for 
endogenous anti-CD138 antibodies to exclude potential competing effects with nBT062-DM4 
variants binding tumor-expressed CD138. An ECL binding assay was performed as 
described in section 3.6.3. As demonstrated in Figure 4-19, WT nBT062 was used as 
positive control resulting in a concentration-related saturation curve with a maximum signal 
intensity of approx. 500,000. The linear detection range for this assay was determined from 
0.0001 µg/ml to 0.1 µg/ml. The use of antibody concentrations above 1 µg/ml led to a 
decrease in signal intensity, indicating a hook effect. Natalizumab, used as negative control, 
was not capable to induce specific CD138 binding. However, concentrations higher than 
1 µg/ml induced false positive detections. The IVIg preparation was tested in triplicates as 
10-times serial dilutions of total antibody concentrations between 10,000 µg/ml and 
0.001 µg/ml. No CD138-specific, concentration-dependent signal was detected for the IVIg 
preparation. Those signals obtained were already in the false positive detection range of 
natalizumab. Thus, it was ascertained that the administered IVIg preparation did not contain 
any endogenous anti-CD138 antibodies which could have been competed with the nBT062 
variants for tumor-expressed CD138 binding in xenograft mice to diminish the efficacies of 
the ADCs. 
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Figure 4-19: Analysis of the IVIg preparation to anti-CD138 antibodies.  
CD138-coated plates were incubated with the IVIg preparation and detection of anti-CD138 antibodies was done 
by electrochemiluminescence measurement after applying a biotinylated anti-human secondary antibody and 
streptavidin-conjugated sulfo-TAG. WT nBT062 was used as positive and natalizumab as negative control. 
Measurements were performed in triplicates and concentrations were tested as indicated on the X-axis.  
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5 Discussion 
Human IgG4 antibodies are known to be the only class of antibodies able to exchange 
randomly half-antibodies in vivo leading to bispecific, monovalent antibodies. This 
phenomenon was shown for endogenous IgG4 antibodies but also for monoclonal, 
therapeutic ones (Schuurman et al. 1999; Labrijn et al. 2009; Young et al. 2014). Aalberse 
and Schuurman published that the mechanism of this half-antibody exchange is mainly 
based on a reduced distance between the two disulfide bonds in the CH2 of the IgG4 
backbone, leading to a more instable hinge compared to the IgG1 subclass (Aalberse, 
Schuurman 2002). Today it is known, that both amino acid substitutions S228P and R409K 
can individually prevent this half-antibody exchange (Labrijn et al. 2011). Based on this 
knowledge the influence of half-antibody exchange on the functionality and efficacy of IgG4 
ADCs was investigated in this thesis using BT062. Therefore, nBT062 model variants 
mimicking potential in vivo derived BT062 species were generated and characterized beside 
WT nBT062 according to their function of CD138 binding and subsequent internalization. As 
the core function of therapeutic BT062 is tumor cell killing, WT nBT062 and respective model 
variants were conjugated to DM4 and tested for in vitro cytotoxicity. The direct impact of IgG4 
shuffling was investigated in vivo using a breast cancer xenograft mouse model.  
 
5.1 Successful generation of nBT062 model variants 
nBT062 model antibodies, mimicking relevant stable or transition species of the half-antibody 
exchange were first designed in silico and respective DNA plasmids were expressed in 
FreeStyle CHO-S cells and purified by protein A affinity chromatography. Beside WT nBT062 
comprising an unchanged human IgG4 backbone able to undergo half-antibody exchange, a 
stable nBT062 was generated containing the stabilizing mutations S228P and R409K to 
prevent any exchange of half-antibodies. By amino acid substitutions C226S and C229S 
covalent interactions of the heavy chains were inhibited resulting in the half nBT062 model 
variant. A bispecific nBT062 mimicking a final product of performed half-antibody exchange 
in vivo was created by incorporation of several mutations and co-expression of two different 
H and two different L chains bearing the CDRs of nBT062 or natalizumab (see section 3.2).  
The four produced nBT062 variants, WT nBT062, stable nBT062, half nBT062 and bispecific 
nBT062-natalizumab were analyzed by SDS-PAGE, IEF combined with western blotting, and 
size exclusion chromatography for correct protein expression (see section 4.1). Under 
reducing conditions, Coomassie stained SDS-PAGE analysis obtained for all nBT062 
variants H and L chains of approx. 50 and 25 kDa, respectively (see section 4.1). This is in 
line with molecular masses expected for IgG molecules (Murphy, Weaver 2017). An 
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additional band at approx. 85 kDa was detected for stable nBT062. This fraction seemed to 
be a result of incomplete reduction of disulfide bonds using 50 mM DTT as reducing agent. It 
is possible that two H chains bound together run coiled below their actual molecular weight of 
approx. 100 kDa. SDS-PAGE using non-reducing conditions demonstrated bands of 150 kDa 
within the WT nBT062, stable nBT062 and bispecific nBT062-natalizumab samples, but a 
band of this size was not present in the half nBT062 sample. Additionally, a band at approx. 
70 kDa occurred in the WT nBT062 and as the only species within the half nBT062. These 
molecular weights of 150 kDa and 70 kDa are in accordance with the literature for full length 
and half-antibodies, respectively (Rispens et al. 2010). The SDS PAGE results gave a first 
hint that the introduced amino acid substitutions led to desired structural modifications as WT 
nBT062 formed half-antibodies, whereas the stable nBT062 and bispecific nBT062-
natalizumab did not contain any half-antibodies. Further, the amino acid substitutions C226S 
and C229S within half nBT062 seemed to inhibit covalent heavy chain pairing. In addition, 
this analysis demonstrated successful purification by protein A as no further host cell protein 
bands occurred.  
Isoelectric focusing of the nBT062 model variants revealed that WT nBT062, stable nBT062 
and half nBT062 had slightly acidic to neutral pIs of pH 6.5 to 7.3, pH 6.4 to 7.0 and pH 6.1 to 
6.8, respectively. On the contrary, the pI of natalizumab was slightly basic (pH of 7.6 to 7.8) 
and bispecific nBT062-natalizumab demonstrated a neutral to basic pI between pH 7.3 to 
8.0. These differences in the pIs between the distinct monoclonal antibodies can be based 
on the one hand on the individual amino acid substitutions, but on the other hand on several 
additional modifications. Such modifications may include glycosylation, carboxyl or amino 
terminal processing at the post-translational level or chemical alterations like oxidation and 
amidation/deamidation which can occur at the downstream processing level or during 
storage (Gaza-Bulseco et al. 2008; Harris 1995; Zheng et al. 2011; Vanam et al. 2015). 
Since the nBT062 variants were produced by stable cell pools but not by single cell clones, 
post-translational modifications might be highly variable for each model antibody resulting in 
a more heterogenous band pattern and a broader pI range. However, the incorporation of the 
natalizumab CDRs and pairing mutations within the bispecific nBT062-natalizumab led to a 
more basic pI. Western blotting of these samples using anti-nBT062 and anti-natalizumab 
antibodies for immunodetection demonstrated that all bands observed in the Coomassie gel 
were specific for either nBT062 and/or natalizumab. In line with the SDS-PAGE results, this 
method further demonstrated the purity of the recombinantly expressed antibody variants. 
Further, this analysis was mainly used as a quality control to identify any monospecific 
antibody fractions within the bispecific nBT062-natalizumab sample. Since 8 out of 10 bands 
were bound by both anti-idiotypic antibodies and thus found to be bispecific, there were 2 
bands exclusively detected by the anti-natalizumab antibody. The extended knob-into-hole 
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technology for H chain - H chain pairing used for the generation of bispecific antibodies is 
one of the most efficient strategies with approx. 95% heterogenic pairing (Carter 2001). 
Nevertheless, it is known that hole-hole homodimeric pairing is possible, while knob-knob 
homodimers do generally not occur (Klein et al. 2014). To prevent interferences of a 
monospecific nBT062 antibody fraction within the bispecific nBT062-natalizumab sample on 
further binding, internalization and cytotoxicity analysis, the natalizumab part of the bispecific 
antibody was chosen as “hole” backbone. The results of this IEF analysis are in accordance 
with those described by Klein et al., 2014 and confirm the absence of a monospecific 
nBT062 fraction within the bispecific nBT062-natalizumab.  
In addition to SDS-PAGE analysis, the nBT062 variants were further characterized by SEC 
to investigate the presence of fragments, aggregates or half-antibodies (see section 4.1). 
While nearly no small antibody fragments were found using native running buffer conditions, 
bigger aggregates were detected in amounts of 4.5%, 7.4%, 7.1% and 25% in half nBT062, 
WT nBT062, bispecific nBT062-natalizumab and stable nBT062, respectively. Protein 
aggregation is a well-known phenomenon in monoclonal antibody drug development, 
although the underlying reasons are only poorly understood (Wang 2005). Aggregation can 
occur during the different antibody production steps including fermentation, purification, final 
formulation, and storage (Vázquez-Rey, Lang 2011). Kiese et al. postulate that full or partial 
protein unfolding exposes hydrophobic regions, which in turn promote intermolecular 
interactions resulting in aggregation or precipitation of sub-visible or visible particles (Kiese et 
al. 2008). These aggregates might finally influence the activity, solubility and immunogenicity 
of the produced drug (Vázquez-Rey, Lang 2011). Individually developed affinity 
chromatography, ion exchange chromatography, SEC and tangential flow filtration are used 
in combination with an optimized formulation buffer to prevent or diminish aggregate 
formation (Ansaldi, Lester 1999; Wan, Wang 1998; Phillips et al. 2001; Wang et al. 2006). 
However, during the nBT062 variant production for this preclinical study no separate 
aggregate-diminishing steps were included besides protein A affinity chromatography. The 
detected higher amounts of aggregates within the stable nBT062 compared to the other 
nBT062 variants might be based on the individual structure in combination with an un-
optimized formulation buffer for storage. Interestingly, when 10% 2-propanol denaturing 
running buffer was applied, the bispecific nBT062-natalizumab tended to form aggregates 
which were not seen with native running buffer. Aggregates of stable nBT062 did also not 
fully resolve under denaturing conditions. This is in line with aggregate categories from 
Cromwell et al. separating them into soluble/insoluble, covalent/non-covalent, reversible/non-
reversible and native/denatured ones (Cromwell et al. 2006). Besides that, the denaturing 
SEC analysis confirms the results of the non-reducing SDS-PAGE analysis: While stable 
nBT062 and bispecific nBT062-natalizumab did hardly contain half-antibodies, WT nBT062 
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samples provided a small fraction of those product related fragments and the half nBT062 
variant was present only as half-antibodies. Since half nBT062 demonstrated under native 
conditions a similar or even slightly higher retention time which is accompanied with a slightly 
bigger protein size compared to WT nBT062 and stable nBT062, this SEC analysis provides 
evidence that dimerization of half-antibodies does occur based on non-covalent interactions 
dependent on surrounding conditions. Such non-covalent interactions are described between 
the CH3 domains of two H chains (Labrijn et al. 2011).  
The capability to prevent half-antibody exchange of nBT062 antibodies due to the 
incorporation of the stabilizing S228P and R409K mutations was investigated by exposing 
mild reducing conditions to WT nBT062 and stable nBT062, each in the presence of 
natalizumab. The in vitro formation of bispecific antibodies was obtained in a mixture of WT 
nBT062 and natalizumab, but they could not be detected in samples of stable nBT062 and 
natalizumab. Thus, as expected and in line with the results from Labrijn it can be concluded 
that S228P and R409K mutations could successfully prevent half-antibody exchange under 
reducing conditions in vitro (Labrijn et al. 2011). 
In summary, it was shown that WT nBT062, stable nBT062, half nBT062 and bispecific 
nBT062-natalizumab were produced in a sufficient quality and incorporation of mutations 
lead to the expected analytical characteristics.  
 
5.2 All nBT062 variants bind CD138 and are internalized 
Specific antigen binding of nBT062 model variants was analyzed by flow cytometry. All 
model variants, WT nBT062, stable nBT062, half nBT062 and bispecific nBT062, were 
capable of specific CD138 binding in the low nanomolar range as observed by concentration 
dependent incubation of Ba/F3-hCD138 (CD138+/CD49d-) cells. On the contrary, bispecific 
nBT062-natalizumab was the only variant able to bind Jurkat (CD138-/CD49+) cells with a 5x 
times reduced avidity compared to natalizumab. While WT nBT062, stable nBT062 and half 
nBT062 showed comparable binding activities towards CD138 on Ba/F3-hCD138 cells, 
binding of bispecific nBT062-natalizumab was significantly reduced. This reduced binding 
might be based on two major aspects: First, it is known that clustering of CD138 on the cells 
surface is mediated by heparin binding domains of heparinase (Ramani et al. 2013). As 
nBT062-natalizumab is monovalent for each antigen this variant is not capable to crosslink 
clustered antigens potentially leading to a weaker interaction. With respect to the SEC 
analysis, half nBT062 antibodies might be present as dimers under the conditions used in 
this experiment and thus act as bivalent antibodies. In 1972, Hornick and Karush already 
described the increasing effect of multivalency on the antibody-antigen binding strength 
supporting this assumption (Hornick, Karush 1972). Second, several mutations for correct H 
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and L chain pairing were incorporated into the framework regions next to the CDRs of the 
nBT062-natalizumab variant which might affect the non-covalent interactions between the 
antibody and its epitope. Taken together, these data on the binding activity provide evidence 
that the generated nBT062 variants can function as model antibodies mimicking in vivo 
derived antibodies species as they all demonstrated binding in the nanomolar range and act 
as expected.  
The mode of action of BT062 and other ADCs is based on the tumor cell specific delivery of 
toxins. Beside ADC binding, this process further includes internalization as an indispensable 
step. Thus, it was important to analyze if all potential BT062 derived species are capable to 
induce such antigen-mediated antibody uptake. Fluorescently labeled WT nBT062, stable 
nBT062, half nBT062 and bispecific nBT062-natalizumab were therefore incubated on 
Ba/F3-hCD138 (C138+/CD49d-) and NCI-H929 (C138+/CD49d+) cells and internalization was 
assessed by flow cytometry as well as fluorescence microscopy. It is known that CD138 can 
be cleaved off from cell surfaces using proteolytic enzymes such as trypsin or chymopapain 
(Beckman Coulter 2011; Sun et al. 1997). Cells were incubated with nBT062 variants for 
either 0.5 h at 4°C or 24 h at 37°C and analyzed by flow cytometry after trypsin incubation or 
not. Both cell lines tested showed significantly higher staining intensities after 24 h than after 
0.5 h. Digestion with trypsin after 0.5 h of incubation decreased the staining intensity of 
treated cells to that of unstained ones, while cells incubated for 24 h still demonstrated high 
staining intensities. Thus, it can be concluded that the increase in fluorescence intensity 
between 0.5 h and 24 h is not based on unbound CD138 molecules on the surface at the 
earlier time point, but on internalization of nBT062 variants. In general, the results 
demonstrated that all nBT062 variants WT nBT062, stable nBT062, half nBT062 and 
bispecific nBT062-natalizumab were internalized within 24 h into both cell lines. However, 
there were slight differences between the monospecific and the bispecific nBT062 variants 
and between the cell lines NCI-H929 and Ba/F3-hCD138. WT nBT062, stable nBT062 and 
half nBT062 demonstrated similar fluorescence intensities for each incubation test set. On 
the contrary, bispecific nBT062-natalizumab had approx. 2-fold lower initial surface staining 
at 4°C but interestingly the detected fluorescence from internalized antibodies was even 
higher for NCI-H929 cells and similar for Ba/F3-hCD138 cells. Thus, it might be assumed 
that bispecific nBT062-natalizumab had a higher internalization rate. It was further 
recognized that within each antibody panel and for both cell lines, the sum of fluorescence 
intensity of surface staining and internalized staining was approx. the total fluorescence 
observed after 24h of incubation. This demonstrates that the amount of surface staining was 
similar after 0.5 h and 24 h and gives a hint that CD138 molecules are expressed to a 
constant level on the surface. In addition, there was a major difference between both tested 
cell lines: As internalization was much higher as the initial surface staining on Ba/F3-hCD138 
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cells for all nBT062 variants, monospecific nBT062 models demonstrated higher surface 
staining as internalization on NCI-H929 cells. However, on those cells bispecific nBT062-
natalizumab was the only variant having a higher internalization fluorescence compared 
surface staining. Thus, this observation might be a further hint showing that the 
internalization rate was increased for the bispecific nBT062-natalizumab. A potential 
molecular explanation could be the lack of CD138 crosslinking leading to an independent 
and thus faster internalization of the receptors.  
Results of fluorescence microscopy qualitatively confirmed the internalization of WT nBT062, 
stable nBT062, half nBT062 and bispecific nBT062-natalizumab into Ba/F3-hCD138 cells as 
green fluorescent spots were detected for each molecular variant, but not for non-binding 
fluorescence labeled natalizumab (see section 4.3.2). Co-localization of all nBT062 variants 
with LAMP-1 demonstrated their transport into lysosomes where DM4 would be released by 
proteolysis. In general, two different mechanisms for CD138 internalization are reported 
depending on the type of ligand: While internalization of atherogenic lipoproteins enriched in 
lipoprotein lipase (LpL) is mediated via lipid rafts, heparinase for example seems to be 
internalized by clathrin coated pits (Fuki et al. 1997; Fuki et al. 2000; Chen, Williams 2013). 
With respect to kinetics the latter type of uptake occurs quite fast within 15 min, whereas t1/2 
is approx. 1 h for lipid raft internalization (Goldstein et al. 1985; Nadav et al. 2002; Fux et al. 
2009; Shteingauz et al. 2014). Based on observations during fluorescence microscopy 
method development, first signs of cellular nBT062 antibody uptake were seen after 1-2 h of 
incubation at 37°C, which would be in line with an antibody uptake based on lipid rafts. 
Endocytosis of bispecific nBT062-natalizumab antibodies indicated that CD138 crosslinking 
which could only be mediated by monospecific, bivalent nBT062 antibodies is not a 
compulsory requirement for the uptake. Efficient lysosomal trafficking is important for ADCs 
to evolve the full potential of the cytotoxic agent. In a recent study de Goeij and colleagues 
generated a bispecific IgG1 antibody targeting the tumor specific antigen HER2 and CD63, a 
protein known to shuttle between the plasma membrane and intracellular compartments. 
Conjugated to duostatin-3, this bispecificity led to an improved cytotoxic potential compared 
to the respective monospecific antibodies (Goeij et al. 2016).  
In summary, these data demonstrate that all nBT062 model variants were capable of 
sufficient CD138 binding followed by internalization and processing due to endosomal and 
lysosomal pathway and thereby provide the potential to specifically transport cytotoxic agents 
into CD138-expressing tumor cells in vivo. 
 
Discussion 
95 
5.3 Conjugation of nBT062 variants to DM4  
The different nBT062 model variants, WT nBT062, stable nBT062, half nBT062 and 
bispecific nBT062-natalizumab were fused to the cytotoxic agent DM4. This was done by a 
two stage conjugation process attaching the SPDB linker to the respective nBT062 variant 
first, followed by conjugating DM4 to the thiol-reactive group of the SPDB linker. Since drug 
substance material of BT062 used in clinic trials has approx. 3.5 DM4 molecules per 
antibody, this DAR was also aimed for when monospecific, bivalent WT nBT062 and stable 
nBT062 were conjugated. Half-antibodies and bispecific antibodies evolved by the in vivo 
IgG4 half-antibody exchange mechanism would result in 50% of the initial payload. Thus, for 
DM4 conjugation of one half nBT062 molecule (HC+LC) and one bispecific nBT062-
natalizumab, it was also aimed for 50% payload, respectively 1.75 DM4 molecules per 
antibody. The DM4 conjugation was successfully performed resulting in ADCs with DARs of 
3.5, 3.4, 1.6, and 1.7 for WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 and 
bispecific nBT062-natalizumab-DM4, respectively. The DAR is one of the major critical 
factors in ADC development as attaching less payload will decrease the efficacy. On the 
contrary, fusion of too many toxic agents will destabilize the ADC resulting in altered PK, 
increased plasma clearance, reduced half-life and increased systemic toxicity (Perez et al. 
2014; Diamantis, Banerji 2016). For example, it was shown that ADCs with a DAR of approx. 
2 to 4 demonstrated comparable PK to unconjugated antibodies, but ADCs with a DAR of 8 
cleared more rapidly resulting in a reduced antitumor efficacy in vivo. This was potentially 
due to an increased exposure of the latter ADC leading to faster clearance and, 
consequently, to a smaller PK area under the curve (Hamblett et al. 2004; Kim, Kim 2015). 
Thus, most of current ADCs approved or in clinical development utilizing a lysine conjugation 
approach provide an average of 3-4 cytotoxic payloads per antibody (Lambert 2013). For 
example, trastuzumab emtansine, a DM1 conjugated anti-Her2 antibody approved for the 
treatment of breast cancer, also utilizes a DAR of 3.5, which is exactly in line with the amount 
of payload used for BT062 (Kim et al. 2014; Jain et al. 2015). Compared to the WT nBT062 
conjugation reaction, 70% and also 50% of each, SPDB linker and DM4 were tested for 
bispecific nBT062-natalizumab ADC generation. This resulted in DARs of 2.6 (74% 
SPDB/DM4) and 1.7 (49% SPDB/DM4), respectively. Therefore, it can be concluded that the 
SPDB linker and DM4 conjugation reactions seem to be proportional and potentially easy to 
adjust for aiming at a specific DAR.  
The DM4 distribution in each nBT062-DM4 variant was determined ranging from 0 to 6, 0 to 
6, 0 to 4, and 1 to 3 drugs per antibody molecule for WT nBT062-DM4, stable nBT062-DM4, 
half nBT062-DM4 and bispecific nBT062-natalizumab-DM4, respectively. Compared to the 
three bivalent nBT062-DM4 variants (~150 kDa), half nBT062-DM4 was measured with 
masses of approx. 75 kDa (HC+LC). Thus, when assuming non-covalent interactions leading 
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to half nBT062-DM4 dimerization, this model demonstrated the broadest drug distribution 
range of zero to eight DM4 molecules per full length antibody. For bispecific nBT062-
natalizumab, the DM4 distribution range was reduced by 50%, proportionally in line with the 
reduced amount of SPDB linker and DM4 during conjugation. In contrast to WT nBT062-DM4 
and stable nBT062-DM4, bispecific nBT062-natalizumab did not comprise any fraction of 
unconjugated antibodies. However, those observations suggest that SPDB-DM4 conjugation 
follows a binomial distribution. This theory is further supported by Goldmacher et al., who 
published an algorithm for identification of an acceptable statistical model for experimental 
drug load distributions in ADCs (Goldmacher et al. 2015). Furthermore, the results observed 
in this thesis are in accordance with other lysine-based ADCs: Trastuzumab emtansine is 
known to contain a distribution of zero to eight DM1 molecules per antibody (Kim et al. 2014), 
while the DM1 conjugated anti-CD56 ADC, HuN901-DM1, displays a drug distribution profile 
of one to six cytotoxic molecules (Wang et al. 2005). Interestingly, gemtuzumab ozogamicin, 
an anti-CD33 mAb conjugated to calicheamicin, seems to be the only current ADC, wherein 
up to 50% of the antibodies are unconjugated, while the other fractions comprise a payload 
of four to six cytotoxic molecules per antibody leading to an overall DAR of approx. 2-3 (Kim, 
Kim 2015). The MS spectrum further revealed, that half nBT062-DM4 had much more 
different glycosylation species than any of the other three nBT062-DM4 variants. 
Glycosylation of IgGs is e.g. known to modulate effector functions and half-life (B. Wong 
2012). The major glycosylation site of the IgG4 subtype is found between the two CH2/CH3 
domains forming the Fc, namely the N-linked glycosylation at position 297 (Vidarsson et al. 
2014). While half nBT062 antibodies lack covalent dimerization, it is conceivable that the 
accessibility during glycosylation taking place in the endoplasmic reticulum and the Golgi is 
increased leading thereby to a higher glycosylation level. nBT062 variants were produced 
from stable CHO cell pools but not from single cell clones, which might result in a higher 
variation in the glycosylation pattern. Nevertheless, these minor differences in glycosylation 
should not influence the efficacy of the different nBT062-DM4 variants. 
Full length IgG comprises approx. 80-100 lysines allocated on the two H and two L chains, 
carrying each an ε-amino group potentially available for random conjugation (Goldmacher et 
al. 2015). This random lysine conjugation results in ADC subpopulations with different 
numbers of cytotoxic moieties attached, but also in different locations of their linkage. MS 
analysis of WT nBT062-DM4, stable nBT062-DM4 and half nBT062-DM4 obtained eleven 
identical conjugation sites in the LCs of each variant. Since no modifications were 
incorporated in the LCs of those variants, this was not surprising. In contrast and compared 
to WT nBT062-DM4, the conjugation site K223 was lacking in stable nBT062 and half 
nBT062-DM4 and additionally for half nBT062-DM4 the K250 was not found to be 
conjugated. K223 is located next to the S228P substitution in stable nBT062-DM4 and 
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C226S and C229S mutations in half nBT062. Known that these amino acid substitutions 
have an influence on the protein structure, the resulting conformational alterations might 
have prevented lysine conjugation of K223 and K250 by steric hindrance. The approved ADC 
trastuzumab emtansine contains in total 88 lysines and 4 N-terminally amino groups, of 
which 82 sites (13 LC conjugation sites, 28 HC conjugation sites) were found to be partially 
conjugated (Chen et al. 2016). Wang et al. have previously reported 36 conjugations sites for 
huN901-DM1, namely six within each L chain and twelve within each H chain, while none of 
those modifications were found in the CDR regions. In conclusion, these results for 
trastuzumab emtansine, huN901-DM1 and the nBT062-DM4 variants demonstrate that 
lysines are conjugated quite differently, probably due to the individual specificities of each 
antibody and the conditions used for ADC conjugation.  
As efficient payload delivery is based on the ADCs' antibody binding, flow cytometric analysis 
was used in this study to examine the influence of DM4 conjugation on the binding avidity of 
each nBT062 variant. No significant difference in CD138 binding between unconjugated and 
the respective DM4-conjugated variant was observed for WT nBT062-DM4, stable nBT062-
DM4, half nBT062-DM4 and bispecific nBT062-natalizumab-DM4 in two cell lines tested. 
Again, similar observations were made for trastuzumab emtansine where neither an 
influence of DM1 linkage on the binding affinity to Her2 was detected, nor a reduction of 
trastuzumab’s anti-tumor effects itself were identified (Junttila et al. 2011; Barok et al. 2011b, 
2011a; Barok et al. 2014). In contrast, Bondza and colleagues investigated the influence of 
biotin or fluorescence conjugation on the binding activity of the anti-EGFR antibody 
cetuximab using the LigandTracer method. Their results demonstrate that minor 
modifications could already lead to a reduced affinity to EGFR, while an anti-CD44v6 
antibody was not influence on its antigen binding (Bondza et al. 2014). Thus, conjugation of 
small molecules to antibodies seems to be individual for each antibody, linker, payload and 
the conjugation technology used. Therefore, the in-depth characterization of the resulting 
ADCs is an important aspect during their development.  
Taken together, it can be concluded that WT nBT062, stable nBT062, half nBT062 and 
bispecific nBT062-natalizumab were successfully conjugated to the cytotoxic agent DM4. In 
addition, each model variant resulted in DARs of the respective antibody species evolved by 
an IgG4 half-antibody exchange. The analytical characterization obtained similar properties 
compared to other ADCs, especially to trastuzumab emtansine. Thus, the generated 
nBT062-DM4 variants provide a suitable model on the different IgG4 shuffling related 
antibody species for comparing the cytotoxic potential. 
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5.4 All nBT062-DM4 variants mediate CD138-specific cytotoxicity in 
vitro 
The cytotoxicity of all nBT062-DM4 variants was assessed in WST-1 viability assays to 
compare the anti-tumor activity and draw conclusions on the influence of the in vivo IgG4 
half-antibody exchange on the efficacy. No significant difference in the potencies of WT 
nBT062-DM4, stable nBT062-DM4 and half nBT062-DM4 were observed (IC50: 
~0.08-0.14 nM). Since one half nBT062-DM4 molecule carried only 50% payload, there are 
two explanations for the similar potency of WT nBT062-DM4 and stable nBT062-DM4 
compared to half nBT062: As tumor cell killing is only associated with the amount of DM4 
molecules brought into the cell, half nBT062-DM4 molecules (75 kDa) had either (I) a higher 
internalization rate or (II) had to be dimerized by non-covalent interactions during this testing. 
In flow cytometric internalization experiments, higher internalization of half nBT062 was not 
seen: Initial surface binding and level of internalized antibodies was similar to the WT 
nBT062 and stable nBT062 models. Additionally, non-denatured SEC analysis provided 
information, that dimerization of half nBT062 took place. Thus, it can be concluded that half-
nBT062-DM4 variants dimerized without hinge-stabilizing disulfide bonds in this experiment. 
However, in comparison to the monospecific WT nBT062-DM4, a decrease in the cytotoxicity 
of bispecific nBT062-natalizumab-DM4 was observed by approx. 50% in the absence or by 
70% in the presence of a CD49d blocking antibody, respectively. This limited cytotoxic 
potency can be related to the reduced DM-4 payload per antibody leading to a lower cellular 
accumulation of the maytansine derivate. Internalization analyses have shown that 
natalizumab-epitope specific binding to CD49d did not lead to any antibody internalization 
(see section 4.3) and no cytotoxic activity was mediated by natalizumab itself. Despite this 
lack of bispecific nBT062-natalizumab-DM4 internalization via CD49d, it can thus be 
assumed that further ADC accumulation on the cell's surface by CD49d followed by potential 
crosslinking to CD138 might induce additional internalization of the ADC via the latter 
receptor increasing the cytotoxicity. Interestingly, there are some approaches trying to 
generate bispecific ADCs with one specificity against a tumor-specific antigen while the 
second epitope is located on a receptor known for fast internalization. Bridging those 
receptors shall lead to a more efficient internalization and prevent ADCs from cellular 
recycling mechanisms without the release of the cytotoxic agent. For example, Andreev and 
coworkers have generated a bispecific antibody targeting both, Her2 and prolactin. Besides 
Her2, the prolactin receptor is also a potential breast cancer target known for rapid 
internalization and efficient lysosomal trafficking. Crosslinking of both receptors enhanced 
the cytotoxicity of a respective ADC compared to the monospecific Her2-binding ADC 
(Andreev et al. 2017). Similar results were obtained by DeVay et al. when targeting Her2 in 
combination with the Amyloid Precursor Like Protein 2 (APLP2) (DeVay et al. 2017).  
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However, to draw conclusions from these experiments for the influence of in vivo IgG4 half-
antibody exchange on the ADC's efficacy, it is important to mention that endogenous IgG4 
antibodies are generally not directed against naturally human surface receptors. As in vivo 
shuffling of an IgG4-based ADC would result in a random exchange, the second specificity 
apart from the tumor-antigen is undefined and thus not available for tumor-specific binding. 
Hence, the approach blocking CD49d should reflect better the in vivo situation. Nevertheless, 
the IC50 of bispecific nBT062-natalizumab-DM4 was still in the picomolar range (456 pM). 
This reflects a similar cytotoxicity as trastuzumab emtansine when killing SK-BR-3 breast 
cancer cells (~323 pM) (Beerli et al. 2015). In addition, this further demonstrates the high 
cytotoxic potential of the monospecific, bivalent nBT06-DM4 variants.  
 
5.5 Human IgG4 reduces the efficacy of unstabilzed nBT062 
variants in vivo 
The influence of in vivo IgG4-related half-antibody exchange on the efficacy of an 
unstabilized therapeutic IgG4 antibody is related to its mode of action. Blocking antibodies 
such as the approved natalizumab known to undergo half-antibody exchange with 
endogenous IgG4 might still perform in a sufficient manner (Hutchinson 2007; Labrijn et al. 
2009; Broug et al. 2010). Other mode of actions where bivalent binding to certain epitopes is 
required, e.g. antigen crosslinking of identical or distinct proteins, the therapeutics might 
become inactive after exchanging half-antibodies. For example, wild type IgG4-based 
1D09C3 was not able to crosslink human leukocyte antigen-DR (HLA-DR) after this process 
anymore. Thus, the development of 1D09C3 was discontinued in early clinical trials for 
advanced B cell malignancies (Hansen et al. 2009; Broug et al. 2010; Schweighofer et al. 
2012). In the present work, the influence of IgG4 half-antibody exchange on the efficacy of 
the ADC BT062 was evaluated in a breast cancer xenograft mouse model using the 
generated model variants, WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 and 
bispecific nBT062-natalizumab-DM4. Therefore, all nBT062-DM4 variants were tested in 
doses of 4 or 2 mg/kg/week either as monotherapy or in combination with an IVIg preparation 
containing human IgG4 antibodies. Administration of IVIgs resulted in serum levels 
comparable to human IgG4 serum concentrations of 10 µg/ml to >2 mg/ml (Aucouturier et al. 
1984). All treatments were well tolerated as nearly no changes in body weights were 
observed (see section 4.6.2). In the absence of human IgG4, WT nBT062-DM4, stable 
nBT062-DM4 and half nBT062-DM4 were highly effective, leading to tumor remissions at 
both dose levels tested. The prescence of IgG4 did not influence the efficacy of the 
monospecific variants at the high dose, but it reduced the efficacy of WT nBT062-DM4 and 
half nBT062-DM4 when administered at low dose in terms of both, median tumor growth and 
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tumor growth delay based on animal survival. The efficacy of stable nBT062-DM4 was not 
significally influenced by the presence of human IgG4 at low dose, but only 3 of 5 mice 
demonstrated complete remissions. Compared to that, stable nBT062-DM4 led to 100% 
survival in the other groups tested (see section 4.6.1). This observation on IgG-mediated loss 
of anti-tumor activity can be correlated to the in vivo half-antibody exchange: Antibody 
shuffling was shown in plasma samples by LBA/LC-MS for WT nBT062-DM4 and half 
nBT062-DM4, but was not detected for stable nBT062-DM4 (see section 4.6.3). Interestingly, 
shuffling of WT nBT062-DM4 tended to be higher at 2 mg/kg/week dosing compared to 
4 mg/kg/week dosing, when measuring plasma samples 24 h post injection. As the human 
IVIg preparation was adminstered at constant levels of 10 ml/kg/week, an increased ratio of 
ADC to IgG4 within the IVIg preparation occured at the lower dose (ratio ADC:IgG4 = ~1:5 
for 4 mg/kg/week or ~1:10 for 2 mg/kg/week dosing). As IgG4 shuffling seems to follow an 
equilibrium reaction, this might explain such observations since increasing the ratio towards 
endogenious IgG4 shifts the reaction towards bispecific antibodies. As described, WT 
nBT062-DM4 and half nBT062-DM4 acted similarly in vivo in the presence or absence of 
endogenous IgG, indicating that half nBT062-DM4 antibodies were able to undergo non-
covalent dimerization under physiological conditions. In contrast, detected shuffling levels for 
half nBT062-DM4 in murine plasma were much lower compared to WT nBT062-DM4. This 
might be based on the conditions of the CD138 pull down assay before sample digestion and 
injection into the LC-MS/MS system. Harsh conditions during antibody-bead binding and 
washing might potentially terminate non-covalent dimerizations, the final eluate would result 
in a deminished fraction of bispecific antibodies and thus result in an underestimation of 
shuffling by this method.  
Bispecific nBT062-natalizumab-DM4 reached only boarderline efficacy when dosed at 
4 mg/kg/week in monotherapy and was ineffective in any other dosing. Thus, it can be 
assumed that bispecific ADCs as a product of in vivo half-antibody exchange were much less 
effective. A possible explanation might be that the cytotoxic agents were not able to 
accumulate to a sufficient threshold for in vivo tumor cell killing. As WT nBT062-DM4 and 
half nBT062-DM4 ADCs demonstrated a significantly higher efficacy, even though half-
antibody exchange occured, it can be concluded that the process of shuffling takes some 
time until an equilibrium is adapted. This hypothesis is in line with results from Rispens et al. 
investigating the IgG4 half-antibody exchange kinects in vitro after either DTT reduction of 
differently labeled IgG4 antibodies or permanently in the presence of 1 mM GSH via Förster 
resonance energy transfer (FRET). They demonstrated that once the disulfe bonds in the 
hinge region were reduced by the strong reducing agent DTT, shuffling took place within 
minutes. In contrast, using the mild reducing conditions by GSH this process took much more 
time (Rispens et al. 2011). Such a time window until IgG4 shuffling occurs in vivo might be 
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used by WT nBT062-DM4 and half nBT062-DM4 to saturate CD138 receptors on the tumor 
cells’ surfaces resulting in transport of higher DM4 amounts into the cells. This hypothesis 
further rises the question if IgG4 shuffling can occure once an antibody has already bound to 
its antigen. An answer might be given by a cellular assay based on two different labeled 
antibodies using FRET. Furthermore, it would be interesting to study the in vivo PK of half-
antibody exchange and comparing them with the PK profiles of the ADC and the antibody 
itself. However, dispite this mouse study demonstrated an improved efficacy of the stable 
nBT062 in the presence of endogenous IgG4, those benefits were only observered at the low 
dose treatment. Hence, it can also be assumed from this experiment that an IgG4 shuffling 
related loss of efficacy might be compensated by an adjusted dosing schedule.  
Interestingly, the IVIg preparation reduced the efficacy of the hinge-stabilized bispecific 
nBT062-natalizumab and also, based on an unsignificant trend at the low dose treatment, the 
efficacy of stable nBT062-DM4. Blocking of CD138 by antibodies within the IVIg preparation 
was excluded as no CD138-antibodies were detected in the ECL assay (see section 4.6.4). A 
possible explanation for these findings might be given by the results of Bleeker et al.: They 
were able to demonstrate in mice that co-administered IVIg decreased the plasma 
concentration of a monoclonal IgG1 by ~40% after 3 days (Bleeker et al. 2001). This is based 
on the competition for FcRn binding, the major receptor responsible for half-life prolongation 
of IgG. Thus, the half-life of nBT062-DM4 variants might be extendet at low total IgG 
concentrations in immunodeficient NMRI nude mice, because FcRn competition is lacking. 
Adding IVIgs then might decrease the ADCs half-life by saturating FcRn molecules. This 
hypothesis can be proven by measuring the PK as already suggested.  
 
5.6 Safety related aspects of half-antibody exchange 
Addressing the influence of IgG4 shuffling on the efficacy of a given ADC is one major issue 
while the patients’ safty is another. In general, side effects due to the exchange of half-
antibodies in patients can not be fully excluded, but seem to be unlikely based on the 
following facts: The self/non-self discrimination of the immune system ensures in people, 
who do not suffer from auto-immune diseases, that antibodies produced by B cells are not 
directed against intact, endogenous molecules. This also applies for IgG4: It is mainly known 
to be associated with allergies and might downregulate inflammatory responses. IgG4 lacks 
proinflammatory effector functions and reacts with the inhibitory FcγRIIb present on 
macrophages, monocytes and DCs leading to the production of anti-inflamatory Interleukin-
10 (Scott-Taylor et al. 2017; Murphy, Weaver 2017; Nirula et al. 2011). Further, the 
endogenous IgG4 antibodies circulating in the human blood system are directed against a 
broad repertoire of antigens. Hence, half-antibody exchange of ADCs would result in 
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bispecific antibodies having one specificity against the tumor-antigen and another one 
against any unknown second target out of a variety of many distinct antigens, e.g. an 
allergen, small molecule or maybe although unlikely an endogenous antigen. The propability 
that a bispecific antibody species against a cellular target different from the specific tumor-
antigen arises and is still internalized in amounts necessary to overcome the cytotoxic 
threshold, seems to be extremely low. In addition, ADCs carrying maytansines, e.g. DM4, are 
only able to affect dividing cells as they inhibit microtubule de-polymerization. These 
assumptions are further supported by intermediate results from a phase I/IIa clinical trial 
investigating BT062’s safety and efficacy in combination with the standard of care drugs 
lenalidomide or pomalidomide and dexamethasone for the treatment of multiple myeloma 
including patients resistant to a prior therapy. The interim analysis has shown that BT062 is 
well tolerated in doses up to 120 mg/m² in above mentioned combinations with encouraging 
activities (Kelly et al. 2016). 
 
5.7 Conclusion and outlook 
In this thesis, the influence of in vivo IgG4 half-antibody exchange on the functionality and 
efficacy of unstabilized ADCs was investigated using BT062, an anti-CD138 IgG4 antibody 
conjugated to the cytotoxic agent DM4. Beside WT nBT062 comprising the natural IgG4 
hinge available for half-antibody exchange, three model antibodies were successfully 
generated: Stable nBT062 incorporates amino acid mutations S228P and R409K to prevent 
IgG4 shuffling, while half nBT062 was used as a model for the transition state as this version 
is lacking the cysteines in the hinge region responsible for covalent heavy chain dimerization. 
Bispecific nBT062-natalizumab was used to simulate a potential product of the in vivo half-
antibody exchange. All nBT062 variants were produced in FreeStyle CHO-S cells, 
purification worked well and all molecules demonstrated their expected analytical properties 
as identified by SDS-PAGE and IEF. SEC analysis suggested that half nBT062 was non-
covalently dimerized under non-denaturing conditions. Flow cytometric analyses revealed 
that all nBT062 variants were capable to bind CD138 with nanomolar affinity/avidity, even 
though the binding activity of bispecific nBT062-natalizumab was slightly reduced compared 
to the monospecific antibodies. All molecular variants were internalized by the 
endosomal/lysosomal pathway after binding to CD138 on NCI-H929 (CD138+/CD49d+) and 
Ba/F3-hCD138 (CD138+/CD49d-) cells. Conjugation with SPDB linker and DM4 was 
succesfully performed aiming at 3.5 DM4 molecules per WT nBT062 and stable nBT062 and, 
respectively, 50% for half nBT062 (HL, 75 kDa) and bispecific nBT062-natalizumab. The 
DM4 distribution patterns were in line with their respective DARs and potential conjugation 
sites were similar for the monospecific variants. Further, the DM4 conjugation did not 
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influence the CD138 binding activity of any nBT062-DM4 variant. Assessing the in vitro 
cytotoxicity on NCI-H929 cells obtained that each ADC model mediated CD138-specific 
inhibition in the picomolar range, but monospecific variants were approx. 4 to 5 times more 
potent (IC50: ~80 to 140 pM) in comparison to bispecific nBT062-natalizumab (~456 pM). 
Investigation of the nBT062-DM4 models in tumor-bearing xenograft mice demonstrated that 
hinge-stabilization prevented in vivo half-antibody exchange and thereby improved the 
efficacy at low ADC dosage (2 mg/kg/week) in the presence of human IgG4. Nevertheless, in 
high dosed mice (4 mg/kg/week) there were no significant differences observed between WT 
nBT062-DM4, stable nBT062-DM4 and half nBT062-DM-4 in the presence or absence of 
IgG4 while bispecific nBT062-natalizumab was only able to demonstrate a borderline efficacy 
in the absence of human IgG4. Based on this observation it was assumed that the in vivo 
half-antibody exchange is time-dependent providing unstabilized ADCs a time window for 
efficient tumor-specific cytotoxic transport. This potential time window could be investigated 
by a PK study in mice or even better in patients from clinical studies using the LBA/LC-MS 
method. A comparision with the PK profiles of the ADC and the unconjugated antibody, 
detectable e.g. by a panel of ELISA assays specific for free DM4, DM4-conjugated to the 
antibody and the antibody itself, could be used to optimize the dosing schedule. To further 
investigate the tumor-specific cytotoxicity, it would be interesting to address differences in the 
tumor-penetration of the nBT062-DM4 variants. For example, this could be done by 
immunohistochemistry using tumor sections from treated mice stained against both, nBT062 
and DM4. The assessment of the systemic antibody distribution and accumulation of 
nBT062-DM4 variants in the presence or absence of human IgG4 would add important 
information to the pool of knowlege. By in vivo imaging in tumor-bearing nude mice, it would 
be possible to study if half-antibody exchanged WT nBT062-DM4 labeled with an IR dye can 
accumulate in any other tissues beside the tumor. As nBT062 only targets human CD138, 
the generation of a human CD138-transgenic mouse model could be considered to study off-
target cytotoxic effects. However, this thesis clearly demonstrated the additional benefits of 
stabilizing mutations preventing the in vivo IgG4 half-antibody exchange and thus their 
incorporation should be considered when designing new IgG4-based ADCs or biobetters.  
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7 Appendix 
7.1 Vector maps 
 
 
Figure 7-1: Vector maps for nBT062 variant expression.  
The orientation of the genes is indicated by the arrow. HindIII, NotI, XbaI are the restriction sites used for cloning. 
enhCMV EF1α is the eukaryotic promotor for the gene of interest. Ampicillin resistance is used as prokaryotic 
selection marker. Puromycin or dhfr is used for eukaryotic selection. The SV40 origin provides the origin of 
replication for eukaryotes and the pBR322 origin provides the origin of replication for prokaryotes.  
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7.2 Markers for electrophoresis 
SeeBlue Plus2 Protein Standard:  Serva IEF Marker pH 3-10: 
 
 
 
Source: 
https://assets.thermofisher.com/TFS-
Assets/LSG/figures/LC5925-chart.jpg-650.jpg 
 source: 
http://tools.lifetechnologies.com/cont
ent/sfs/manuals/IEFmarker_card.pdf 
 
 
  
 
7.3 Supplementary information for section 4.4.3 
 
Table 7-1: Binding of nBT062 variants to Ba/F3-hCD138 cells - Statistical analysis. 
Significant values are shown in green. 
Table 7-2: Binding of nBT062 variants to NCI-H929 cells - Statistical analysis. 
Significant values are shown in green. 
Table 7-3: Binding affinities of unconjugated or DM4 conjugated nBT062 variants - individual experiments. 
 
Normalized nonlin fit: P-values of 
LogEC50 comparision WT nBT062 Stable nBT062 Half nBT062 Bispecific nBT062-natalizumab WT nBT062-DM4 Stable nBT062-DM4 Half nBT062-DM4 Bispecific nBT062-natalizumab-DM4
WT nBT062 0.2551 0.0013 <0.0001 0.1877 0.2733 0.0404 <0.0001
Stable nBT062 0.0139 <0.0001 0.7805 0.9443 0.2874 <0.0001
Half nBT062 <0.0001 0.0405 0.01 0.1432 <0.0001
Bispecific nBT062-natalizumab <0.0001 <0.0001 <0.0001 0.1643
WT nBT062-DM4 0.7271 0.4731 <0.0001
Stable nBT062-DM4 0.2478 <0.0001
Half nBT062-DM4 <0.0001
Bispecific nBT062-natalizumab-DM4
Cells DM4-conjugate
1. 2. 3. average 1. 2. 3. average 1. 2. 3. average 1. 2. 3. average 1. 2. 3. average
NCI-H929 No 1.13E-09 1.38E-09 9.84E-10 1.16E-09 1.56E-09 1.92E-09 1.24E-09 1.57E-09 2.12E-09 2.29E-09 1.22E-09 1.88E-09 1.07E-08 8.30E-09 8.71E-09 9.25E-09 4.73E-10 4.94E-10 4.03E-10 4.57E-10
NCI-H929 Yes 1.75E-09 2.00E-09 1.28E-09 1.68E-09 1.82E-09 2.14E-09 1.41E-09 1.79E-09 2.12E-09 2.44E-09 1.51E-09 2.02E-09 7.40E-09 8.87E-09 7.40E-09 7.89E-09
BaF3-hCD138 No 5.10E-10 4.14E-10 7.13E-10 5.46E-10 5.71E-10 6.28E-10 9.17E-10 7.05E-10 9.91E-10 1.07E-09 1.30E-09 1.12E-09 2.78E-08 1.91E-08 2.08E-08 2.26E-08
BaF3-hCD138 Yes 4.71E-10 6.34E-10 1.08E-09 7.28E-10 4.86E-10 6.24E-10 9.89E-10 7.00E-10 6.72E-10 7.89E-10 1.24E-09 9.00E-10 1.58E-08 1.53E-08 2.27E-08 1.79E-08
Jurkat No 2.16E-09 2.07E-09 1.93E-09 2.05E-09 3.03E-10 4.90E-10 3.97E-10
Half nBT062 Bispecific nBT062-natalizumab natalizumab WT nBT062 Stable nBT062 
Normalized nonlin fit: P-values of 
LogEC50 comparision WT nBT062 Stable nBT062 Half nBT062 Bispecific nBT062-natalizumab WT nBT062-DM4 Stable nBT062-DM4 Half nBT062-DM4 Bispecific nBT062-natalizumab-DM4
WT nBT062 0.195 0.0587 <0.0001 0.1116 0.0665 0.0259 <0.0001
Stable nBT062 0.5385 <0.0001 0.7467 0.5504 0.3295 <0.0001
Half nBT062 <0.0001 0.7768 0.9997 0.7151 <0.0001
Bispecific nBT062-natalizumab <0.0001 <0.0001 <0.0001 0.5873
WT nBT062-DM4 0.7828 0.5214 <0.0001
Stable nBT062-DM4 0.7233 <0.0001
Half nBT062-DM4 <0.0001
Bispecific nBT062-natalizumab-DM4
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7.4 Supplementary information for section 4.5 
 
Figure 7-2: Cytotoxicity curves of Jurkat cells incubated with nBT062-DM4 variants. 
Jurkat cells (CD138+/CD49d+) were incubated with different concentrations (4, 1, 0.4, 0.2, 0.1 0.06, 0.04, 0.02, 
0.01, 0 nM) of WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4, 
as indicated in the presence or absence of an excess of natalizumab. After 5 days of incubation, a WST-1 assay 
was used to determine the viability. Concentration dependent inhibition curves are shown. No cytotoxicity was 
detected for the concentrations tested. 
 
 
  
7.5 Supplementary information for section 4.6 
Table 7-4: Body weight loss and survival rates from MAXF 1322 xenograft mouse experiment.  
Group 
ID  
Therapy  Dose Level  
[mg/kg/day]  
Last Day of 
Group  
Max. Median  
BWL [%] (Day) 1  
Overall Survival 
Rate ²  
Euthanasia for Tumor-
Related Reasons (Day)  
Adjusted 
Survival Rate ³  
Other Deaths / Euthanasia 
(Day)  
1  Vehicle Control  10 ml/kg  51  1.0 (2)  0 / 5 (0%)  5 x ATV > 2000 mm³ 
(23,27,27,44,51)  
100%  -  
2  IVIg 10 ml/kg  37  0.3 (2)  0 / 5 (0%)  4 x ATV > 2000 mm³ 
(23,30,37,37)  
1 x accessory tumor (23)  
100%  -  
3  WT BT062-DM4  4  86  1.9 (2)  4 / 5 (80%)  -  80%  1 x labored breathing (48); 
Necropsy  
4  Stable BT062-DM4  4  86  0.3 (2)  5 / 5 (100%)  -  100%  -  
5  Half BT062-DM4  4  86  n.r.  5 / 5 (100%)  -  100%  -  
6  Bispecific BT062-
natalizumab-DM4  
4  71  n.r.  0 / 5 (0%)  4 x ATV > 2000 mm³ 
(27,37,41,71)  
80%  1 x ongoing BWL >2 days (8)  
7  IVIg //  
WT BT062-DM4  
10 ml/kg //  
4  
86  0.6 (27)  5 / 5 (100%)  -  100%  -  
8  IVIg //  
Stable BT062-DM4  
10 ml/kg //  
4  
86  1.5 (2)  5 / 5 (100%)  -  100%  -  
9  IVIg //  
Half BT062-DM4  
10 ml/kg //  
4  
86  n.r.  4 / 5 (80%)  1 x ATV > 2000 mm³ (76)  100%  -  
10  IVIg //  
Bispecific BT062-
natalizumab-DM4  
10 ml/kg //  
4  
44  1.3 (2)  0 / 5 (0%)  5 x ATV > 2000 mm³ 
(23,27,34,37,44)  
100%  -  
11  WT BT062-DM4  2  86  n.r.  4 / 5 (80%)  1 x ATV > 2000 mm³ (37)  100%  -  
12  Stable BT062-DM4  2  86  n.r.  5 / 5 (100%)  -  100%  -  
13  Half BT062-DM4  2  86  n.r.  3 / 5 (60%)  2 x ATV > 2000 mm³ 
(79,83)  
100%  -  
14  Bispecific BT062-
natalizumab-DM4  
2  37  n.r.  0 / 5 (0%)  4 x ATV > 2000 mm³ 
(27,27,37,37)  
1 x ulcerating tumor (20)  
100%  -  
15  IVIg //  
WT BT062-DM4  
10 ml/kg //  
2  
48  0.7 (2)  0 / 5 (0%)  5 x ATV > 2000 mm³ 
(23,27,44,48,48)  
100%  -  
16  IVIg //  
Stable BT062-DM4  
10 ml/kg //  
2  
86  1.9 (2)  3 / 5 (60%)  2 x ATV > 2000 mm³ 
(23,55)  
100%  -  
17  IVIg //  
Half BT062-DM4  
10 ml/kg //  
2  
76  9.4 (41)  0 / 5 (0%)  5 x ATV > 2000 mm³ 
(23,30,37,55,76)  
100%  -  
18  IVIg //  
Bispecific BT062-
natalizumab-DM4  
10 ml/kg //  
2  
48  1.1 (30)  0 / 5 (0%)  5 x ATV > 2000 mm³ 
(16,23,27,34,48)  
100%  -  
1 Day on which the minimum median body weight was recorded; n.r., not relevant, no body weight loss recorded (i.e. group median RBWs always >100%). 2 Number of animals that would have survived 
beyond the last experimental day over total number of animals in the group. 3 Survival rate adjusted for (i.e. including) all animals that were euthanized for tumor-related reasons. 
  
 
Table 7-5: Mantel-Cox statistical analysis of animal survival from MAXF 1322 xenograft mouse experiment. 
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